var title_f35_30_36320="Syncope ED algorithm";
var content_f35_30_36320=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F69774&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F69774&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 570px\">",
"   <div class=\"ttl\">",
"    Algorithm representing the emergency department approach to an adult patient with syncope",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 550px; height: 677px; background-image: url(data:image/gif;base64,R0lGODlhJgKlAsQAAP///wAAAIiIiERERLu7uyIiIpmZmd3d3WZmZjMzMxEREczMzO7u7lVVVXd3d6qqqoCAgLCwsPDw8MDAwCAgIODg4KCgoNDQ0GBgYJCQkDAwMBAQEHBwcFBQUEBAQAAAACH5BAAAAAAALAAAAAAmAqUCAAX/ICCOZGmeaKqubOu+cCzPdG3feK7vfO//wKBwSCwaj8ikcslsOp/QqHRKrVqv2Kx2y+16v+CweEwum8/otHrNbrvf8Lh8Tq/b7/i8fs/v+/+AgYKDhIWGh4iJiouMjY6PkJGSk5RFAZeYmZqbnJ2en6ChopuVpaaDAX+pp6yteat9sK6ztG6ye7e1urtjua+8wMFfvnjEwsfITsZ2y8nOz0PNdNLQ1dY4vg6YCAxiAQQAB9so1Nfm5y65DwoHAAsJ7WHfJAsBCyfl6Pr7JOoK4CMKCADAQMEDAQUKBEjQrcElBQAEXEpwb+ElAwAIKAyAkcSASwMYEPjGcQRChQwB/3wMEBIBpnji4pXIx6/mOV8CEgRQMNBAAQA+IxY4UNAAwnj17iEYACDAQAEQFWBcRwIhAwYJBIwcWHVoUatYB84TAbWjCZo200JbtsBgQQIJMApgCqCAAQQIRgTN+HPeSHGZZOIli2Ckibki7A6OmHdsXbNn1UpOm0sAN3f/IiaAGJGu3aMikgJowHSeg59ST4AVaLgE4serxT5IN7n2vlxwMXFl4JSsZ4wrIUpcWPFSAXAajZdYGbJ11d8qQXZzGaCd3RRobWunVY6Agm4zHFfJvr38qXIJHNQQT4W8+feT3K+RD79+I/pp8Nvff0j/Gf/8BRgIgGUQKOCBuKiC4P+Ckozi4IMQRgghgxSWZ2CFGGJ4YYYcIrhhhyDu92GIJJo3Yoko1nZiiizatGKLMKLzYow0TiHhjTjmqOOOPPboIyc18jMjh0MGeZ+R6yEpo5LhMWlOkRo6eQ2UFVIpJSFWMpjllQNySZuXzmzpIZit/ChmHWamqeaaE5Jp4w5nTvNMnG7OBCcvdOqRZ50iELgnHH/eEaibfuI5J59RFLrLoGgiCsUt6ZFVAHgtMMrGhgnkFYdzMljq5S1JHWAQDJ6q0YxEDSTGVQoGJAAEpz+8pgKspDr6RGUJNJDqAToFkJc2l9zTj6EqQJWaQCsUMBsZsqZA6wulXulLAd+Nlpf/qPUsG9miKyAEFQPIDkcRCeKAl1xJ5xJjgAKXDOTQQiKlspGvBqwyGEcFFLYRZCSs2+42c0l0AHPxuoPsuympEK2UOHmWiVEKXTYst8VOqgACAom2FAkajZAaVQqo96xK6pGVUlbOebdAvSLcmyoAH3NmwgAldyYpOGChbM9xmnWT1QoLO9mwCA1oWkJqE+ty6k/DCbBXxyNADdhL1WVETG4DLEDdJYWt4tM9LANwLzhTXyITxzpl/dpri1k2UsgtZ2I0ObYqoxpdvGLS1kSU9klsCggl5pRopJEbAHhIi8BTRKnUA1AJRedEqWE+xfMXr40BlLg77BGNQE6+SXoV/2vfLC75l3UvoajS3f4EVG/iChvQsuf+VG8ACtnskXH3vMuRYZkw9ZECmTYFUO26j7BSAQvs/Tld0bFUcFt5+c7vtqkrsXotF7baOgAJPG5E+Ldmr/qdFPNQ/GEPif+L+Ulsz92h8CMh/yxB21K//T/+jUKzMBjAqqwwshN452xJ2l97btIt6MVAgM95FHJoAkAa5M9WF5TDqRwYwAFWUHsThAFvENgkBb7pSa1DSTeGw7yppcR3q5ra8wSGCYaE7V4boY6rXNi33Ulva/XSiQLucS7gzMV1P7tBBhG1REC1jihSacs9HPCycATgIENRiQfpghDxieMBN2zMQDB2AP9xPO6LqplUWIxnNXAMIC8xUwk8RvA5bJjwhFNqYGIMcDverYQji4GgSbhIlwX8kY/2ypzuvmFITFxPbJqyDBtbg5eyVUeQLRugBe8ohSa+YYN7lCIdXcUbiI3Og67SHQJI+bvqYI6Nr/nGKglSksKZRI3IuqLVWgZHyGASfJosISfLh8JiQWc4vvIO7jiClZ0gawTOe40yFQKcnRRvHrEkwDRLkhkfhkRsF0kkX5SDyRHacZjEzKMaHsBBHnywU+hMpzU8yYQD5oCeZMLnpegXTybocz787Kf2GBgmgfqToMn4J5cUmh82OfShEDXo+czHUInaD34VtagRMloNjmr/FAgW0EQGUufRj/qgApq4AElNmggKYGID2SspS3mAAUx0wFYhzcRIZzqICGDCArZCaSZUylNBSAATFaibSy8B06IOQgMBoEDqanqJmzpVEBAIAAZS59NLAPWqgZhAACKQuqNeIqlgHZAEsgdVqaY1EBAwX1a3+ta6lkGsZLWrXr2x1r361Qtx/atgB0vYwtYHoogdhWH3J1O6qSKxkI2smdDZWHwAorLeoGyjFLSkYWLWTpxF6B0/m7RY6IO0a9msH1DrBdYWVAm/JIJrgXZazZ5gXtXp4zNrENv/0aW30LpsbT2LguvoxXVQCWYHW/DOGMxWYSrQxiN70LkChqG5/02xrQmMK4K9aAZyfENWQR4ARC2aESi224YMIRg7OXINO8JFQUEG0E4jWBcM2H3uMYiB2wN4l1Ony0rgAjdK887Du69jwGsEqDHhMeUvjl0tq9hRtZHohHlN6ZURBzCUXqkHIexiyEhGUi8C8HAjP0FY3zgMEoWwoy68y/BFwDnjdIWjV3lByER6NZsiypgjMozwaIsLGe+Cjo5ye0tcIsIu3BkYHEFp1UsW7DTXdQyCMREyH4xBMy1arXepgh1EBjBHXWGGALHZSp/OeMXWBHiA9H0dOHZbF/XAznUtcxXcDFO0cAzxKOIYI1PieOfkWZa4ty0ycjd3OjpSiwFoPP+Nl0vC4ToD4AHVOTKD7TEa4Q0ky4eW8AnK9hM392WCA+OKcQdglN92bQSMPCQl5eaRgbRGgAzYmiKDAhXjZNkwuG31mjtjyfPyur6w1m4J+qvb61nPilxZ3k/YOxGmGac6zqM2cbwMauyZVjWpHG9rrgkOSQvSzI5DjKgM4BxZspLdh+vZCSB4a6fFm9zojTRqnpKKPg9y2IjZ3IGZlkotK9C1+jW4qujYgJFMpB2Y4Jkg8xaAD2MiVe3WJruo2cwUO7LWuzRvr/LFxqBI+3XLvPGU6YLNB6O45D9xnsLrh/D4tgBWnfOtFwh8hIQHo+ahZQHO3Qc4ZE9hON3subL/4+Bzb6uTk0AXtWhNSJM3isCMtLpv/GxeTKgHUFPnNeCgmg7aqR/861f/BuWarGPcUVxkJFnXCgv+A7KX9ulDVgF18vLHS2gzFV0WQWvQ/Q81P+bwQbA7rCXL+MbfaOkrsLoV/56RtC2gNauG9yAfgGcgKH6xpqg62NUui6KNpCGpcpxzCpLExIMeo2ifvGGWt4COvz3kInBAtYTw+ddTgk7Apa7vY+oETPew7sNfqZySj0HVMp9PUX9+nWiytZLwVrkzizb2WdB76R/pBYs5QvBr5f3pwyD8crz0EPuY440kgMeT1jCNOdJHA2h7XBaxvtPLv9AV7H3+JZErSZdg/4DWGxsDQYVWYIK0aUpRGk/ReXfHf9JyfnNjRSUjZWaTTTaDgFDGNE02bdr3NKeGXjMngUpCfRWYK/NQAOqBaQeggYjBgfmmS+ZWMgzYaTBXgiZoJNT3MAOQKlCxACyUaSyHM56Wgyd3O/bHb9s2cDq4gzUSfVDIJFI4hUhShVYYJFiYhTSyhVwIIz34cT4xEVA2ctt3UV94hRRIApjWEZ9jeNildGnIg2s4Ag1QM55jBd03h1KHAv9XffbHL8jicBB4UHwYhXWYhyTgbyT4KIeIiOA3N5jGFZ+DaSXDc3bziDEShjPWayxRhsZxhnKoiS3ihaTYIaZ4ihmSiqpYJf/O14ohwoqwuCCyOIsHUou2GCCO13i52E972Iu6CIwm+IvCaB/EWIzwcYzIaCLL6H3K2IyTUQETIFbTiFbQaFhd9VPXuFhmhVTbuFhQdQlu9Y2FxQGYQFfkSFhidQl5lY6EhQl95Y6D1QEBoAHyWFgZEAAccI+EdQEBMAH8SFhNFZCC1Y4EeZAImZAKiQW72JCRtZCP8Iw6IJEQuX+uQJEVGYEXmZGMgJFKxJGL4JE2IJIZSZKbBJKJ8Fm/1Fw5hw9EF2ooaQjEsDXkw0Y9EIcqEHwreYQz8ZIuWX9PGJPfZgKL4RKyUwU6uUXY4ZNn8ThQEZRCmSAnEH53aDw8NBr/uvFjGKFMqeEvToEYwMJpJsE7DBAc9VdeZPZeMSgAZfkQWqlyvgKXjoFgGhmVQUcC4YcYjvFFUNEOCPiAMNMT3xF4NqNLJSBKVHR6yqNJs/SDnCOEnqaYfQKYfYYttjQPuYZhMGmXXTKVRlOVseZIgSQWHQhq1YE1kCkUvkIpfeRk2rA4guSJINgnwgZBr0maJBhsxjUP3WaRnDmUJVCUVeNutGRK4IKbQWE6u2ctzZI4onSYl6Qe+uZlLriW0FQdTsiIo5F6LVl2v8l1eFlDwqJ2G8dMZpiDXFlNuAOZBcE3VbENDheXSnhyf/QUkTkOTkhx2IYSvFk1UPmdr2gD/+AyXVIJoHdpQSCBJQYKnvizoAe6kQ4KnPMToVvmPxRaDBZ6oczgkBz6UBpqGyb5od8nolRHonlnooyFomenojTHojWxVB0aozI6ozSqI1wYord4o6qIo9vBo8GYhT7KH0GqIjuqo6c4pPPUI77nI37lH0j6Wh+5V066pPfUpFX6elMqpVcKelmqV126WF9aV7AgKstiZqgDpuzzMnT2nyYlC1axDiQEX1h6GApwLKKYXVrqERjDhMzTljvhnYZVGQLxHeEyEUfpN3k6AuLAFIjZcPHmm4IlqAWxpw0GqU6VCxDUmj9xm4BaWILKOE4hgpZaVJg6EM9JD/6JqFx6GP+uoxACQDjt9KQTCnKgmkzjUJeRyqrdBTuGOqo8FaaeuqV2BazvKKxiaqzBek5eiqzFqqzDyqyDRaxgxaRYqqTJJ6vvga0uUqRAyq1WqK0WMoU5hQk7lYYTAAFZha4AKYFChQlEZa6aYJDlB6MDOYeaEI/8R1UBYFV86AGYYI87mI1fxYf5eAn7uIPdaI1z6I+XsK472FakuAGXYIVzRYo15QFWiFekGFLlCoUBgK98iFLvCoWBRYoA66LZM7Iou7LeUKMu66G38bIyCyRQOk9CEnoB1VE3WwrgGlxd11mV0LNnqrO3gbM1S7TDFbQ5m1pFy7NLOwxMSatXILRRagn/UfsC4zdQRwtNvbJkT2CdNhl5d9oEVDuS88YVvbkeRKd1yzG2G/W04HOJFegEgtSdUquHO9u2aRennXK1LpC1W7e1IpAADiR335V/W7kRAnB7IAYvWOm4IsAbR2kQc1F/iOsaeqNtLVRD8UJii/gQPBRGABCWC0Bxc5tsTau3VvSCCeG4KtaX62Zh62mVnGsYJ+G67glD/cJ2G0Myt5sSyCSEvZqWcWm6mykMxKA1IHEP13EdhbY4RJN6/xAbb0YCWXEAdtEWG8gVCRgajsFgQzS6VfRFhndLCPRFomuY1uJnh4q6SUurMXEUX3EyA+EA72drnGZme9lmqSC/UvFm/6DxS4QZE/HrFVE0FpXqmElRmeHbqT/HArM0F5w3bJWTqpm3YHhBayNARQjAeQIAhDzphMdVa5raSBdBK+FnwvQnTjrGDcHGpsh7tt6rYL9RfZpSAKlkasajwpr3GoohN6OJNixxDwLkADn2G94lqnU7hh/nwMBADF67MazHvR0YmHbInWjGFOvWaIepAClmOsJTMiLsvY8DvrIzS6VEK6AhNu92OeujOAagnTD8wCZwGu2AMbrzGQmTexyGv4ObOWjcSnlsFHscGyfQZxoRvj5sAI7jvb1zhC4ox06coblXQ/Gge+DhhMrkFIx7cUTTxB4zEC5oM0o4xmSRuUyYTP/lqXkz0z6rHB3Eww1NxhD6ybdlm0Al4KfjssiPyxFWUQ/w9nDGs009DB3W00xeDGcxBj6EtEe1KrzbVp9ySUK3DF1Y67aHYXR9aHY6wLY/8BY0ALiTnD4sYHw0gJMFCrQ94M0+YL/XR34Jxc0267SCW89I+3twG8+pi8/2jAzVLEz8rM94J88ROScze9DUeloIjdDKR4r/PM8ObaQR3a1HKtGa+ND3/IgYnQzjegkdy4Xnmq4Q4LDl166XoLJZuI6YIK/eR68anQkg6336yq9z6K+XcLISKLCPWLD6CIUJ+4gM+49TCLGaKLEbnQwVq4kXm7FjtbEB8NHDGNNpKLL/WViymojTLIsoKJ3VXI0mCz1ZIPLVHTomGBrWI/qjghKLZy2k74OKay0ibU0kb22Mcb2Kc31YdR0lHUnWaW3WOcDOM+Bwfot8OWoC7zARBCoC4mwEQXa8rjgrERdCJcC2OEllwGRoOofZAM3WJhApjCEGouGrAtIMEObOKEDZ2hw6JDCAeoQ+o30ChIu5s4svS8GE44IsMeGVA3Qu9vZevZu9vQKEy7y6jk0hpF01ZrZ27WIYC0BnpLsNAsRh7LdelhGKLtcu0w0wD8YuqUG8pzvOzGjY1JE1jdoUL3ODG4Pb0XkC0Nsvh/PbhAxN4UtFZLE5uEqLKxCfA9AOs1cz/yPR3O6jvgs2R3pxOJbdclZcAvVCw6GzOHIXZxBmza+td3GRCSOoRaKq3geAmoqaqhhYHfB9AA4RF5rqzHOM15DtXy9mGKj5NngoKatp2UDRK0So2Lg5F9324S9ISKaZasQt4WhtvW6YNQ08bFoEqyqRY6mqne3NgpeWaaWWOAhxqpWi1ik+uiJWel3jHdj3v6kkSE5enV9+44O2KmGeaakUcE8xmJ+WqieuFtlgybWqSF7WXg6nEwMz3BnBdkNYRijxvx+HTDdMoEedic7in/Q1e7zD3BczAu0JL9nGFX0e6bC03e0y6ezyPHu+E0b043I64X3t1ntd2KEu16MO6v/MYOUhydep7terTuqtLuqvjuoB+tizHuS1btx3nYxindBE0usNmaIVTdET/a3eOoWF/r4ee+zLPuzG/nowCuyMV4pUeuookuz0fOslgu1Ka+3bXu3aTiLcHtCKMO7yFKhgIO08AtGe9dWuV9ZMC3lT++6l3s+wxwUnknDmjqfyjreel9f+7ItdkO8Av18Cj+/0rgToDNnOxe5eh/D/jgJpe87ttPCH3vAZfaI2YPGTLQ0EL/FufpOpLXRose/7rkEpIHlYNzT5jRsen/Al0G2313qjgYfRLRBMQbqI4RNsxjeyG742Bs/53KIooPLdyfEc8/IRP2pLLr0EQN9WV+T/ctQOeqktlUvgMc+/bgRHfiz09k5RKT96lKefaNa6e9wZEsEyus3ca+q+PmAM3ZZ560DIVEGriNHCCsYu2hIaspZIv1byDq/xy6EJlNcAqfQN/gsZXbRLhPnfPPPmQ2s4MoFu81CnL6gAVWTjqg3HOVFieNnG4mQ6gG8K0a7upq9Y8D4zYg9sHYH40PFvu9TiO/Hi4G22II8J++1hRMMUpaS6c/HoDLHz+kfMlJQXt6MTGJ/t25r6y7H6/YbFvAz7nGJ6pbN9H1/v8SEZ+h72aUd5zb1MWWziqq3o68no3339sd7tlFHwLlAPfMsD6J/rkHDytMX8LhCf2Gz7hI39/w0CAoA4kqV5oqm6sq37wnAQ07X9zrce5zva+4LCFXBoPCJFxSSz6eQ9o7SldNqkRgOEHSEnGOCq4vEISz6jrem0eX1q7+BMLVf+duOH9jz/vO8H/bkJQqEcBCAmMCwkIDYYKDAACCQABBQgIiQCdDUWLGgiHggkLlhiBoRWHiYyoBZ8caIKpBAC3tre6h7l7sr4mvS2yB0+UJIUGAAkW9IiFBwcEnSZNjRYbi0EmCKABThDS48Ud4nEKtASAa/fsbs7Cb//INLX29/j5+vv51+lLAygZ+BAgwAJlH15UEDJlljYyk1aSMfAQlnYJoHBBlAgxC+HDrCIJ88Hv5L1Rv+itGTSZEo0IsmYQVCJQQBl5hYyUJAgHR2HWiAmQGDpAQBt1bw1zKhFJgCaBrpIOpdOxcuWauJYfVe1atYwKM0QUHCpJilENh1EYoiRYZdEIEONKnXR5zSxmAww8BQrLKKpwbqK2Qp4neDBWVLGG+AXBUQ+XA1TDQR5V+HJcxDfeBBA0orGeR5b/ksyNKDKpI2APnxa3WrUklsPeg1btrzUWmcLAZLAwU3OIXGzMUHq2rLF7YDrsA0PeQnlpIEYPaCAqAvnzGsJV6BAGazf121YTxLe13jIRShZk2WWQcAACpp/DywcVqTuZROYgh//au2V/v8DGOA++/EnQgFpbQf/wAMKQHUcgf6UIEABOT0jgFEAdCPag9VtWEiHhAkHBiv0HOCAe4uVR+ASEk7SF0UiEFARCSkORqNhNn5Yw4oZJViCNiCVkaN48xn4zYUNZDSjkKwtGVmTuuwI4yttpaLfk7TdJIIB37RoUH5KXqlhmFaOiYdpZeqI5ZMR2MNBmRnYkwGaa5w55y+joWlPBGVeYM8FdrqkJqDDCNqkB/VIgCYF9FAwqB+FOoodnmVCQI8Gc2JADwaRjlEnp5JihWafiEAwpwX0WPBpFQL2o2pIrN5j5waITDBnBfQk6upnukqBY2sdIAKoBgFcyquZxj7h62qndgAoBwG4iSyd0kJo/+ytctrJ5p7UBsotEsquRsGfdkoArrfmDopuaKUOyq63ML3LS7zz0nuDunbeW6++H+ab577/AixmwHciBqvBByMcIFUJM9xwScaeWg+2A68Ap8RfAdpGv51a6yfFLIxKTwUY4+vkdxt3tSgiG3zcwqyINErynBrvh3JWmSLSbMsr4BzApjL7C+p1NlvFJiKp7qxCxAEgPRLRlJmc2xZsTC20q+UiMnLSKdyKSK5OT1G1GAdgYlyyUSNDTwMgefaD2E7EQsdFaLs6bMxbp7BosUCX0AiQM75dgmIrOPSCA0lybPUIzBwwwITVBZ7s1HIrrmqlP+ONwrPR8j1CWDsFE//5Ew2YrdoPKDAjwnTlQNIXAAW5Z0kjNWEoEACKOX7A7HTArsgINH0JwHRfhBLAIbPbJLCrEwSwbeYnsFkrZicg8EhFutNDgISJzE6UYuwh8p6JiCywl1gJDjC7UCNsKUp7AzDQRRfJu1b5MskrVs4AvN30N5csjoAp6QNJAyqBDUpIAnQj2AnZDLCA98RtcrQAoPJcFYCvPa8E5bIKFXLygJxsAUkMkVA0uJSh/G2mDNRZCzoAAAn2gKELf7vdBCeUFwF0oXSQsgTqkre6GRCgEQMAxfrU8iIBiOUSNDSQTZZSjyICwAENQIBCBHCNCBpRRmTilbsyaIIugs0E7cv/xP1GqJSkLNFELdweAhjgEeMpoXG0+AgJBoeA9QkAAW2Tl/0Y5zhOAGGKJCzDFihSjCguZHCvu4Y2tOc7EzxwIQ1YozeoMxEtgsmLmnTMCfYHo82kp5F0WYsiiwJH1RlAKpOIxODoOILBSYgBrsBheGh2AlQEoAGS0B8iPnG78F3kRe0pQCLTsQBMYCKEtiNBCzUDkljA5ZKn84PDqmnNa2LzJJlbwiG+BItjGkQLo4wFCjORk1aYzz3KaOUpRaDI98WvlnQ7w49W1a1NbjE52dxnNQs0JluigUo6/NY98Rmk3OTIFk+D0jxxA66FNukxEJWPh4I2zZMV1KA8RCi///wZJoCWoC1vI+dAQfQojR50h8xRaBBKmYc92quhCowQGFzauV6hNKWT2hBLfWBTFLyzpDeAKXgayqATkDQrD82pEvSQUI/S4KedFKoPiJqmyoUCGrPjTVLvswDgMXOFWxLBHW+nPpyeVAV+e0Lh6kjV2ojuojtlgVQJ2QKrhlSeFR3HWbvjweKtUwDieBFgx2gAWMolnLRL2yVMoVhlxIgeTrUf7xjJIJJeKEMMTMYDSTBWDAllAIzchukSl4LPvRUJdeVgXB0UKhOkjpQDpZwKytHWE+B1roQywRQBIJ3yLYSCGKqEYgarRQGmQzGZ9UYNUceb/y2khbklmGvtmv+6AaSypgJ4kUWkSEVYEEdLOSirIhe7nLSioHrcTR8ZJSQWRciPLIlFHg0dB02BGDay5gUkJhQAO96MUSgSwoQiRuQ72P2vl45FhSpE0Lt4NkIBoCCR/JikWyaaYLVz68weppscj+KyJiA8yCp7SUPjlliJQeVujIKpRQYUTyiXpKOHOUTZEI5We9o9Ehgi+boWes54ugstLZxZWoqiwIMgvN1ogStLWOTQlNxg7irN+kzEIReVCnpPkLdQADB8VrxuhEZOklcMJIJEuRKO4jVMGA5x+m4nFR6AjKdW4YZeFbbJS6pM4tJYbGTodvyTkmRjMb5tYC+XnXCPKV7hWIr/6BGXvj1rdb1Tgt6S4BmROKQDimmJdUIjAETptKDdaSHSilCa7EthUFwsvAlKtKF0SDRXtdsl/KiuyO10p3ta3R4uHdmeKRhjlcqbXXfqMQcslsgWZKjIWCDRxOysx98gMjjW7W4UGeHsrw1QVhoSm9lrAfQTIVJW2lr6wmU0h3Yz9EBTSBEbH3FlrgG5FlGPQISf3AKdkfFc4iiAN+Xo7W8rbWG+ksi3wB6mp++TyF4upH2HhbWXXI3wS9TZhRFPRKztJwYNExS9GeYfVAbnzFhI5yk54PFFSP3sAXA6kfzrUV5Nbe8C8Obk2/b2TMhiw2+u2a50QWCQySpj6jjl/+AfvuWea6odkIT7IopxABRpPANoY6KNsTV3G2N8Easvox7006mNZ4bnKoCcj/AyBGkN9AV6UDyX9jZHYnvJ73SQE+IuNIt+tWhtWti2l8ZzSDL4cpe89DLuGR8lglVu9NoZTyHpfm0JYktOqkPj3YCTRdBHsMarI247+p77HbeUwIy/ukWvg6LBz74kkK40o3T1y22p0lpAuGLsRnCAUDsO23rw+RNlqZLcEoA48YYTI+c0CAMS3QCuJ7oAqG8fJiad8Aoq/aOuX81SYeDS2tfi9p9BxPFlH1MkLDkNwt0+9p8Ee+R0P6e+370ByVCWo+6WujoAv3nY/xzzb9L8Pf9IT/lAUkWBbZXfG4hf620URoncC9SYsQigikAVDfAfWyXgZM0DP3GgwjygCawVCeQWyF2gkExgzXiU8xlYPM3P8Nmao3VJ2/GXe/yX9QUAVxET88kQPSAArWEEKUjDoq2ZCzIgxcABatXcv5xgfBAgCYzeOIhalDWSbPnbFOaVl4HZDITSZZHZdiCgg1mW9hTA5EwDHdCZNhAF+E2UA6aAelWEfl0dKiRA99AQ+MTOoZVPDJ3POlHaAGogT4FY8mwE3ylbRZAUjPEgdyXhtc3AdR3b/XzhumFX4fzEeCEAd6mhF7WBkh2VdMVhCTmDdjWIEqyQKr3QAMTQrjGhHnT/YCvCikeNHlM4BUSwnGKYHgAEhRWKYA4w4iKZko4xkW0ZUCiJU5JUotGxXPt9TBsQWw/CUST2hK2pUQ2lghvB3CkZDzvN0CpaxhrK1cU9n13URGOognZFn4DRw5f8nb35IOE53gOlQjsaYxk+XlYloDfGXgp4EiDlBKyNWzQukQjUEyqpEhKxxxypIhv2X0vgYxVgWj4ljRl00+JsF8f9IxqVUzUmkSKkE/og5DYq5I1wUI60RwKAZANuE1OhpEgyZMZooko2ZNnd1JXEpEPBZGjUJNn900syVU5mnzv45AfuTFCGZI2MZMlkEFEODU4epdkl5U12Iwe54lT2U1JS/+VVYqXDMKW0KKVKQo38UUtXeiUu9GRYjqVZgiVXnqVapiWyiOVa7kpbSiBczqVc8spb0uW02KWu4GVeAiBPuqVfWlBZsqVgckpftgZixoZhHiZhBiZjRopinoZkBgdkOgplbuVjWiaaLA0iTEwGWQw9fGakGA09cM5mPknX0MO4eFHIZA1f1oPzoOaTqEwAsAw+vUwA3I2qHAquzGaY9IzObFLPYI7lWMpvhklpNo0mLc1yfkrIgBFy5gjWBIDWbJJqYpCqvIz0SGeT2A1K6Q2yAAtmdqcOXA5KbQ6yMEt5PgnzyOYmRQ+yXAt7ul92atIGSYu40GeTROcm9afl7P9ngArogOZGVhrogfJTdSDogiLoMDDog0IoNnHUZu4BeYbRT3YnV1goCuZfRHbofmrobFZoSk4efYYoao4o3tjBhtLkhFpmim7NihLoiVKoTA7lh5qoi0ImjHpoibInjerBAsYLjwJCCUalj0KgMKCbL2hYBOqlutGdI5ykAjppYSrdcLjdGRjgDhjpX2bSK62POCyphy3pktYW6LFAbpmp4AxUlXqp/pFAp5lC4wjpmu4Lka5SgnSH/WXg/5VovylcXLmpXVlgn6pWm+IjkJbAdJQAYNWXVmUP6/CgDYZXFKWjX00He1XJ6wATPMmOWajHfmXmldLHLHXJJ6AY7kD/6g1S6grGVyrRg615VQzGECrwYXvVquscy5+GKR3wDtwJYfC8qhYwgiNgQ15Uqn4JwBeQwpaMSA+eFbPWxAwEWHOUYYSZwvABhGBJExza4PqgYh8o6oxMqQCZ5OuckWeY3hOqEPtEXCKl4ihAQ2/cUDNUWYIsSGLaaERQCNDB29pI0wD54gMRALsq3ANIIUAqF2l1AxqykDLka7jKkCqJK47+GiJsgTgpQJrREr9BUZQdUP0NxUzV2000G5qunm9JmIScrGelECHNGQLoYnFJkyembMGFKydBCs2ZQxJ52rodowFkW2yRABvJEoOQmDZ+G2iZQ8btILVx376ySFlU/yQ9hFoh/awjxtYgjmMhshu4vWEyGOI1Ups2vtGUvmlTCU6vZiwBfBsKPV7RMQRBGIQy9FoJ0JtDRGKIPSK2XR9bWKIintiMPWMjih1DQUqnbUHjbMmo/Swx0iPOKYjxGCwzIUQCcJnZziu/miodkBrPRi2OAlDZaF4ZgFpAQm4s9pzjSRm60hCPsRzPmi0YAJnOKh2giqkYPhktxe0nEWpEfJrxLepU6O3VDSMUFe8y5NyuHSNozSwt0M4ffV7K1pGhmhblmUCMNY7eKRI4NQI9lgUmRMPshNfy+Q5NJNdH/lLseKrVNtsr6KvoVsSWKN6t/awPOp/hdW0AJYKsyv+FPYaqp31EOgHbYt4u2x7r7ECZJe4iIQ2f3RJAXjwSJyTRsmZEOcAjtJJI8oYv89Ij02orYhnExiVfosFRzsYllOJBWPgGDwjpkSLpSDxkU/pfCeQeXY5rH+yGvbzwZOCpPJQk2t5GDG+g9WpUDgvmDxshjv6ojjKmEg+MjA4oEg9B2tkcX+7rMjJxkkpBlyKlCq+Aiegem6pAULmAFRflN4ZxkkBCE3ixURLxCWjG+gxqoZLAiCgRAyAYbyCiIwQPh4JxCuQECgPVQJkxFm8xCgzkPibBGwOGFL8AKqZFHcdAW9EbLvpOEFmZbz1Ch1DxCkACHUnrlsyPpjrjyT7/sClHBPcggvfQAgx6charFUJOGKjiYTvKIR3yxXY86y4jhGK0Ex5i6gOoMqfGzqw+VqiOcVHFMd5uAzMsmi8lszw261j4FyIA2KRacjtpQwsPpAk68RnzBiyNISAlV7yWFXmdMyDJKyhiiK0tzqD5YSKjwDG0FVPgGxgWBRe6c4a00As5xD9HAss2h1i96+3E6yC1bob8z3vgK5eplNq6gD2nYjW0WXNtoRieLBbuncta4x3Xwxhi0me1xzLnYyCfAB4H1wX3gDaGBR2Z8QCfkWz18aYCIj2fAPAwQ7QpkdE64jhdI5AMnohgo7bNRzWOWGAp3AEs7bJdxNP+Lfaq/7EKhNgBdIS4vchPs7TN+a0obPPffLMp/Q3RArJUt8AxNMXwbLXNwXQCEMc+zq5akNQttlos4/QJFNCm4RupeZ4BQC5Qp55BovUaDXSfJgglZO5HKjTLeW50mfT5YagJjOL+AEXGvchfr3UvSq7OgfQMzSHbVMIc5gfociNKw9ZUVE/ysjUcacbUSFxcz4U5KjDrlXUNj8Ac89olTMhGNt9WXeRa+PI+p0Jw35b5SgL6rnaaARMy210A/6HHZW94QQKVnKs0yaPvLlHgjYVRQ6HV+lZ7BFxTFE8D/HFpmzUGzgsUGwYLg0cPM3NkI+cnJ4F0rNC5yDJk7HB7B1sR/v+mfMOlegMMJAeof68lgCvhXYtoOONCXL2xSMVvM1dBW1Hyhdr2GpBNAdcAGrtNVxC4ZG9qF9C21MCUhGMByQ5Dy7KDgdvwHsfAIX+t3H7GB484PMO3RA+DTYxV7TlyCxyOT0GvewMuDS9dDLSFJGhCiAcCgxux6ri3nSIuhJPAHO6SyLZAXZH4LdSYFQt4SOC4Gew4C5COjycHkFdsRONWAHyPTpwyP86qtjqqqpowPVbrlQ8Y82XVnAMz3boHYM2ADwarAdc4CXRz5SnYp0mfLxuWCKP5LmLrC01CJSRz+D6a9N1ytOagIhSr3GnBlDQiLXjQFxhWWqD1l0J3MHT/+VrgIQ9SM5pnBCNTsDqNUbXNAp4DIYL9+AoaM0TbYNBWsDErQrW2Dpc8GFqZdl5RRB71WzrLLMMO0ZKaKwGlKxCYHp13IQR7NEEr9FNrYRjGLKDbdos5lyUAHC2cYvpOIYl7bBkxQ0NrXrzJ3VDkm1D8FgmV2ag/RA7YVnCtdEAyA1mv5FTXgj3cWylmREYT9LztmkAf5PCK0WZg+7wODuWc2eY6YbSXmjnE2VSYHiMTnYlfhpl7+IUDhFC8tPEsm+DydNY2kZxnG53vXDC1fEYsrbZLIuvOvFAqIyTtWk1nnCtlY/piIuJwHUZInrZHndz4tNi5I92SWPOWQ1JT/yHRY5KNl3pznDrWVaM7utMj0hDVdXYcuRS9Ce0Gyzy4/jjXeluIp84xBhGa13ImjL0otP0QFY9Nn1ex76JRA2r6NBm6WmHMoW6OlcNmD3UDaz0dED53Zzu+DZzgM/CTBnqUn2sQ0TXqETZ78M/CHkUDM21OKFBjl65aWO4Ma32WVOIujdeBREVN8Y/nm82WE8HVh14qDWOOFU6MdF69GaRN1W7iO0Qsda7brm6255vjOyECEJ2BLO/fCNIEu261nDeH/Q2gtnaU4loIc68xEdgxdjB3++7hN4TgeT94Q95Y+fnjVyaUjwN4O8A5zk1wv7Yz9C/nfxtacIb7xmDGGf+3CXM3CBSGEJQGEBBMEhREAABHIMTCABgm4ChMDIzBgkTgsIhEnXKwG0NRSjAWUMSBFXAAbsEEjkiAKk6DWjBcEpBagQMXsAooCrUUuhAglxTBBZ5F8AIwUFKwANBQkreGd0DYcpi4o0CQZHmJdIS5qbnp+eYZKjpKWmp6GtRpqYraKlpmVOk6uwmb6clKG/okq+v7u/nwBZyqm3t6oPBAzNzszBl6/Hz6EPAj1DuNWn1dJG2kfemQEF5ubvotmn7O3v68juIuP7+KS3+Pfw4Pnd/vXwpv37+BqNYJJIgw4cF6zFLgynZJEDNbCflZrJjEIcaLDDEKArUxCKFh8hb/ZjSVwAwABA28Qcz4MolEUxSLwNIYkkhAUgagBBiw4CPJiENmksKZ8xbHe0hjCE0K5IEPfCaVkhJQIMaTZTpjugxllFRNImOhCok2ikGAZQwaLNky1FJYdF6hGgz51CzIeVW9mVJbqScAPJBQEGAZY4ADHTEQIDA8IwqDFy/evmCh4BCjQ4QNKSG8A4gkGoZ7pkEkOXIAKQuwtNxsbqcotSoBvFDt+IsI1VI6C7pSQgvWPz86H0LqQJGfGlsHYHmMWs6gEgN+rN5BgPDbWXdbAQ/w2DSNy4VhS+KTgvfkJgNmVHrRjbznPAUQZN+RvMSC74+dl4B+3haFHAIEGmOo/7adO33pdEoDWtRUgBZ2tLFAG4yt9BhOMzzwQm22OTQAAlQc4kBLQESIgoljYXXAIHUQoBgQAkgBQEpAbDgjECPyYGI4soliwCMIrAdXY7q9taFEgjTQEhUEsPjEdigitRYQBmR15SA43MaiDQUwsEIdNQjAxxgASOVLd6g08FgyC8ToVACRNLBjiV1ic+NaTzmG4RlyItJSACaaiWaVMbApQ2YDbNnGnXX2CIACNfTEwF4lGUONAjMcwAACimRYSRkOhDcEnym8qYgBc0nkmA6KfOnpf4Yl5iGfLhpGAAtAxfofqiYckEgCBrhaSGxo/ZWAA3khcKSveSgJgwiJjf9wZKefziojHkPyIuytm9ra5xagfqhaCS3SouYpoD2ra1BDYEVsC+Aa5qyq7NmmaRt+ejlruY1qy8C6QdbwLXRMvJrnuY3GpSCmpyjgBRM/JDBuT5SQewWoCJCjlr1FsCpiZlZaU+O4g2gRBFZg0oEtIgjM2M3GcOSR7Y7s/OgJjIeE+RE5W2QVhgEydwzfh4ACUOGTR+owsclEmDkjH97+e67KAb/IQ1ZmApOuKYgWwaZEFNv887mGDf3svYMkAKnRJWO79dMGfE2rDFTHQHYQkm7hg6UNo4tKcid8Vx+2BQxDCMSg3pH2x6U+tgZ4hJvs6ltxzPHiI56NpioUeIz/kKqAspaD8ybAKtKSIFRI/scYjBsQhwswfCfckZO3/IRkM5sBy6bTSfdIdSgU8l5nadrjHRZtaO5uFC1G3t8euHre+BvVQPSC89je10LuqzHw3fIE6/sIH9CfIcYJfrezYDFmvW8s8vBvEkY3R9V1/FK/zEWLpfzPT4z2gQOABGzIsQqYhGQVBH8Ow4QAiUKMZHBlXwhsxgPjUcEMuqJ0GkxK1zoIQsCJMIQk1J9VSriRD6JwhQfcYEXWhydLHAAPaijBCjlYirKw438P+ZsDXQHDU4xEJhdkoV9GOIrsrcZsSOAhJrigw6YQwQE4AAz9inizFtqAZgJKEFmw5kBZ/0jxFPwLYgyzaEJRmPESTZGK/WLhRCMWpIFJJF/bfBHEMYqmBhUyIgdJ4LPPXUKHMCFGGRnWFR+yEYiI7GHKGuk2Of7igia5TdmeAxcSMOY7DVAPZRahCBzAwjgts4124vUflm1KPAL4DRaEUwDiIOSPsSSAMGgmCRqNBmsBMg6v3PO76pBHZDIqQ6MGJAhiWeFT/JGB8hhoQfmdYjjfi44UPJkCRZgrBggi5YRWcqRPgq4wkvwhEkVxmxWwpE2Zwcp7YNCAuCSJNEkrEoQklA1C8QEWElHl8lBmNCYhjRJQits/aCkAluhgBDRKSZdu8qQCMDEGUxJjRMGUEsoMwv9gP6vEo4zCtDcgyk3xPKM+pGmKgjJ0YiqZpxmaspeKCoJZFLUXH0VWonKakzumUGJvtEmtOA3mLfWSSJbsKQBryUpD2hSf2/x5gFz9xF1DndYbpEUQWs4APULTpmOgA1FwKRU82EqBrRIKskfGIF6yy4Hy3KAboGJVj9NQ4Siu2tVPFfUIMK0irxYHA5oO1ajazIpOO+LCUljyUBx9w5KGgTaPIe1PJS0D096GFIPycwghEpDZwgbPJqUAr7PU4s8QUYeVZmtlL7rTZSmGAq6M9ktXS2sx8UZMo6GoGm7wGd2OVk/2obQUeIUZECI7E0Pd9rWAPW3QJJK3w57knGD/0Rc33+rY2bnmdTOJVcTKcDukcC8rm43TdRyBTO0Gp0hVzappsZKKE3DuciwD0R5uFytgBo9I4bLBMKD3kUJQqArhO4AfrgNNA6YxFKTlHHePkN/bhjcQs2udZEVHVumesBVY1LA/cOhhRSI2xJKkJIlBCOITx2+nKvYjHVtMwBTDuK7DnXEITWzjGJs2xzReMELiSFdLgCSOXyktddUISXzEkZDvk/Em1ggMKOfErkl4BGmQXAQpQyuMxCUJkRNpZJ5WWREe8q9HvlGGL2MEh2QqQQPe+AYp1y0TFhVykjmRYJuUmcM1tkRnX0AgVGi5KN8IchKGfBBD8+XFInkM/6CzfGd6LHnP8ONgNQbHNiLEOdJAIKSi2bvAfFAZCZ2NlKq08xkEsJIL+ZETMzFJzZ+2QBAs20oqQkUdBuRURj7zEhSk4Mr10s6ZisiGf8h6AxKc7nutcTMDyjeY8cFV2bl8o/vETGrojAGqUCTMAPCgKdEl4DhYOIEyM/mTL8DJKahmA3ii8CEWeGYN43ZRMn3SSjYoQBIAHQgHHaQja5TByuCJ9Q/2++w9EOtKA/qlQwKULeIIVjHyOcR+f1ntYZJIObCgt8UxqY4+V5lUyThBoVQEUC4oV6TsXIBKt5ylo8bCailBE00bUBur0WFJTaKEQJ1U0lIOQLQud8EWGv+qhl4XjaLSdufRWTriOY6cCTNsuihxoINK0KFCh6ApaeA7skoZfVO+A4I+UVADBEjUPY9mEtfBaW8YrFujh2OCQkzLMm4uLwHP+4JKaZ7vboyloti4U8okGiWyt6HtOKetjRxi3IyCKEMTLMPbaboocoXcx2RJlb+AaZt2cQEr4KlUXFOF1y1zK0FmhU5C1SKMxeSWvSGi9RIGcKXb596ktljEF3gluWCdIDl74/bvvRr1UxzDyicw/q0kYlnDZmdWMccu4gQwqiB8HvJf+ObPjjr9NMNAqkCBfg3ULNzhAhxvAjfDpmt61scQvwawGKvJWo8E0orK0e+qj+vHBXz/9vE4P1N60cduUzNRi8R5jaY329EUbAISY5AjLqNWg0UyEhE1LqFzNdAAY0AFUiNhrhNak0UAP5cCJmhsNcBbcUYjmmZYk+UIkLMwNtCCCohtNsFRnaVsUHR+nCUAb1dSDpEluzWD7DZ7pnZr7OV9Y0NZopRvQQBadYN+aLQUC+VMLWELE1hctJV3MBgjzBVbhSdRkFZTpiQyYvMyXFgHy2BcQtVfpmZ5TYiAm8ditcBR44UtzOMEPsEaBGZ9NRU7EkEbX7FffNM0moY6RjNsw3ZggCASZAZqnBM59iIr2cMCcCUaoTNdN0gWdxgFM1het+Jx1JcVjFCEMRAxYGA8/9yHDT71PFFgcU/IPOYXSf62Y20mKAdnBqvzMkcSTOshK5WDBYWTX/YlHbfVXqnoir+4EubiYI/jPVLQcbA4hzt2RPNTPxXBZFSYWAjBCzy2iXU4P99Yi2smciGhQNpIaenHif8wDuAYjjZIQO/ohiExavAIQDiGj3Zhjfs4Sefoj03GaAF5dwBJkHy2gAeZQgPZDNuokPGYfA/ZjfJIDZ6hCw65EevWD/poE6QBeqiAkbcikU4mkQBhkJtQABP0CpQGUaEQVcSWBU7hOYEGktDxkUFAjhvJkIPQCDdJE+tYktcojkEpdUM5CgbQa6NASCGJNx1YCQI1Q8uwN/TYCv+l5pNAkH0ftpMhsijAVG0XYipXYh/pI4rUyD1yNybKoSOuQSlHhwLlZkppMGxY8Ws/UG38eJJEeZLtgwAo02yC0pYwUz4LN4otCXEF4hwqkWmI4AAV8gNG8QLgxm8EuBpYsAxW+XCQeCYgKGpbKYAk8CRIB5YZMiiT4gNx2HU4oABaIAhx+BITWIbS8nVaoxI/R1BqGHlAaYt5qZdGySBVuQSwWVUisHS3cnlOaBiGNzIcFZdyoCyEZjZ0h3VNsHakgXlN9SThZgszcFCeGR2H4VWj2S/WJT7gJ1H60poCIHPaJ3xw8QCGJYTnaTZYhXtvECIBiJcJ2ZsUCZFisQT/p9MtN/CeMTB/t2Ket4J/TZSYSCApjlmLtJgXrIiZhwFWZsCdWnlkidEmJRCa8dEGGQM3Y3KaPyiHe0MCLhJc+ZcVT2AjpBgptSlaSpMoqiWQuNBUN4qjOaqjO8qjPeqjPwqkQRqkvJkEfemCcAAxtVEhjqAFQIics5WAOuKUIjEVU5mUEKo2EmqTs8VaMYAmGNqOnQYdnvKUoZM4sKURBkIGabkah+AqeFCW+iEjmtgD1xCf+CKXr4RhJsI5+bmfndkKSLlFoVGnHxKMJlCYWANtSfCSkVFveGqRblheb6CleqcCw2gGWamTGeoOYCcWumlnGdRhf4qQrZCSVQaq/xoUMCeQk4AapuywBhdDCtwwTZy2kKTqqtsQqVFBMn5EHYnRb7laqri6aMTKFMZqjpyKrNowqstKh87ancq6QXn2RLZ6aF7WrCKRqjsJre/gCkwZDtnTC+AaqlW5rQr2qpvQakNCZ/1jrSJpZgWSrZ12runarc4gEH/ZLUw5hSjhIeRagXKGVHMmYkU5ClLRIq0RpZ/2ZO9KhvI6DQA7rPfqI6OQjgkFr5jQr6Ugq/Raq/H6qQTLjhMpClKRDYIlm3DJK2v6bSvbnGoQS9+jceIWixiGrZihGQOCAoThXYmRa+JEH8yCSeoRHaRxl6MwrxS7YZiQip02tHqabIU1s//cAzvQ1mo06XGx8oJrIysDlxVfyUyfYnBdUBsOcgMLd2zMWbHSKmSYkXa++HWcKTPOwUQyszdewikiGCoi8ieYR6KVgGh7+yhotxLVeVE8c2WCkhiMYjY4op1JB3VIq7Qr5gkLECtAoSXkYpsR9U5xsrdIaLK9GoZEcJylNAhER7dPVyMqEVJ+h3gGlVOd1U7ImbmLRbkTWwpU8AAoewIOwSU+QV7uB7xlx17E+TgHaoCg5jatUlizQqkUagMCGAt1syn1YitlgJ+SO7lrWwpzK230GVRuAzKfV6Ckx65rJX1Z0RS9NzCNEZ5/WLzbIRUMhSY8SL3WdbsGq0bs6iT/8BU0s+IA57kMATw1A0ybyGi8jcG3keCETkpBjpE3rJicaphcstA7bRBZG9iGJrm9zGqxS+C3dgMsMZpdjzmABsV+ZhM3Dry+KuhUqktRWrCCPkNaeqMpZPIaooQyFxyl3sq2TaQ8BGNhwzNrvxNLIqk5QINvqTeAidqMq4GtCoxh4/K8v1jB9xtV1AM7mFq0XuSbHZw/odBqfIeAc/kFgTiA46VEQ8KH9jOK6wuJFCGJAmZgVVDDolFFNMMFlcPD3Ii7YKwVWKW/gMw1hHwpP9ytoWSvhvzHjNxji+zIHBzJYTzJHozIlayfmPzFmsyt2tsQdSGxz7CxhXRSnEyy//lIrc0wyqTTyZawrtZmutrqSD0FD6tcZPlrykdBFancroNUr4q1DlvGvafsCQiLNGR8y3qmDWpmy2CGy7n8rCXBy8nsDl/WzMrXykhgskHAu2+JHYSRbIMxIILhlumhCMB2HbPHSsZTbdiEk+UDTPBxHTQTPkqjbIXobj1rTbDcn9Dcj2o0zlKTIxmXzparCI0LtcaE0MXWzUF7E3B5logICeQ8I+7Mu+rhG+oVk2MLyf98CTMiB29bhnH7oh57Ig4QJUjIVBwyeSIBUBiIdHnC0n4SM49hKmPytd3HuT+DUWJSuAfgHrkZzf481KTwKCktgUinUZ31gD2301Co0/8NrSI+DV+rWYtHbSZxM09w1152M9MB5dQqdcmbvAm629DvRLxlYH/uCZ8EsFdSXCDtwipe9dZBUKBh4Dt3OlcyGi4YK8FmhXweTdT9DCTNK6BZEYBp1RTgayl7fdZ1E5++A1KGPQAD+ta8W9e2Z1W+2NFEKiP8e5v40ruVQMB36yJgOAN5Z1Yc0zhvKBoC+AMbjFyssKRrYyJ3ioJxpobOq9MbXNSDTdaYkDepPSY1qNgqCVyjFRe5rcSjDdmBccAnqiOzR9wrwdoe479jMNsmnNx8LciNLMlJFMQyMMSv8h74Bl7DOKZTMT1sIFnzwjyx08UP5iejcz14kiWNqNz/nZZrvI0nfSrYwP2brXA+K8HezyjFEXZd62Up+k0AM7QaZqIRLRlzAibRGYYAU0HfEJ4ArqPFaAyTtVOGnZ3JKiawpSzgAS5JnkpCHOmPElSQKe7ZJBSr0+yn4C3j15bj/LnjujzWwJ20gBzk8ANb8kpXDAvM+NLDM07YGRTK4VpEQ97BAjGhBO6w3idD7/Sr4vZGgnorLboKKYiqdQSy4Y3jjHqjNq685ZqEvixE5yrMGhvlPR7cYmqpVk5Gx7AAU3ojyvB26XgiyN2xpCyyrSCI+OvjJP6w2nDiha7KhJYzc07nETl1dgO46SWZ66VMuLGI25VNWWc8Z7CgpNso/zRMEjNwDdhbLHPapt6cBwvnsg/9zbNuQ6j4ywOk6JrWfWLpTXB5tVxAtVwrOdcSC3/5Ghz3tLJCepVZApfJpn+id5LRGZ1xbpykOl2IzZPe5B2pTW6NUw0gnXYXdiLl1EH3IS9FYUWgA2orzmPiumfwgi0ZcKlJuGSSsdaNoDgNumXSg8d162fx4xWouEEwJfq+cqppcvvEuJYyWr2Wopl3GyPVTtUp0q4pQ3oC6UHANOYOaEZHzNqOQaEwoWyFpW510DWMe4JcwfwDI2AOBKuqhV4W72CEvgfouy+Mi8FLitvXIt317yH/8Z+g03DwVy5qvqb3eTzM8A8ufOvJw/8CU8U8uJ46wnzCjJQHrfLOGfCDTeVb6u2BVvJE2FuHEqMcz1cUxs97fjEvkygkegiAbjepTvOTxcAATF5asCFZg6DQjYRml5ZA4PKeHPQNi98kg6Z8b3ZBpVlNl5RnhBUPL22/FfUNLEXb/SHFIcNtYPZh8PM6DvK47glVDmA+aDSmWMeSo6fWfvbyzajQ7WaDWoMUxRXyzur1Zt4HEySFoPN3ioeuwgJageiCf+YfPfQTlgNf0sbAbjw8zIu3NokY9ibSVmCTH6fQDql5EDuxY/qqP1DsLvyfD/Qt5uUE0eigP/w5LuXbm/5QUeT/gNeDnO3gD/DyP//0X+clzvX/9l//+r/tIACII1kGJZqqK9u6LxzLM62eNZ7rO9/Hty8oHBKLNh+wSAgECMGBwDhqSo3JKjar5V1rUJJgsIWFx7HytotTixYJZsIAoLq+iSh6Rh99q3uzDhvgIGGWoAoCU0AUQJ9IXmEJpNCkiKNKpdShjGCCwyNCjYJTzl8joyZpJM3mqusrq4xDwQIAgULUZWbkrtRlSi9RK0ynGAlVg2JUwFuAHFRiQEEZQQGTgIFiqECBdQJDdMABX3MoQDIzw5K1AvrnbYCCXJiAc5N9s1y4XLUiwEG5QsNgESyYYqAIBQ9GCEhwCkA9JmL6OTs1oAAJa9JqRQwwUaOcEQcU/31b8kYBR0XGRIyEw8ANkwYMBjBRYEtBPH4aBZTZl42JAYrzVI5B2ELQgmgDajURoGDcl0UQMUZ1UgYXimwMuB1gIG+OKksTxTVkAODOEicFxGQDgNWAgq0FnCxhJJUbCQQOFbw70SDUAZSEjBosDAvhSFUGqApYQOWqnAc2ByQYl6KAA8cLIQOQnGLkg7SNEDi2upIE6IYjlphNGAWuV1SQ9D50Gxnl49NYCK8YRrsJAnNVASx+mHukZeLNyBorIMfUF+ThAiBYYinKEuQimIuwvt1JcadMCmi3rhHoYMPq15uQoZChQyjFIQ5oqejAL3Da5oexzyT5AjQB5V1w/P+dFqAiBhyQTBwAOBCPANrNISF9EOEkzUP+OYNRhWkgsUKDACAgRlMFMMDANGARx5iKV6GCWWfcAeDcHAuREB1Z36x2wxfWYeXUVsZ4p+JioDmI0Y9+mRMJb+w5qYVRCNByUy6NBVBLA2J8xQcqImh1FmlXnqNlSCXQxoAzBIaJ5WlnVvQIhwA4FhgecWH1SH0BLDRLI5/YNoJjbBb1oQoPwjFOEww0kyIVxQ1HzYU8jScjjdEkh+M46KTJI3YnwPMVGkM2StV4GP1kzT/LJWdGk0+6asUM4TDyRTQJfDRebSItGko0a9miUZw3SbOpCMGJCMdp8FhjQEdBaSPsV/D/LFKGgN0QNyCwxzKjmx+E1oBima8Ogddh4prL5Hp/nftkqyg0SdS6PUQ0CkHtxnsvJ4UJWBm+6tl7TL8BCyMwwUH8WzDCR3mbMMM/NPywwxBLXMrCRejCLQtDTszFxh23Z1gwKnpcMcU1IMgEAjOhxyUYGK+g8cg1HByzqzMTAQnMTViHRsg0A9xDk1410B2/v1wsA8w+R6w0xDaP6/IUqvTM9M8c00BuCUYHRA1Iv6JHkdMTh011QQdTFGEzn3ADRzMLffpMGNMUgFNJJwCkCAHZacM1eoaKqbTNTY643X+5WjJ0oJx59tXinZKd7+MMH3znOYiPwtVIUQz+VlyU/43DzYnTWJfldzsbo7hNej4eeA1Ya2e0XczmqYg4tNc+TtKRH6E7wv9SSGMjsn9Hn4Ti9IHGANWdALzOJ/A8+31rp8w06zQENoBZcxr+0APcbZlQuEny7sLY4wvEA+UNIN6UMbm5VedMjJQRmLOVy9k8RA5V+D0J/MdcPQ1ORh2VvckSyqgQRTCSwGsxo3wPc6D5AGG2SN0tAGprn2mgBbdHKGJo1lmAN/C3AJwggG/S8IpLqEeyCJ4Lgiz00AubtsIY1oyG93KhDc8HtBy2kIc99GHBAAhEJ+FwiAYzosCEiETDFHGJO2giQ6BmCyiiICIyC8sv6jVDFmjIFE7c4f8X/RWDJcDrBabL2BW86MUcoCksnMBil8q2RRdMLYyxsGNhEJKdHAQjd+5yow4cUwo4ihGMrWvfYqQ0ngUkZkWN0MhF4jEOYNViiVTE49JcsMdiJeiREmHHAUzXSNbs6CRMIQBMAvCX6MGBKYuhCV0C0BoDegRFKBsBAZ8yqlTh7RwHjAgtTBKPSkpwji1AgypLgJlGOootVEjRCGBkSUwaRI+0UwVtBuBMtQjgjMYy1o6ckDywqCZq96vF4JIpIl4taSonQssVSPmPXZKOnOQ5xQhr4YAGiGacg1CiDJDpBP2gjJks8g4UCEodJ16SmuQbozgYcqGDcuqMt6DQFIv/FYomLIgZzwEPh6ohsotGdATgFIDyUPAgXBh0RiEBjnCwQbu53ACcxTTk1TB4LbMkYKPPoOh1vtRThjpUizDYpJH41KOKOs8YlBkaCdQksqnU6JxjmupTJWEiFHWTDXOqyEXsVxrQcTWfO9JoenA6A4HyUhrbgANQT1HBArRziA0tam8geqlSPQShXe1Q99wo1aZ00lIRScApRxBYFAgIezAj40IPixEQNpAAiopHijqS0nWm1Wp4RddnV3FXPGWhjh4DaGgHlVodmiEwNpKCa82H2tUagradta1RPYtbKO2WVb3N7RPNlcWXjRa0v60tIPxIBikeBJA+m20LIDsX/xgMNwbVTYFyH3hc3ia3qYd8QR/WSDPoonEcDtBfHeI4g+uiILsNKy5tR+veYzL3OsNbnTFVsEf1iag5z8nHT+wBUvrUo6Pp8OU1SACXa3CDbuqwW0AquI1uHPiG20WuDtBhE0rOIZFgq9A+vCYVhhBFKNpyRoCzkQ+qkZe4EhnH4Fw6hzplaJfcsIqO7sAVww3AT+7k6ugAgxJ1BWYBXPFKuH54YU3sYMfK/IQ6sXJGk+5FvaXZ323yEh+74CFY480vdsUBFxj7V0XZwdGA0TCd4MQ0qm9YCvJSep4N0U54MrbwkpmsA5sqdKNOKI93xSMNjHqJQ/2x3QEEzSIief/5f2Bub0TPK5ebfPRIfdrOTztUFoZsFZol+Mv85BFkEqgriiIAXrzgu9p/OVmofnYNRJqaVCRZWUyk+96sL81oFj+6BJvU5gG88RVFTPcnzIJrhxDsjMsqwNONWGRHPAjh+1SQUkk2l6pTezABPWVXIvvJGypULQVGKi/IEjGppGEqoOxShWoVgniLYFrt5hlW9f5nr1nhXCPM+733LkK2L9zif9+R4Ec0OAx1i/BALDzfDV+Dw1fB3sgF/LMVP+7AwzyefTNWvTKYeMuOenGGPzy4JdezwkVuXvS2AOQscDlpHX3yks18YO82Y0T5G2MaNRDFCbIxFMSBDh1pqkv/EhaxZiuotrmlwzoVhKolthZ0AxP9gD3XRycpc0sEKyDGPc5rzWUWdpunHOcv7u+pn0NjNDvyxvnjKU/ueQkio4RyaODvCAlAVtH5BWMDWJ+Rp7tpHT/FOF3WciPGkuh7zvMAhK7a2DMZ+bKLnQbZGTPaZUyFM0ehpWqmHZvtG806l7RDwBuAnZNnnmvXxhmf1wY4hxOeidb4ADY9hQPq+rHJE4P3Ed/dDPYoabzcotJK9RNYMcIzHcEpdF0qNawfoT+8s+8fou57Cr7QvUSfjvk/ZhRIc40pJ/9KMGD3Pflsp/71s7/97n8//OMv//nTv/72vz8Tfv/r+gj7ORtn/+CxMYPyrYSmGACzOVu1hVKkjBB1KF2sxURGPd2N/BIBJshlScMyDNi41d6zxYMI2IrCoJ8IYlsqqMe8wRwuoZoOeAXHbccIvmANWUEL8kJ93YjH2YBE+MB5PRQM9mAh+SDkAaEQitYQTkERHiFruQoKAg4SNqFvWR6xzSDL5MASskC/fdwNopwTbqEW6pWDsNzLZSF4iWFBVCHlcSEanmF52c/O/RdQpBjQFdjQmUXRoUbazEgUeMUDhBgUXERPZF1AgIEiXBlr+E2zqFYaJqL+qQSZpd2MWUiNpZng5VjcQcXzWY7eKV+wZBO/zEZ8KB6g7ME3bdRrmaHJKSIqkv9c8IlZ4bWhmRlP5wEdJ8Fem0VTSKAeCzaIotVGGewipozAfHSHLn2ONaSMKapiKiajHtSA8H0D8Q2bExwfpj2Spnnf3l3i/TiBlMSF+MlPnuwJi1DIlZED1IHP1z2hMqZj70GhZQBb/83B/xmbZCVbAR6g0d3hPM0KXx2PGGzgL5IYE9TCYqFQOhgbIqojQp6fMEhhv1xhFyYkRBqhDEpMbAFXRF7kyFFTRl7kv20kHnkkR+YZSIbRSIbkdpUkUZlkRKLkNKkkRLIkEsGkS8YXEsrkTGpbTd4kQuIfT/akT/4kUAal++kkURalUR4lUialUi4lUzalUz4lVEalVE4bJVVWpVVeJVZmpVZuJVd2pVd+JViGpVgWZQgAADs=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_30_36320=[""].join("\n");
var outline_f35_30_36320=null;
var title_f35_30_36321="Patient information: Shin splints (The Basics)";
var content_f35_30_36321=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/87354\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?22/7/22641\">",
"         Tibia (shinbone)",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?19/39/20083\">",
"         Patient information: Exercise (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?12/33/12819\">",
"         Patient information: Shinbone fracture (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?7/42/7844\">",
"         Patient information: Exercise (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Shin splints (The Basics)",
"    </div>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H183854102\">",
"      <span class=\"h1\">",
"       What are shin splints?",
"      </span>",
"      &nbsp;&mdash;&nbsp;&ldquo;Shin splints&rdquo; is a term people use to describe a pain they get in their shins when they exercise. The medical term for shin splints is &ldquo;medial tibial stress syndrome.&rdquo; Even though shin splints hurt a lot, they are not usually anything to worry about.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H183854117\">",
"      <span class=\"h1\">",
"       What are the symptoms of shin splints?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The main symptom is pain along the front of the leg, below the knee and along the shinbone (",
"      <a class=\"graphic graphic_figure graphicRef82795 \" href=\"mobipreview.htm?22/7/22641\">",
"       figure 1",
"      </a>",
"      ). This pain usually starts during or after intense exercise, such as running.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H183854149\">",
"      <span class=\"h1\">",
"       Should I see a doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;No, you probably do not need to see a doctor or nurse. But if you think there is any chance you have a broken bone, do see a doctor or nurse. This is especially likely if you fell or had an injury. But some runners can get &ldquo;stress fractures,&rdquo; meaning they break a bone just by exercising or running too hard. Stress fractures feel different from shin splints in that the pain is suddenly much more intense and usually affects 1 specific spot.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H183854164\">",
"      <span class=\"h1\">",
"       Will I need tests?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Probably not. If you do see a doctor, he or she will probably be able to tell what is wrong by talking to you, doing an exam, and asking you to do certain things with your leg. If the doctor suspects you have a broken bone, he or she might send you for an X-ray or another imaging test.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H183854179\">",
"      <span class=\"h1\">",
"       How are shin splints treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Treatment involves:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Rest &ndash; If you are a runner, you should either stop running or reduce the number of miles you run until your symptoms improve or go away. While you wait, you can try another type of exercise that doesn&rsquo;t stress your shins, such as swimming.",
"       </li>",
"       <li>",
"        Elevation &ndash; Prop the affected leg up on pillows or a chair when you are resting.",
"       </li>",
"       <li>",
"        Ice your shin &ndash; Put a cold gel pack, bag of ice, or bag of frozen vegetables on your shin every 1 to 2 hours, for 15 minutes each time. Put a thin towel between the ice (or other cold object) and your skin.",
"       </li>",
"       <li>",
"        Take a pain-relieving medicine &ndash; If you need it, take an over-the-counter pain medicine, such as",
"        <a class=\"drug drug_patient\" href=\"mobipreview.htm?19/35/20021?source=see_link\">",
"         acetaminophen",
"        </a>",
"        (sample brand name: Tylenol),",
"        <a class=\"drug drug_patient\" href=\"mobipreview.htm?14/17/14614?source=see_link\">",
"         ibuprofen",
"        </a>",
"        (sample brand names: Advil, Motrin), or",
"        <a class=\"drug drug_patient\" href=\"mobipreview.htm?43/35/44597?source=see_link\">",
"         naproxen",
"        </a>",
"        (sample brand names: Aleve, Naprosyn).",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H183854194\">",
"      <span class=\"h1\">",
"       Can shin splints be prevented?",
"      </span>",
"      &nbsp;&mdash;&nbsp;It&rsquo;s possible you can reduce your chances of getting shin splints by wearing shoes with extra cushioning.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H183854209\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?12/33/12819?source=see_link\">",
"       Patient information: Shinbone fracture (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?19/39/20083?source=see_link\">",
"       Patient information: Exercise (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?7/42/7844?source=see_link\">",
"       Patient information: Exercise (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"mobipreview.htm?35/30/36321?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 87354 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-221.179.173.170-77B11294E8-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_30_36321=[""].join("\n");
var outline_f35_30_36321=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H183854102\">",
"      What are shin splints?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H183854117\">",
"      What are the symptoms of shin splints?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H183854149\">",
"      Should I see a doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H183854164\">",
"      Will I need tests?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H183854179\">",
"      How are shin splints treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H183854194\">",
"      Can shin splints be prevented?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H183854209\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/87354\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?22/7/22641\">",
"      Tibia (shinbone)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?7/42/7844?source=related_link\">",
"      Patient information: Exercise (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?19/39/20083?source=related_link\">",
"      Patient information: Exercise (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?12/33/12819?source=related_link\">",
"      Patient information: Shinbone fracture (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_30_36322="Shoulder external rotation exercise with resistance";
var content_f35_30_36322=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1140px;\">",
"  <div class=\"videoplayer\" h264=\"./images/EM/86068/Sh_ext_rotat_resist_video.mp4?title=Shoulder+external+rotation+exercise+with+resistance\" style=\"width:496px;height:288px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Shoulder external rotation exercise with resistance",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Active external rotation agains resistance is&nbsp;among the progression of exercises designed to strengthen the muscles involved in shoulder external rotation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Craig Parsons, MS, PT and the Physical Therapy Network.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_30_36322=[""].join("\n");
var outline_f35_30_36322=null;
var title_f35_30_36323="Treatment and prevention of Q fever";
var content_f35_30_36323=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment and prevention of Q fever",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/30/36323/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/30/36323/contributors\">",
"     Didier Raoult, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/30/36323/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/30/36323/contributors\">",
"     Daniel J Sexton, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/30/36323/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/30/36323/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?35/30/36323/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 9, 2011.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H20750956\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Q fever is a widespread zoonotic infection caused by the pathogen Coxiella burnetii that has both acute and chronic manifestations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36323/abstract/1\">",
"     1",
"    </a>",
"    ]. The designation Q fever (from Query) was made in 1935 following an outbreak of febrile illness in an abattoir in Queensland, Australia. The name remains apt, however, since many questions persist about this special organism and interesting infection. The disease is reportable in the United States and its agent, Coxiella burnetii, is a potential agent of bioterrorism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36323/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/46/22247?source=see_link\">",
"     \"Identifying and managing casualties of biological terrorism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The treatment and prevention of Q fever will be reviewed here. The clinical manifestations, diagnosis, microbiology and epidemiology of Q fever, and Q fever endocarditis, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/13/12502?source=see_link\">",
"     \"Clinical manifestations and diagnosis of Q fever\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/53/22357?source=see_link\">",
"     \"Microbiology and epidemiology of Q fever\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/57/15255?source=see_link\">",
"     \"Q fever endocarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26082803\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute Q fever is usually a mild disease that resolves spontaneously within two weeks. Thus, clinical evaluation of the efficacy of antibiotic therapy is difficult, and comparative studies are scarce. Consideration of therapy is warranted only in patients who are symptomatic. There is no value to treating patients after spontaneous cure of the disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26082810\">",
"    <span class=\"h2\">",
"     Medical therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A randomized trial comparing",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    with placebo showed a reduction in fever in the tetracycline group [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36323/abstract/3\">",
"     3",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"     Doxycycline",
"    </a>",
"    therapy is now recommended instead of tetracycline due to its improved pharmacokinetic properties and less frequent gastric intolerance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36323/abstract/3\">",
"     3",
"    </a>",
"    ]. In children, doxycycline should be prescribed when the disease is life threatening.",
"   </p>",
"   <p>",
"    Clinical trials have assessed the utility of antimicrobials such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/60/35776?source=see_link\">",
"     ofloxacin",
"    </a>",
"    (200 mg three times a day) and pefloxacin (400 mg twice a day), which have been used successfully. However, fluoroquinolones are contraindicated in children and pregnant women.",
"   </p>",
"   <p>",
"    Macrolides may represent a potential alternative in these populations. The efficacy of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    is in some dispute and it is now rarely used because there is a small risk of sudden cardiac death due to QT interval prolongation that is higher when other drugs metabolized by CYP3A4 are taken concurrently [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36323/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/55/23418?source=see_link\">",
"     \"Acquired long QT syndrome\"",
"    </a>",
"    .) Newer macrolides are more potent in vitro than erythromycin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36323/abstract/5\">",
"     5",
"    </a>",
"    ] and preliminary clinical studies showed that they may be of clinical use [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36323/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Anecdotal reports indicate that other antibiotics may be effective in the treatment of Q fever pneumonia, including",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/24/43396?source=see_link\">",
"     lincomycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/54/1897?source=see_link\">",
"     chloramphenicol",
"    </a>",
"    . Pneumonia again is usually a self-limited febrile illness; thus it is difficult to ascertain the clinical benefits of such antibiotic regimens. In vitro experiments have shown that cotrimoxazole may represent a potential alternative in patients for whom both tetracyclines and fluoroquinolones are contraindicated, but more clinical data are needed.",
"   </p>",
"   <p>",
"    The slow regression of symptoms in patients with Q fever hepatitis has led to anecdotal reports of possible benefit from the combination of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    and an antibiotic. However, this may favor evolution to chronic disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26082817\">",
"    <span class=\"h2\">",
"     Pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of the pregnant woman with Q fever infection is difficult because many of the drugs recommended above are contraindicated during pregnancy (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    , fluoroquinolones). We suggest the use of long-term cotrimoxazole therapy (320 mg",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/36/26182?source=see_link\">",
"     trimethoprim",
"    </a>",
"    and 1600 mg sulfamethoxazole for &ge;35 days) due to retrospective data suggesting a benefit of this approach in decreasing the risk of placentitis, obstetrical complications, and maternal chronic Q fever infection. Clinicians need to be aware that cotrimoxazole has only a bacteriostatic effect and carries a theoretical risk of inducing neonatal hyperbilirubinemia if used prior to delivery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26082824\">",
"    <span class=\"h2\">",
"     Q fever endocarditis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prolonged therapy (minimum of 18 months) with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/26/2471?source=see_link\">",
"     hydroxychloroquine",
"    </a>",
"    in combination with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    is the preferred treatment regimen for Q fever endocarditis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36323/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/57/15255?source=see_link&amp;anchor=H13#H13\">",
"     \"Q fever endocarditis\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26082831\">",
"    <span class=\"h2\">",
"     Recommendations",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"     Doxycycline",
"    </a>",
"    (100 mg PO twice a day for 14 days) is the recommended regimen for symptomatic acute Q fever. We suggest adding",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/26/2471?source=see_link\">",
"     hydroxychloroquine",
"    </a>",
"    to doxycycline (minimum duration 18 months) for the treatment of Q fever endocarditis and for 12 months for prophylaxis in patients with underlying valvular disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36323/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Fluoroquinolones are a reliable alternative to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    , particularly in patients with Q fever meningoencephalitis because they penetrate the cerebrospinal fluid. A macrolide or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    may be other alternatives. No reliable antibiotic regimen can be recommended for children.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26082838\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26082846\">",
"    <span class=\"h2\">",
"     Vaccination",
"    </span>",
"    &nbsp;&mdash;&nbsp;An effective whole-cell vaccine for Q fever has been developed in Australia and has protected humans in occupational settings. Efficacy of the vaccine was illustrated in a retrospective cohort survey of all employees at abattoirs between 1985 and 1990 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36323/abstract/7\">",
"     7",
"    </a>",
"    ]. Q fever occurred in 2 of 2555 (0.08 percent) vaccinated employees compared with 55 of 1365 (4 percent) unvaccinated employees. The two cases in vaccinated employees occurred within a few days of vaccination, before immunity had developed, and represented preexisting disease and not vaccine failure. However, this vaccine is not commercially available in the United States.",
"   </p>",
"   <p>",
"    An acellular vaccine (CMR) is available in the United States for individuals engaged in research with pregnant sheep or live C. burnetii [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36323/abstract/8\">",
"     8",
"    </a>",
"    ]. But, few data from human studies are available on this vaccine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36323/abstract/9,10\">",
"     9,10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Prior to vaccination, persons should have a skin test to determine of history of previous exposure to C. burnetii, as those with previous exposure should not receive the vaccination because of severe local reactions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26082853\">",
"    <span class=\"h2\">",
"     Other measures",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to vaccination, other measures used to prevent and control Q fever include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36323/abstract/11\">",
"     11",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Educate the public on sources of infection",
"     </li>",
"     <li>",
"      Dispose appropriately of placenta, birth products, fetal membranes, and aborted fetuses from facilities housing sheep and goats",
"     </li>",
"     <li>",
"      Follow biosafety protocols for bagging, autoclaving, and washing of laboratory clothing",
"     </li>",
"     <li>",
"      Consume only pasteurized milk and milk products",
"     </li>",
"     <li>",
"      Quarantine imported animals",
"     </li>",
"     <li>",
"      Locate holding facilities for sheep away from populated areas. Routinely test animals for C. burnetii antibodies.",
"     </li>",
"     <li>",
"      Exclude from high risk situations, unless immune, persons at high risk for developing chronic Q fever (eg, cardiac valvular disease, those with vascular grafts, pregnant women)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26083085\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute Q fever is usually a mild disease that resolves spontaneously within two weeks. If the patient has moderate to severe symptoms, we suggest",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"       doxycycline",
"      </a>",
"      (100 mg twice daily) for faster clinical resolution. (See",
"      <a class=\"local\" href=\"#H26082803\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The treatment of the pregnant woman with Q fever infection is difficult because many of the drugs recommended above are contraindicated during pregnancy (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"       doxycycline",
"      </a>",
"      , fluoroquinolones). We suggest the use of long-term cotrimoxazole therapy (320 mg",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/36/26182?source=see_link\">",
"       trimethoprim",
"      </a>",
"      and 1600 mg sulfamethoxazole for &ge;35 days) to decrease the risk of obstetrical complications. (See",
"      <a class=\"local\" href=\"#H26082817\">",
"       'Pregnancy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with Q fever endocarditis, we suggest dual therapy with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"       doxycycline",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/26/2471?source=see_link\">",
"       hydroxychloroquine",
"      </a>",
"      for a minimum duration of 18 months. (See",
"      <a class=\"local\" href=\"#H26082824\">",
"       'Q fever endocarditis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      An effective whole-cell vaccine for Q fever has been developed and has been demonstrated to be protective among humans at occupational risk for Q fever. (See",
"      <a class=\"local\" href=\"#H26082838\">",
"       'Prevention'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36323/abstract/1\">",
"      Raoult D, Marrie T. Q fever. Clin Infect Dis 1995; 20:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36323/abstract/2\">",
"      Raoult D, Marrie T, Mege J. Natural history and pathophysiology of Q fever. Lancet Infect Dis 2005; 5:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36323/abstract/3\">",
"      Fenollar F, Fournier PE, Carrieri MP, et al. Risks factors and prevention of Q fever endocarditis. Clin Infect Dis 2001; 33:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36323/abstract/4\">",
"      Ray WA, Murray KT, Meredith S, et al. Oral erythromycin and the risk of sudden death from cardiac causes. N Engl J Med 2004; 351:1089.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36323/abstract/5\">",
"      Boulos A, Rolain JM, Maurin M, Raoult D. Measurement of the antibiotic susceptibility of Coxiella burnetii using real time PCR. Int J Antimicrob Agents 2004; 23:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36323/abstract/6\">",
"      Gikas A, Kofteridis DP, Manios A, et al. Newer macrolides as empiric treatment for acute Q fever infection. Antimicrob Agents Chemother 2001; 45:3644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36323/abstract/7\">",
"      Ackland JR, Worswick DA, Marmion BP. Vaccine prophylaxis of Q fever. A follow-up study of the efficacy of Q-Vax (CSL) 1985-1990. Med J Aust 1994; 160:704.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36323/abstract/8\">",
"      Waag DM, England MJ, Tammariello RF, et al. Comparative efficacy and immunogenicity of Q fever chloroform:methanol residue (CMR) and phase I cellular (Q-Vax) vaccines in cynomolgus monkeys challenged by aerosol. Vaccine 2002; 20:2623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36323/abstract/9\">",
"      Fries LF, Waag DM, Williams JC. Safety and immunogenicity in human volunteers of a chloroform-methanol residue vaccine for Q fever. Infect Immun 1993; 61:1251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36323/abstract/10\">",
"      Parker NR, Barralet JH, Bell AM. Q fever. Lancet 2006; 367:679.",
"     </a>",
"    </li>",
"    <li>",
"     www.cdc.gov/ncidod/dvrd/qfever/index.htm#prevention1 (Accessed on March 03, 2006).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16219 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-210.101.131.232-6DA085BC69-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_30_36323=[""].join("\n");
var outline_f35_30_36323=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H26083085\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20750956\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26082803\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26082810\">",
"      Medical therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26082817\">",
"      Pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26082824\">",
"      Q fever endocarditis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26082831\">",
"      Recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26082838\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26082846\">",
"      Vaccination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26082853\">",
"      Other measures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26083085\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/55/23418?source=related_link\">",
"      Acquired long QT syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/13/12502?source=related_link\">",
"      Clinical manifestations and diagnosis of Q fever",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/46/22247?source=related_link\">",
"      Identifying and managing casualties of biological terrorism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/53/22357?source=related_link\">",
"      Microbiology and epidemiology of Q fever",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/57/15255?source=related_link\">",
"      Q fever endocarditis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_30_36324="Danaparoid: Patient drug information";
var content_f35_30_36324=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Danaparoid: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/18/41254?source=see_link\">",
"     see \"Danaparoid: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F156561\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Orgaran&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10028813\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700437",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       People who have had recent spinal anesthesia, epidurals, or spinal taps are more likely to have bleeding problems when started on this drug. This bleeding rarely happens, but can be very bad. Tell your doctor if you have had any spinal care. Do not take any other blood-thinner drugs including nonsteroidal anti-inflammatory drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705929",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor you use this drug before you get spinal anesthesia or a spinal treatment.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10028815\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691655",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to thin the blood so that clots will not form.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10028814\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701888",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to danaparoid or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701038",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to pork products, talk with the doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697143",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a sulfite allergy, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3503803",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Bleeding problems, high blood pressure, low platelet count, surgery on your brain, eyes, or ears, or ulcers.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10028819\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697780",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wear disease medical alert ID (identification).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697633",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell dentists, surgeons, and other doctors that you use this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697795",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may bleed more easily. Be careful and avoid injury. Use a soft toothbrush and an electric razor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697622",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before using products that have aspirin, blood thinners, garlic, ginseng, ginkgo, ibuprofen or like products, pain drugs, or vitamin E.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697760",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use care to stop injury and avoid falls or crashes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10028820\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698189",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Irritation where the shot is given.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697901",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Bleeding problems.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10028822\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698653",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A fall or crash when you hit your head. Talk with your doctor even if you feel fine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699117",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Weakness, numbness, or tingling.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10028817\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696001",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into the fatty part of the skin.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695245",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It may be given as a shot into a vein.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696360",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Your doctor may teach you how to give the shot.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Move the site where you give the shot with each shot.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696118",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Throw away needles in a needle/sharp disposal box and take the box back to your doctor when it is full.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10028818\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10028823\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10028824\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12353 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-D8E5382BBA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_30_36324=[""].join("\n");
var outline_f35_30_36324=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156561\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028813\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028815\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028814\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028819\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028820\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028822\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028817\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028818\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028823\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028824\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?40/18/41254?source=related_link\">",
"      Danaparoid: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_30_36325="Muscle cramps in dialysis patients";
var content_f35_30_36325=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Muscle cramps in dialysis patients",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/30/36325/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/30/36325/contributors\">",
"     Jean L Holley, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/30/36325/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/30/36325/contributors\">",
"     Jeffrey S Berns, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/30/36325/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/30/36325/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?35/30/36325/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 25, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Muscle cramps are a common complication of hemodialysis treatments, occurring in 33 to 86 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36325/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]; they often result in the early termination of a hemodialysis session and are therefore a significant cause of underdialysis. The exact etiology of cramps in dialysis patients is unknown. Since cramps tend to occur most frequently near the end of hemodialysis treatments, changes in plasma osmolality",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    extracellular fluid volume have been implicated.",
"   </p>",
"   <p>",
"    The pathophysiology, clinical features, and treatment of cramps occurring in association with dialysis will be reviewed here. A general overview of muscle cramps and other acute complications of dialysis are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/38/4711?source=see_link\">",
"     \"Nocturnal leg cramps\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/9/8343?source=see_link\">",
"     \"Acute complications during hemodialysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;A cramp is a prolonged involuntary muscle contraction that occurs in a muscle which voluntarily contracts when it is already in its most shortened position [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36325/abstract/3\">",
"     3",
"    </a>",
"    ]. The increased frequency of cramps at rest and during the night may be caused by the placement (by the plantar-flexed foot) of the calf and ventral foot muscles in the most shortened and vulnerable position during sleep [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36325/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Electromyography reveals that cramps begin with fasciculations in various muscle parts that subsequently progress to high frequency action potentials. The origin of a cramp is therefore neural, not muscular [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36325/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The etiology of hemodialysis-associated cramps may include contributions from one or more of the following factors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36325/abstract/1,3,4\">",
"     1,3,4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Plasma volume contraction",
"     </li>",
"     <li>",
"      Hyponatremia",
"     </li>",
"     <li>",
"      Tissue hypoxia",
"     </li>",
"     <li>",
"      Hypomagnesemia",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?21/16/21766?source=see_link\">",
"       Carnitine",
"      </a>",
"      deficiency",
"     </li>",
"     <li>",
"      Elevated serum leptin levels",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Of these, volume contraction and hyponatremia, either alone or in combination, are the most likely underlying causative factors; this hypothesis is supported in part by the reduction in the frequency of cramping in association with sodium modeling or ramping, a technique whereby gradual decrements in dialysate sodium concentration occur over the course of a hemodialysis treatment. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/32/31240?source=see_link\">",
"     \"Hemodynamic instability during hemodialysis: Overview\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Leptin, a middle molecule, is able to affect neuronal activity and therefore may be implicated in the development of cramps. Hemodialysis-related cramps may be associated with older age and increasing tertiles of serum leptin levels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36325/abstract/4\">",
"     4",
"    </a>",
"    ]. Additional study of this phenomenon is needed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cramps occurring with dialysis treatment most commonly involve the muscles of the lower extremity, but the muscles of the hands, arms, and abdomen may also be affected. Cramps occur more often in older, nondiabetic, anxious patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36325/abstract/1,3\">",
"     1,3",
"    </a>",
"    ]. Low PTH values and high serum creatine phosphokinase concentrations are also more frequent among patients with dialysis-associated cramps [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36325/abstract/5,6\">",
"     5,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Multiple factors related to the dialysis procedure enhance the risk of cramps. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Solute concentrations of the dialysate bath, particularly low concentrations of sodium. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/32/31240?source=see_link\">",
"       \"Hemodynamic instability during hemodialysis: Overview\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/25/33174?source=see_link\">",
"       \"Renal replacement therapy (dialysis) in acute kidney injury (acute renal failure): Metabolic and hemodynamic considerations\"",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H4\">",
"       'Treatment'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Increased ultrafiltration required to remove excessive fluid ingested in the interdialytic period.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment is directed at two goals: reducing the frequency of cramps and relieving symptoms when they occur.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Interventions to reduce the frequency of cramps",
"    </span>",
"    &nbsp;&mdash;&nbsp;The minimization of interdialytic weight gains, the prevention of dialysis-associated hypotension, the use of high concentrations of sodium in the dialysate,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/16/21766?source=see_link\">",
"     carnitine",
"    </a>",
"    supplementation, and the administration of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/46/15080?source=see_link\">",
"     quinine",
"    </a>",
"    may all reduce the frequency of dialysis-associated cramps.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Minimize interdialytic weight gains",
"    </span>",
"    &nbsp;&mdash;&nbsp;Minimizing interdialytic weight gains will avoid plasma volume contraction and hypoosmolality that occurs with high rates of ultrafiltration required to achieve the patient's dry weight during a brief dialysis session; such measures may prevent or at least reduce the frequency of dialysis-associated cramps.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Prevention of dialysis-associated hypotension",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since dialysis-associated hypotension may precede or accompany dialysis-associated cramps, measures which prevent volume depletion and hypotension may also be effective in reducing cramps. Such interventions include sequential",
"    <span class=\"nowrap\">",
"     ultrafiltration/dialysis,",
"    </span>",
"    and sodium ramping or modeling. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/32/31240?source=see_link\">",
"     \"Hemodynamic instability during hemodialysis: Overview\"",
"    </a>",
"    .) Infusions of hypertonic saline,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/42/3752?source=see_link\">",
"     mannitol",
"    </a>",
"    , or dextrose may also prevent hypotension during a dialysis session (see below) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36325/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Higher dialysate sodium concentration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Higher dialysate sodium concentration and oral salt loading reduce the incidence of hemodialysis-associated cramps. However, the increased thirst and interdialytic fluid gains associated with higher dialysate sodium subsequently led to the development of sodium modeling or ramping.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Carnitine supplementation",
"    </span>",
"    &nbsp;&mdash;&nbsp;A deficiency of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/16/21766?source=see_link\">",
"     carnitine",
"    </a>",
"    may enhance the risk of cramps, a problem that can be corrected by dietary supplementation. Carnitine may be administered intravenously (20",
"    <span class=\"nowrap\">",
"     mg/kg)",
"    </span>",
"    after hemodialysis or orally (330 mg two to three times per day). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/55/14200?source=see_link\">",
"     \"Carnitine metabolism in renal disease and dialysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Quinine sulfate",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite limited and varying results in clinical trials,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/46/15080?source=see_link\">",
"     quinine",
"    </a>",
"    sulfate has been prescribed for cramps for over four decades [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36325/abstract/1,3\">",
"     1,3",
"    </a>",
"    ]. One double-blind placebo controlled trial of nine hemodialysis patients found that the administration of quinine sulfate at the start of the hemodialysis session reduced the frequency of cramps [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36325/abstract/7\">",
"     7",
"    </a>",
"    ]. These beneficial results may be caused by decreased excitability of the motor end-plate to nerve stimulation and increased muscle refractory period, thereby preventing prolonged involuntary muscle contraction.",
"   </p>",
"   <p>",
"    However, the FDA has issued a warning stating that the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/46/15080?source=see_link\">",
"     quinine",
"    </a>",
"    for the unapproved",
"    <span class=\"nowrap\">",
"     prevention/treatment",
"    </span>",
"    of leg cramps is not justified, given that this agent is associated with severe adverse events. These include cardiac arrhythmias, severe allergic reactions, and HUS-TTP. Quinine should therefore NOT be administered in this setting. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/61/36826?source=see_link&amp;anchor=H21#H21\">",
"     \"Causes of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults\", section on 'Quinine'",
"    </a>",
"    .) Further information is available at",
"    <a class=\"external\" href=\"file://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/default.htm\">",
"     www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/default.htm#Quinine",
"    </a>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Vitamin E",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vitamin E may be effective for the prevention of hemodialysis-associated cramps. In a randomized controlled double-blind study of 29 chronic dialysis patients, vitamin E (400 IU) and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/46/15080?source=see_link\">",
"     quinine",
"    </a>",
"    sulfate (325 mg) were equally effective and significantly more beneficial than placebo in reducing the number and severity of nocturnal cramps [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36325/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A second placebo-controlled, double-blind study found that the short-term administration of the combination of vitamin E and C reduced cramping, with vitamin E and C alone both being relatively less effective [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36325/abstract/9\">",
"     9",
"    </a>",
"    ]. Another study of 19 patients reported a 68 percent reduction in cramps when hemodialysis patients were given vitamin E 400 IU [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36325/abstract/10\">",
"     10",
"    </a>",
"    ]. It is unclear whether such therapy is safe and effective when administered chronically.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Others",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of additional medications",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    agents have been used to prevent leg cramps. They are of variable efficacy and have rarely been tested in controlled trials in either dialysis or non-ESRD populations. These include short acting benzodiazepines (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/50/10022?source=see_link\">",
"     oxazepam",
"    </a>",
"    ),",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/5/12377?source=see_link\">",
"     nifedipine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/48/35594?source=see_link\">",
"     phenytoin",
"    </a>",
"    , creatine monohydrate,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/30/27112?source=see_link\">",
"     amitriptyline",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/19/19768?source=see_link\">",
"     gabapentin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36325/abstract/1,3,11,12\">",
"     1,3,11,12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A preliminary study of five patients demonstrated the effectiveness of a traditional herbal medicine called shao-yao-gan-cao-tang (Japanese name: Shakuyaku-kanzo-to), which is equal parts paeony and licorice roots, in reducing cramps in hemodialysis patients and, in vitro, inhibiting skeletal muscle contraction in rats [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36325/abstract/13\">",
"     13",
"    </a>",
"    ]. Controlled trials in larger numbers of patients are needed to better assess its efficacy and safety.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Approach to treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;A reasonable clinical approach to the patient with frequent dialysis-associated cramps is to minimize excessive interdialytic fluid gains while reevaluating the patient's appropriate desired weight. An increase in the frequency of hemodialysis may be helpful. Sodium modeling on dialysis should be tried with or without prophylactic measures, such as vitamin E, while paying close attention to assessment of \"dry weight,\" as interdialytic weight gains may occur with sodium modeling. Switching dialysis modalities to peritoneal dialysis may also be considered.",
"   </p>",
"   <p>",
"    As with the non-dialysis population, measures to prevent nocturnal leg cramps may be effective and, therefore, encouraged in dialysis patients complaining of frequent nocturnal leg cramps [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36325/abstract/2\">",
"     2",
"    </a>",
"    ]. Measures may include riding a stationary bicycle for a few minutes before retiring or performing stretching exercises (such as holding for 10 to 20 seconds and repeating three to five times in succession four times daily for one week, then twice daily in the evening and again before retiring).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Treatment of cramps during hemodialysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite the possible preventive measures, cramping while on dialysis remains a common problem, particularly in the subset of patients with large interdialytic fluid gains. The reversal of low blood pressure should be the first priority in the management of the patient with muscle cramps in association with hypotension. If necessary, ultrafiltration should either be stopped or the rate decreased, the patient should be placed in the Trendelenburg position, and the blood flow rate should be reduced. The clinician must also be aware that hypotension may be a manifestation of a potentially serious medical condition requiring immediate attention. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/32/31240?source=see_link\">",
"     \"Hemodynamic instability during hemodialysis: Overview\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Further measures to treat dialysis-associated cramps are generally aimed at increasing plasma osmolality.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Hypertonic saline versus dextrose",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a double-blind, placebo-controlled study of 20 patients with 100 episodes of muscle cramps, hypertonic saline and 50 percent dextrose were equally effective for the relief of cramps [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36325/abstract/14\">",
"     14",
"    </a>",
"    ]. The investigators suggested that hypertonic saline may be preferred among those with volume depletion. In most cases, however, hypertonic dextrose may be the better therapeutic option (in nondiabetic patients) because it does not adversely affect salt and water balance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Mannitol",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/42/3752?source=see_link\">",
"     Mannitol",
"    </a>",
"    infusion, given at a dose of 12.5 to 37.5",
"    <span class=\"nowrap\">",
"     g/dialysis,",
"    </span>",
"    is also effective in the management of dialysis-associated cramps [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36325/abstract/1\">",
"     1",
"    </a>",
"    ]. However, mannitol may accumulate in the extracellular space, particularly when administered near the end of a hemodialysis session.",
"   </p>",
"   <p>",
"    Thus, hypertonic saline or dextrose are preferred for the treatment of dialysis-associated cramps occurring near the end of dialysis treatments [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36325/abstract/1\">",
"     1",
"    </a>",
"    ]. In addition, local massage of the affected muscle and the application of moist heat may provide some comfort.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?15/9/15506?source=see_link\">",
"       \"Patient information: Nocturnal (nighttime) leg cramps (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14812236\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Muscle cramps are a common complication of hemodialysis treatments, occurring in 33 to 86 percent of patients; they often result in the early termination of a hemodialysis session and are therefore a significant cause of underdialysis. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Changes in plasma osmolality",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      extracellular fluid volume may cause muscle cramps. Minimizing intradialytic weight gains, increasing dialysis treatment time to reduce ultrafiltration rate, using sodium modeling, and avoiding hypotension may reduce cramps during dialysis treatments. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pathophysiology'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5\">",
"       'Interventions to reduce the frequency of cramps'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cramps occurring during dialysis treatment may be treated with administration of hypertonic saline or dextrose and local heat and massage of the affected muscle. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Treatment of cramps during hemodialysis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Prophylactic treatment of cramps may include a trial of vitamin E 400 IU QHS. Although frequently prescribed, benzodiazepines,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/19/19768?source=see_link\">",
"       gabapentin",
"      </a>",
"      , and other medications have not been evaluated in clinical trials. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Vitamin E'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H12\">",
"       'Others'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The FDA has issued a warning stating that the use of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/46/15080?source=see_link\">",
"       quinine",
"      </a>",
"      for the unapproved",
"      <span class=\"nowrap\">",
"       prevention/treatment",
"      </span>",
"      of leg cramps is not justified, given that this agent is associated with severe adverse events. Quinine should therefore NOT be administered in this setting. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Quinine sulfate'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?35/61/36826?source=see_link&amp;anchor=H21#H21\">",
"       \"Causes of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults\", section on 'Quinine'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36325/abstract/1\">",
"      Canzanello, VJ, Burkart, JM. Hemodialysis-associated muscle cramps. Semin Dial 1992; 5:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36325/abstract/2\">",
"      Kobrin SM, Berns JS. Quinine--a tonic too bitter for hemodialysis-associated muscle cramps? Semin Dial 2007; 20:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36325/abstract/3\">",
"      McGee SR. Muscle cramps. Arch Intern Med 1990; 150:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36325/abstract/4\">",
"      Hung CY, Chen YL, Chen CS, et al. Association of leptin with hemodialysis-related muscle cramps: a cross-sectional study. Blood Purif 2009; 27:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36325/abstract/5\">",
"      Noordzij M, Boeschoten EW, Bos WJ, et al. Disturbed mineral metabolism is associated with muscle and skin complaints in a prospective cohort of dialysis patients. Nephrol Dial Transplant 2007; 22:2944.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36325/abstract/6\">",
"      Hernando P, Caramelo C, L&oacute;pez Garcia D, Hernando L. Muscle cramps: a cause of elevated creatine kinase levels in hemodialysis patients. Nephron 1990; 55:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36325/abstract/7\">",
"      Kaji DM, Ackad A, Nottage WG, Stein RM. Prevention of muscle cramps in haemodialysis patients by quinine sulphate. Lancet 1976; 2:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36325/abstract/8\">",
"      Roca AO, Jarjoura D, Blend D, et al. Dialysis leg cramps. Efficacy of quinine versus vitamin E. ASAIO J 1992; 38:M481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36325/abstract/9\">",
"      Khajehdehi P, Mojerlou M, Behzadi S, Rais-Jalali GA. A randomized, double-blind, placebo-controlled trial of supplementary vitamins E, C and their combination for treatment of haemodialysis cramps. Nephrol Dial Transplant 2001; 16:1448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36325/abstract/10\">",
"      El-Hennawy AS, Zaib S. A selected controlled trial of supplementary vitamin E for treatment of muscle cramps in hemodialysis patients. Am J Ther 2010; 17:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36325/abstract/11\">",
"      Chang CT, Wu CH, Yang CW, et al. Creatine monohydrate treatment alleviates muscle cramps associated with haemodialysis. Nephrol Dial Transplant 2002; 17:1978.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36325/abstract/12\">",
"      Serrao M, Rossi P, Cardinali P, et al. Gabapentin treatment for muscle cramps: an open-label trial. Clin Neuropharmacol 2000; 23:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36325/abstract/13\">",
"      Hinoshita F, Ogura Y, Suzuki Y, et al. Effect of orally administered shao-yao-gan-cao-tang (Shakuyaku-kanzo-to) on muscle cramps in maintenance hemodialysis patients: a preliminary study. Am J Chin Med 2003; 31:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36325/abstract/14\">",
"      Sherman RA, Goodling KA, Eisinger RP. Acute therapy of hemodialysis-related muscle cramps. Am J Kidney Dis 1982; 2:287.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1886 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-89.32.226.102-5846377118-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_30_36325=[""].join("\n");
var outline_f35_30_36325=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H14812236\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Interventions to reduce the frequency of cramps",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Minimize interdialytic weight gains",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Prevention of dialysis-associated hypotension",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Higher dialysate sodium concentration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Carnitine supplementation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Quinine sulfate",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Vitamin E",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Others",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Approach to treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Treatment of cramps during hemodialysis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Hypertonic saline versus dextrose",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Mannitol",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14812236\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/9/8343?source=related_link\">",
"      Acute complications during hemodialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/55/14200?source=related_link\">",
"      Carnitine metabolism in renal disease and dialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/61/36826?source=related_link\">",
"      Causes of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/32/31240?source=related_link\">",
"      Hemodynamic instability during hemodialysis: Overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/38/4711?source=related_link\">",
"      Nocturnal leg cramps",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?15/9/15506?source=related_link\">",
"      Patient information: Nocturnal (nighttime) leg cramps (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/25/33174?source=related_link\">",
"      Renal replacement therapy (dialysis) in acute kidney injury (acute renal failure): Metabolic and hemodynamic considerations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_30_36326="Red blood cell survival: Normal values and measurement";
var content_f35_30_36326=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Red blood cell survival: Normal values and measurement",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/30/36326/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/30/36326/contributors\">",
"     Stanley L Schrier, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/30/36326/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/30/36326/contributors\">",
"     William C Mentzer, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/30/36326/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/30/36326/contributors\">",
"     Stephen A Landaw, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?35/30/36326/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 19, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;During its approximately four-month lifespan, the human red blood cell (RBC) travels approximately 300 miles, making about 170,000 circuits through the heart, enduring cycles of osmotic swelling and shrinkage while traveling through the kidneys and lungs, and an equal number of deformations while passing through capillary beds [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36326/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. It has been speculated that accumulated damage to the RBC, especially to its membrane, renders the aging RBC unfit to circulate, leading to its destruction, via mechanisms which are poorly understood.",
"   </p>",
"   <p>",
"    The normal time of RBC senescent death in adults is approximately 110 to 120 days. Hemolysis is usually defined as a shortened survival of circulating red blood cells to a value of less than 100 days.",
"   </p>",
"   <p>",
"    This topic will review the mechanisms of normal RBC destruction and the methods used to measure RBC survival, which may be used in the evaluation of patients with suspected hemolysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36326/abstract/3\">",
"     3",
"    </a>",
"    ]. Approaches to the patient with hemolytic anemia and with anemia in general are presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/3/18489?source=see_link\">",
"     \"Approach to the diagnosis of hemolytic anemia in the adult\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/46/29418?source=see_link\">",
"     \"Approach to the adult patient with anemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MECHANISMS OF RBC DESTRUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In normal subjects, RBC are destroyed by two different mechanisms, one related to increasing RBC age (senescence) and the other to a random process which destroys intact RBCs, or portions of an intact RBC (eg, vesicles) independent of their age (random hemolysis). These two processes may not be fully independent of one another [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36326/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Senescence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Virtually all RBCs in normal subjects die of processes associated with \"wear and tear\" associated with prolonged circulation within the intravascular space. These processes include, but are not limited to [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36326/abstract/5\">",
"     5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Shearing forces across high pressure areas in the circulation, such as the aortic valve.",
"     </li>",
"     <li>",
"      Multiple deformations subsequent to passage through capillaries and splenic cords (see below).",
"     </li>",
"     <li>",
"      Oxidative challenges to the RBC from transported oxygen molecules and circulating oxidant molecules. As an example, age- and in vitro storage-dependent oxidation of Band 3, the major membrane transmembrane protein, increases the affinity of normally circulating anti-band 3 antibodies [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/30/36326/abstract/6,7\">",
"       6,7",
"      </a>",
"      ]. Such antibodies, when membrane bound, lead to partial complement activation on the red cell surface, which may be associated with decreased red cell deformability [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/30/36326/abstract/8\">",
"       8",
"      </a>",
"      ]. These, in turn, are recognized by complement receptors on macrophages and removed from the circulation.",
"     </li>",
"     <li>",
"      Multiple cycles of osmotic swelling and shrinkage when passing through the lung and kidneys [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/30/36326/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A slow decline in RBC enzyme activity with advancing age, since the initial endowment of a RBC cannot be replaced during its lifespan.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Senescent death takes place mainly in the spleen, within the cords of Billroth. These unique vascular channels end blindly, unlike others in the body. The only way for an RBC, which has a diameter of 7 to 8 microns, to escape from these cords and return to the general circulation is to deform sufficiently to pass through 2 to 4 micron slits in the walls of the cords (",
"    <a class=\"graphic graphic_picture graphicRef53105 \" href=\"mobipreview.htm?25/59/26544\">",
"     picture 1",
"    </a>",
"    ). Cells that negotiate this process survive; those that cannot find themselves in a hostile environment, surrounded by cells of the monocyte-macrophage system. It is at this stage that senescent signals on the RBC membrane are detected by phagocytic cells. Aging cells that fail this quality control step lose part or all of their membrane, with approximately three million RBCs being totally destroyed per second through these processes.",
"   </p>",
"   <p>",
"    Senescent death of RBCs can be approximated mathematically by a Gaussian distribution (the \"bell shaped\" curve), with a mean time of senescent death (mean potential RBC lifespan) in normal adults of approximately 120 days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36326/abstract/5,10-12\">",
"     5,10-12",
"    </a>",
"    ]. Senescence signals most likely arise from alterations in membrane proteins on the surface of aging RBC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36326/abstract/13\">",
"     13",
"    </a>",
"    ]. Candidate processes include exposure of cryptic alpha-galactosyl residues or phosphatidylserine on the RBC surface, alterations in the anion transporter (band 3) protein, altered expression of CD45 or CD47 on the red cell surface, increased membrane immunoglobulin, and accumulated damage from the effects of reactive oxygen species [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36326/abstract/14-21\">",
"     14-21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Random RBC death",
"    </span>",
"    &nbsp;&mdash;&nbsp;The rate of random or age-independent RBC destruction is quite low in normal subjects, in the range of less than 0.05 to 0.5 percent per day; this value can be appreciably increased in hemolytic states, especially when destruction in an enlarged spleen is part of the hemolytic process [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36326/abstract/10\">",
"     10",
"    </a>",
"    ]. It has been estimated that, in healthy individuals, up to 20 percent of the RBC's content of hemoglobin is lost during its lifespan secondary to loss of membrane-bound hemoglobin by the process of vesiculation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36326/abstract/4,22\">",
"     4,22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When the rate of random hemolysis is sufficiently high, RBCs may die solely from this exponential process, since few survive long enough to die of age-related changes. As an example, when the rate of random hemolysis is 0.5 percent per day, the chance that a red cell will survive to an age of 100 days is 61 percent. On the other hand, the chance of survival to 100 days falls below 1 percent when the rate of random hemolysis is &ge;5 percent per day.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     DETERMINATION OF RBC LIFESPAN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Three general methods are available for accurate determination of the RBC lifespan: random label and cohort label RBC survival studies, and quantitative erythrokinetics. Only the first of these is used to any extent in clinical practice, since they are extremely time-consuming, expensive, and unnecessary in the vast majority of patients. Less accurate but clinically useful estimates of RBC survival can be obtained from easily available information, such as the reticulocyte percentage and hematocrit (HCT).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Estimation of red cell survival from the reticulocyte count",
"    </span>",
"    &nbsp;&mdash;&nbsp;In order to maintain a constant RBC mass, the bone marrow must produce as many new RBCs (reticulocytes) per day as are being destroyed. At a mean RBC survival of 100 days, 1 percent of the RBC mass is destroyed and replaced each day. This is the RBC turnover rate, the reciprocal of RBC survival:",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp;RBC turnover rate",
"    <span class=\"nowrap\">",
"     (percent/day)",
"    </span>",
"    &nbsp; = &nbsp; 100 &nbsp;&divide; &nbsp;RBC survival (days)",
"   </p>",
"   <p>",
"    Thus, reticulocytes, which survive in the circulation in normal subjects for one day, represent approximately 1 percent of circulating RBCs. The actual lifespan of the reticulocyte is about four days, three of which are spent in the marrow. It is possible, under steady state conditions in which the secretion and response to erythropoietin are intact, to estimate RBC survival from a knowledge of the reticulocyte percentage, the hematocrit, and the reticulocyte lifespan (RLS):",
"   </p>",
"   <p>",
"    &nbsp; RBC survival (days) &nbsp;&asymp; &nbsp;100 &nbsp;&divide; &nbsp;[Reticulocytes (percent) &nbsp;&divide; &nbsp;RLS (days)]",
"   </p>",
"   <p>",
"    For this calculation, the RLS equals 1.0, 1.5, 2.0, and 2.5 days at hematocrits of 45, 35, 25, and 15 percent, respectively (",
"    <a class=\"graphic graphic_figure graphicRef61552 \" href=\"mobipreview.htm?32/34/33325\">",
"     figure 1",
"    </a>",
"    ). The reason for this prolongation in RLS in the circulation is that, with worsening anemia and increased erythropoietin stimulation, reticulocytes leave the bone marrow at an earlier stage in their maturation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/46/29418?source=see_link\">",
"     \"Approach to the adult patient with anemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The clinical utility of this approach can be appreciated by the following example. An adult with sickle cell anemia has a HCT of 27 percent and a reticulocyte count of 15 percent. Using the above formulas, the estimated RBC survival is 13 days (100 &divide; [15 &divide; 2]) and the rate of RBC turnover is 7.5 percent per day (100 &divide; 13).",
"   </p>",
"   <p>",
"    This turnover rate (7.5 percent per day) exceeds the adult marrow's maximum sustainable capacity (5 percent per day compared with 1 percent per day in normals). Thus, this patient's marrow can only deliver 67 percent (5 &divide; 7.5) of the needed RBCs, resulting in a HCT of 27 percent (67 percent of the normal value of 40 percent). If this patient's bone marrow is suppressed, such as during an intercurrent infection, an even lower HCT will rapidly ensue [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36326/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As an example, if this subject's RBC production were 100 percent suppressed, as may occur following parvovirus B19 infection, the rate of fall of the patient's HCT will be 7.5 percent per day, since no new RBCs would be entering into the circulation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/54/22377?source=see_link\">",
"     \"Clinical manifestations and pathogenesis of human parvovirus B19 infection\"",
"    </a>",
"    .) After seven days, during which time the patient's reticulocytes will have vanished from the circulation, the HCT will have fallen to approximately 15 percent, with obvious severe clinical consequences.",
"   </p>",
"   <p>",
"    The outcome is different when transient erythroid aplasia occurs in a hematologically normal subject (RBC survival of 120 days, reticulocyte count of 1 percent, HCT of 45 percent). In this patient, the RBC turnover rate is 0.8 percent per day (100 &divide; 120). After 7 days of erythroid aplasia, the HCT will fall to 94 percent of its initial value, to a level of 42 percent, which will not be noticeable.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Random label red blood cell survival method",
"    </span>",
"    &nbsp;&mdash;&nbsp;In this method, a sample of circulating RBC, containing cells of all ages, is labeled in vitro and reinfused into the patient. Blood samples are removed periodically, and survival is measured from the resulting plot of RBC activity versus time after injection. Two major parameters can be obtained: the RBC half-time, and the time of RBC senescence.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Red blood cell half-time",
"    </span>",
"    &nbsp;&mdash;&nbsp;The RBC half-time is the time at which activity in the patient's circulating RBCs falls to one-half of the initial (or 24-hour) value. For a \"perfect\" label, this occurs at 55 to 60 days (ie, the normal RBC lifespan divided by two). However, the most commonly used isotope (Chromium-51, or 51Cr) is not a perfect label, and elutes from the RBC at a rate of approximately 1 percent per day [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36326/abstract/24\">",
"     24",
"    </a>",
"    ]. Thus, the observed half-time is shorter than the theoretical value, in the range of 28 to 37 days for healthy adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36326/abstract/24,25\">",
"     24,25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While corrections can be made to adjust for label elution, the Cr-51 half-time can be used directly as a semiquantitative measure of RBC lifespan. Its advantage over the cohort method described below is that an estimate of RBC survival can be obtained in less than two weeks.",
"   </p>",
"   <p>",
"    When the use of radioactive isotopes is not appropriate, as in the neonate, children, or pregnant women, RBCs can be labeled in vitro with",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?9/25/9618?source=see_link\">",
"     biotin",
"    </a>",
"    , and activity monitored by using fluorescein-labeled avidin and flow cytometry [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36326/abstract/25-29\">",
"     25-29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Time of red blood cell senescence",
"    </span>",
"    &nbsp;&mdash;&nbsp;The time of RBC senescence can be measured by sampling the patient's blood until activity is no longer detected in circulating RBC. The time when the last labeled RBC has left the circulation is called the \"extinction time\", and represents the time of death, by senescence, of labeled reticulocytes present in the original sample. This value is equal to the mean potential lifespan of the subject's RBC, and ranges from 100 to 132 days in normal healthy adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36326/abstract/24,25,28\">",
"     24,25,28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Similar reasoning applies to the determination of the lifespan of fetal red cells transfused into the maternal circulation via an unplanned, large volume fetomaternal hemorrhage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36326/abstract/30\">",
"     30",
"    </a>",
"    ]. In one report, fetal red cells, as measured by blood type-based flow cytometry, remained within the maternal circulation for 15 to 17 weeks (105 to 119 days) following delivery, suggesting a lifespan similar to that of adult red cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36326/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Sites of red blood cell destruction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chromium-51 studies can also be used to detect the sites of RBC destruction, by placing probes over the liver and spleen. This technique is used to document the presence of dominant splenic (rather than hepatic) sequestration in patients with hemolytic anemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36326/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. The degree of splenic sequestration has been used to help predict whether splenectomy would be beneficial; however, no method permits the setting of strict guidelines that are fully reliable in this regard [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36326/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Cohort labeling technique",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cohort labeling technique involves the administration of a radioactive precursor of hemoglobin, such as C-14 labeled glycine; the isotope is rapidly incorporated into RBC precursors, producing a group (or cohort) of labeled RBC of defined age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36326/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. Their survival can be determined by repeated blood sampling. The rate of random hemolysis and the mean potential RBC lifespan can be obtained via analysis of the resulting curves of activity versus time after isotope injection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36326/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A serious drawback to this technique is the need to continue the study for at least four months to obtain valid estimates for the mean potential lifespan. During this time, the patient must be in a steady-state condition. Such studies are no longer generally available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Quantitative erythrokinetic studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Erythropoiesis can be quantitated following the intravenous injection of labeled transferrin-bound iron (Fe-59) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36326/abstract/35\">",
"     35",
"    </a>",
"    ]. Using appropriate kinetic models, rates of erythropoiesis and estimates of RBC survival can be obtained [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36326/abstract/35-37\">",
"     35-37",
"    </a>",
"    ]. These studies can also be combined with placement of probes over the various organs of interest (sacral bone marrow, spleen and liver) and information can be obtained concerning the presence or absence of ineffective erythropoiesis, hepatic and splenic erythropoiesis, and splenic sequestration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36326/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Endogenous carbon monoxide production",
"    </span>",
"    &nbsp;&mdash;&nbsp;Estimates of RBC survival can be obtained from the rate of endogenous production of carbon monoxide, taking advantage of two salient facts:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Under the action of heme oxygenase, one mole of CO and one mole of the bilirubin precursor biliverdin are produced in vivo for each mole of heme degraded within the body [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/30/36326/abstract/38,39\">",
"       38,39",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The CO thus produced is rapidly and quantitatively exhaled in the breath, where its production rate can be quantitated.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    With appropriate corrections for CO arising from non-hemoglobin heme sources (eg, cytochromes), RBC survival estimates can be made which are quite similar to those obtained using more laborious isotope-based techniques [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36326/abstract/40,41\">",
"     40,41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19582868\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The human red blood cell (RBC), a cell without a nucleus and with limited regenerative properties, travels approximately 300 miles, making about 170,000 circuits through the heart, enduring cycles of osmotic swelling and shrinkage while traveling through the kidneys and lungs, and an equal number of deformations while passing through capillary beds.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19582914\">",
"    <span class=\"h2\">",
"     Normal RBC lifespan",
"    </span>",
"    &nbsp;&mdash;&nbsp;The survival of RBC in adults is approximately 110 to 120 days. There are no clinical settings in which the survival of red cells is significantly prolonged. Under steady state conditions, red cell lifespan can be estimated from the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Reticulocyte percentage. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Estimation of red cell survival from the reticulocyte count'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Use of a random or cohort red cell labeling technique. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Random label red blood cell survival method'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11\">",
"       'Cohort labeling technique'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Determination of iron, bilirubin, or carbon monoxide turnover. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Quantitative erythrokinetic studies'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H13\">",
"       'Endogenous carbon monoxide production'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19583006\">",
"    <span class=\"h2\">",
"     Modes of RBC destruction",
"    </span>",
"    &nbsp;&mdash;&nbsp;RBC are destroyed by two different mechanisms. These two processes may not be fully independent of one another. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Mechanisms of RBC destruction'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Senescence",
"      </strong>",
"      &mdash; Destruction related to increasing RBC age. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Senescence'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <strong>",
"       Random hemolysis",
"      </strong>",
"      &mdash; Random hemolysis is due to processes which destroy intact RBCs, or portions of an intact RBC (eg, vesicles) independent of their age. Most clinical conditions associated with shortened RBC lifespan are of this type. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Random RBC death'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/3/18489?source=see_link&amp;anchor=H10#H10\">",
"       \"Approach to the diagnosis of hemolytic anemia in the adult\", section on 'Causes of hemolysis'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36326/abstract/1\">",
"      ALLISON AC. Turnovers of erythrocytes and plasma proteins in mammals. Nature 1960; 188:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36326/abstract/2\">",
"      Lux SE. Spectrin-actin membrane skeleton of normal and abnormal red blood cells. Semin Hematol 1979; 16:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36326/abstract/3\">",
"      Franco RS. The measurement and importance of red cell survival. Am J Hematol 2009; 84:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36326/abstract/4\">",
"      Willekens FL, Werre JM, Groenen-D&ouml;pp YA, et al. Erythrocyte vesiculation: a self-protective mechanism? Br J Haematol 2008; 141:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36326/abstract/5\">",
"      Landaw SA. Factors that accelerate or retard red blood cell senescence. Blood Cells 1988; 14:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36326/abstract/6\">",
"      Arese P, Turrini F, Schwarzer E. Band 3/complement-mediated recognition and removal of normally senescent and pathological human erythrocytes. Cell Physiol Biochem 2005; 16:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36326/abstract/7\">",
"      Kriebardis AG, Antonelou MH, Stamoulis KE, et al. Storage-dependent remodeling of the red blood cell membrane is associated with increased immunoglobulin G binding, lipid raft rearrangement, and caspase activation. Transfusion 2007; 47:1212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36326/abstract/8\">",
"      Karnchanaphanurach P, Mirchev R, Ghiran I, et al. C3b deposition on human erythrocytes induces the formation of a membrane skeleton-linked protein complex. J Clin Invest 2009; 119:788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36326/abstract/9\">",
"      Li CK, Li EK. Mechanical fatigue as a possible determinant of in vivo longevity of red blood cells. IEEE Trans Biomed Eng 1983; 30:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36326/abstract/10\">",
"      EADIE GS, BROWN IW Jr. The potential life span and ultimate survival of fresh red blood cells in normal healthy recipients as studied by simultaneous Cr51 tagging and differential hemolysis. J Clin Invest 1955; 34:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36326/abstract/11\">",
"      CLINE MJ, BERLIN NI. Red blood cell life span using DFP as a cohort label. Blood 1962; 19:715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36326/abstract/12\">",
"      SHEMIN D, RITTENBERG D. The life span of the human red blood cell. J Biol Chem 1946; 166:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36326/abstract/13\">",
"      Tartakover-Matalon S, Shoham-Kessary H, Foltyn V, Gershon H. Receptors involved in the phagocytosis of senescent and diamide-oxidized human RBCs. Transfusion 2000; 40:1494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36326/abstract/14\">",
"      Galili U, Flechner I, Knyszynski A, et al. The natural anti-alpha-galactosyl IgG on human normal senescent red blood cells. Br J Haematol 1986; 62:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36326/abstract/15\">",
"      Kay MM, Wyant T, Goodman J. Autoantibodies to band 3 during aging and disease and aging interventions. Ann N Y Acad Sci 1994; 719:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36326/abstract/16\">",
"      Kuypers FA, Yuan J, Lewis RA, et al. Membrane phospholipid asymmetry in human thalassemia. Blood 1998; 91:3044.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36326/abstract/17\">",
"      Gifford SC, Derganc J, Shevkoplyas SS, et al. A detailed study of time-dependent changes in human red blood cells: from reticulocyte maturation to erythrocyte senescence. Br J Haematol 2006; 135:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36326/abstract/18\">",
"      Marinkovic D, Zhang X, Yalcin S, et al. Foxo3 is required for the regulation of oxidative stress in erythropoiesis. J Clin Invest 2007; 117:2133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36326/abstract/19\">",
"      Khandelwal S, van Rooijen N, Saxena RK. Reduced expression of CD47 during murine red blood cell (RBC) senescence and its role in RBC clearance from the circulation. Transfusion 2007; 47:1725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36326/abstract/20\">",
"      Burger P, Hilarius-Stokman P, de Korte D, et al. CD47 functions as a molecular switch for erythrocyte phagocytosis. Blood 2012; 119:5512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36326/abstract/21\">",
"      Franco RS, Puchulu-Campanella ME, Barber LA, et al. Changes in the properties of normal human red blood cells during in vivo aging. Am J Hematol 2013; 88:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36326/abstract/22\">",
"      Willekens FL, Roerdinkholder-Stoelwinder B, Groenen-D&ouml;pp YA, et al. Hemoglobin loss from erythrocytes in vivo results from spleen-facilitated vesiculation. Blood 2003; 101:747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36326/abstract/23\">",
"      OWREN PA. Congenital hemolytic jaundice; the pathogenesis of the hemolytic crisis. Blood 1948; 3:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36326/abstract/24\">",
"      MOLLISON PL. Further observations on the normal survival curve of 51 Cr-labelled red cells. Clin Sci 1961; 21:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36326/abstract/25\">",
"      Mock DM, Lankford GL, Widness JA, et al. Measurement of red cell survival using biotin-labeled red cells: validation against 51Cr-labeled red cells. Transfusion 1999; 39:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36326/abstract/26\">",
"      Cowley H, Wojda U, Cipolone KM, et al. Biotinylation modifies red cell antigens. Transfusion 1999; 39:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36326/abstract/27\">",
"      Valeri CR, MacGregor H, Giorgio A, et al. Comparison of radioisotope methods and a nonradioisotope method to measure the RBC volume and RBC survival in the baboon. Transfusion 2003; 43:1366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36326/abstract/28\">",
"      Cohen RM, Franco RS, Khera PK, et al. Red cell life span heterogeneity in hematologically normal people is sufficient to alter HbA1c. Blood 2008; 112:4284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36326/abstract/29\">",
"      Mock DM, Matthews NI, Zhu S, et al. Red blood cell (RBC) survival determined in humans using RBCs labeled at multiple biotin densities. Transfusion 2011; 51:1047.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36326/abstract/30\">",
"      Sebring ES, Polesky HF. Fetomaternal hemorrhage: incidence, risk factors, time of occurrence, and clinical effects. Transfusion 1990; 30:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36326/abstract/31\">",
"      Dziegiel MH, Koldkjaer O, Berkowicz A. Massive antenatal fetomaternal hemorrhage: evidence for long-term survival of fetal red blood cells. Transfusion 2005; 45:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36326/abstract/32\">",
"      Najean Y, Cacchione R, Dresch C, Rain JD. Methods of evaluating the sequestration site of red cells labelled with 51Cr: a review of 96 cases. Br J Haematol 1975; 29:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36326/abstract/33\">",
"      Recommended method for radioisotope red-cell survival studies. International Committee for Standardization in Haematology. Br J Haematol 1980; 45:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36326/abstract/34\">",
"      Ferrant A, Cauwe F, Michaux JL, et al. Assessment of the sites of red cell destruction using quantitative measurements of splenic and hepatic red cell destruction. Br J Haematol 1982; 50:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36326/abstract/35\">",
"      HUFF RL, HENNESSY TG, AUSTIN RE, et al. Plasma and red cell iron turnover in normal subjects and in patients having various hematopoietic disorders. J Clin Invest 1950; 29:1041.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36326/abstract/36\">",
"      Ricketts C, Jacobs A, Cavill I. Ferrokinetics and erythropoiesis in man: the measurement of effective erythropoiesis, ineffective erythropoiesis and red cell lifespan using 59Fe. Br J Haematol 1975; 31:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36326/abstract/37\">",
"      Pollycove M. Iron metabolism and kinetics. Semin Hematol 1966; 3:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36326/abstract/38\">",
"      Landaw SA, Callahan EW Jr, Schmid R. Catabolism of heme in vivo: comparison of the simultaneous production of bilirubin and carbon monoxide. J Clin Invest 1970; 49:914.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36326/abstract/39\">",
"      Berlin NI, Berk PD. Quantitative aspects of bilirubin metabolism for hematologists. Blood 1981; 57:983.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36326/abstract/40\">",
"      Stevenson DK, Vreman HJ, Oh W, et al. Bilirubin production in healthy term infants as measured by carbon monoxide in breath. Clin Chem 1994; 40:1934.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36326/abstract/41\">",
"      Mitlyng BL, Singh JA, Furne JK, et al. Use of breath carbon monoxide measurements to assess erythrocyte survival in subjects with chronic diseases. Am J Hematol 2006; 81:432.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7082 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-61.234.146.186-0E8BE10A25-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_30_36326=[""].join("\n");
var outline_f35_30_36326=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19582868\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MECHANISMS OF RBC DESTRUCTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Senescence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Random RBC death",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      DETERMINATION OF RBC LIFESPAN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Estimation of red cell survival from the reticulocyte count",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Random label red blood cell survival method",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Red blood cell half-time",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Time of red blood cell senescence",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Sites of red blood cell destruction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Cohort labeling technique",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Quantitative erythrokinetic studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Endogenous carbon monoxide production",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19582868\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19582914\">",
"      Normal RBC lifespan",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19583006\">",
"      Modes of RBC destruction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/7082\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/7082|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?32/34/33325\" title=\"figure 1\">",
"      Reticulocyte shift",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/7082|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?25/59/26544\" title=\"picture 1\">",
"      Red cells in the spleen",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/46/29418?source=related_link\">",
"      Approach to the adult patient with anemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/3/18489?source=related_link\">",
"      Approach to the diagnosis of hemolytic anemia in the adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/54/22377?source=related_link\">",
"      Clinical manifestations and pathogenesis of human parvovirus B19 infection",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_30_36327="Splenic vein EUS";
var content_f35_30_36327=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F69269&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F69269&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Splenic vein and portal vein seen on endoscopic ultrasound",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 341px; height: 603px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Radial EUS image showing the confluence (CON) of the splenic vein (SV) and the portal vein. Top: Anterior to the confluence, the pancreatic parenchyma and the pancreatic duct (PD) are shown. Bottom: Simplification of top image.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Lyndon V. Hernandez, MD and Manoop S. Bhutani, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_30_36327=[""].join("\n");
var outline_f35_30_36327=null;
var title_f35_30_36328="Management of recurrent malignant gliomas";
var content_f35_30_36328=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Management of recurrent malignant gliomas",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/30/36328/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/30/36328/contributors\">",
"     Tracy Batchelor, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/30/36328/contributors\">",
"     Helen A Shih, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/30/36328/contributors\">",
"     Bob S Carter, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/30/36328/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/30/36328/contributors\">",
"     Jay S Loeffler, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/30/36328/contributors\">",
"     Patrick Y Wen, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/30/36328/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/30/36328/contributors\">",
"     April F Eichler, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?35/30/36328/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 22, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The malignant gliomas are rapidly progressive brain tumors that are divided into anaplastic gliomas (anaplastic astrocytoma, anaplastic oligodendroglioma, and anaplastic oligoastrocytoma) and glioblastoma (GBM) based upon their histopathologic features [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36328/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/17/36117?source=see_link&amp;anchor=H7347120#H7347120\">",
"     \"Classification of gliomas\", section on 'Histopathologic and molecular classification'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Despite the survival benefit associated with adjuvant RT and chemotherapy, the majority of patients relapse following initial therapy. Progressive disease can be difficult to distinguish from radiation necrosis or other radiation-induced imaging changes, and this distinction has important implications for further treatment. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/22/37226?source=see_link&amp;anchor=H16#H16\">",
"     \"Complications of cranial irradiation\", section on 'Radiation necrosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The optimal management for patients with recurrent or progressive malignant glioma is unclear, and there are no randomized trials that directly compare active intervention versus supportive care. The benefit of reintervention must be balanced by the risk of iatrogenic neurotoxicity and its impact on quality of life.",
"   </p>",
"   <p>",
"    The management of patients with recurrent or progressive malignant glioma, including surgery, radiation therapy (RT), and systemic therapy, is discussed here.",
"   </p>",
"   <p>",
"    Other aspects of the management of malignant gliomas that are covered separately include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The diagnostic approach to patients with suspected brain tumors (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/3/25657?source=see_link\">",
"       \"Clinical presentation and diagnosis of brain tumors\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Initial surgical management of malignant gliomas (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/60/35784?source=see_link\">",
"       \"Clinical manifestations and initial surgical approach to patients with malignant gliomas\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Adjuvant radiation therapy and chemotherapy following surgery (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?4/38/4712?source=see_link\">",
"       \"Adjuvant radiation therapy for malignant gliomas\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?41/25/42391?source=see_link\">",
"       \"Adjuvant chemotherapy for malignant gliomas\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Management of anaplastic oligodendroglial tumors (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?11/24/11655?source=see_link\">",
"       \"Treatment of oligodendroglial tumors\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Experimental approaches for the treatment of malignant glioma (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?19/13/19674?source=see_link\">",
"       \"Experimental treatment approaches for malignant gliomas\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EARLY PROGRESSION VERSUS PSEUDOPROGRESSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Distinguishing treatment-induced imaging changes from progressive disease has important implications to avoid premature and inappropriate discontinuation of a treatment regimen. This can be particularly difficult in the period immediately following completion of RT. This phenomenon has been termed pseudoprogression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36328/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The frequency of pseudoprogression following RT plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/47/11000?source=see_link\">",
"     temozolomide",
"    </a>",
"    was assessed in a single-institution series of patients with malignant gliomas treated with RT plus temozolomide over a six-year period [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36328/abstract/2\">",
"     2",
"    </a>",
"    ]. The results of this analysis were presented at the American Society of Clinical Oncology meeting in June 2007.",
"   </p>",
"   <p>",
"    Pseudoprogression was a retrospective diagnosis based upon imaging findings consistent with progression four weeks after completion of RT combined with a lack of any further progression for at least six months while treatment was continued with the original chemotherapy (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/47/11000?source=see_link\">",
"     temozolomide",
"    </a>",
"    ). Overall, 36 of 85 patients (42 percent) had evidence of progression at the first MRI following completion of RT. Of these, 33 continued on temozolomide, while treatment was discontinued in three because of clinical deterioration.",
"   </p>",
"   <p>",
"    Based upon review of the imaging studies and subsequent clinical course, 18 patients (50 percent of those with early progression by imaging criteria and 21 percent of the entire cohort) were classified as having pseudoprogression. Within this group, three patients ultimately had complete responses. Specialized imaging studies were not able to reliably distinguish between patients with pseudoprogression and those with true disease progression.",
"   </p>",
"   <p>",
"    Similar findings were observed in another series of 51 consecutive patients with newly diagnosed GBM, in which 26 (51 percent) had evidence of early progression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36328/abstract/3\">",
"     3",
"    </a>",
"    ]. In this group of 26, 15 were managed surgically, and seven had treatment-related necrosis without tumor.",
"   </p>",
"   <p>",
"    Patients with imaging evidence suggesting progression four to six weeks after completion of RT and concurrent",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/47/11000?source=see_link\">",
"     temozolomide",
"    </a>",
"    should be continued on their planned adjuvant chemotherapy unless there is evidence of clinical deterioration or until there is evidence of further disease progression on imaging.",
"   </p>",
"   <p>",
"    In a series of 103 patients with newly diagnosed GBM, pseudoprogression was associated with the presence of methylation of the promoter for methylguanine-DNA methyltransferase (MGMT) and with a better overall survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36328/abstract/4\">",
"     4",
"    </a>",
"    ]. In contrast, early progression was significantly more common among those without MGMT methylation and was associated with a shorter survival.",
"   </p>",
"   <p>",
"    Surgery may be required to distinguish between treatment-induced tumor necrosis and progressive disease. If the predominant finding at surgery is necrosis, continuation of adjuvant",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/47/11000?source=see_link\">",
"     temozolomide",
"    </a>",
"    should be considered [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36328/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     BENEFIT OF ACTIVE TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The value of reintervention at the time of relapse was suggested in a retrospective review of 168 patients with recurrent GBM who were treated at a single center [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36328/abstract/6\">",
"     6",
"    </a>",
"    ]. Patients undergoing reintervention were more likely to be progression-free at 12 months (21 versus 8 percent), and to be alive at both one year (71 versus 15 percent) and two years (32 versus 5 percent). Although these results are suggestive, there is a selection bias inherent in comparing patients who were retreated compared to those who were not.",
"   </p>",
"   <p>",
"    One of the most important prognostic factors for benefit from reintervention is the pretreatment performance status (",
"    <a class=\"graphic graphic_table graphicRef58785 \" href=\"mobipreview.htm?2/11/2236\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36328/abstract/7-10\">",
"     7-10",
"    </a>",
"    ]. Other factors that are useful in predicting the likelihood of benefit from second-line therapy include the volume of residual disease, the histologic grade (both at initial therapy and at recurrence), the relapse-free interval, and recurrence pattern (ie, local versus diffuse) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36328/abstract/11-15\">",
"     11-15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     SURGERY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Reoperation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgery in the setting of recurrent disease may involve either biopsy or repeat debulking of tumor.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Biopsy is frequently necessary to distinguish recurrent viable tumor from the effects of treatment, such as radiation necrosis. Both of these entities will enhance on post-gadolinium MRI scanning, and biopsy can provide tissue to differentiate between these two entities. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/60/35784?source=see_link&amp;anchor=H4#H4\">",
"       \"Clinical manifestations and initial surgical approach to patients with malignant gliomas\", section on 'Biopsy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The indications for a debulking reoperation in a patient with recurrent disease are not firmly established. The median survival for patients undergoing surgery for recurrent GBM ranges from 14 to 36 weeks [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/30/36328/abstract/7-9,15-17\">",
"       7-9,15-17",
"      </a>",
"      ] and ranges from 56 to 88 weeks for patients with AA [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/30/36328/abstract/7,8,16\">",
"       7,8,16",
"      </a>",
"      ]. The same imaging advances and intraoperative techniques used in the initial treatment of patients with malignant gliomas are valuable in patients being treated for recurrent or progressive disease. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/60/35784?source=see_link&amp;anchor=H9#H9\">",
"       \"Clinical manifestations and initial surgical approach to patients with malignant gliomas\", section on 'Intraoperative techniques'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There is no evidence to suggest that these results are better than can be expected with radiation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    chemotherapy alone. However, selected patients may benefit from reoperation. The most significant predictor of longer survival after reoperation is a Karnofsky performance status of 60 or greater (",
"    <a class=\"graphic graphic_table graphicRef58785 \" href=\"mobipreview.htm?2/11/2236\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36328/abstract/7,8,16,17\">",
"     7,8,16,17",
"    </a>",
"    ]. Other favorable prognostic variables include young age, a longer interval since the original surgery, and the extent of the second surgical resection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36328/abstract/7,8,15-18\">",
"     7,8,15-18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Particular caution is required in patients who had been treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    preoperatively, because of the risk of wound healing complications. (See",
"    <a class=\"local\" href=\"#H530204220\">",
"     'Side effects'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Carmustine wafers",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/39/33399?source=see_link\">",
"     Carmustine",
"    </a>",
"    polymer wafers may prolong survival following reoperation for locally recurrent disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36328/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. In a phase III trial, 222 patients were randomly assigned to have either carmustine or placebo wafers implanted into the tumor site after surgery for locally recurrent disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36328/abstract/19\">",
"     19",
"    </a>",
"    ]. The carmustine wafer group had a significantly longer median survival (31 versus 23 weeks with placebo). Central nervous system (CNS) toxicity was not worse than in the placebo group.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     RADIATION THERAPY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Involved field RT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reirradiation with conventional involved field RT is usually not feasible in patients with relapsed disease. The administration of a tumoricidal dose is limited by potentially fatal treatment-related toxicity, since most patients will have undergone adjuvant RT with maximally tolerated doses at the time of primary therapy. However, focal reirradiation may be possible in selected patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36328/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Stereotactic radiosurgery and stereotactic radiotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Experience with stereotactic radiosurgery (SRS) and stereotactic radiotherapy (SRT) is limited, and interpretation of results is limited by the lack of randomized clinical trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36328/abstract/22-25\">",
"     22-25",
"    </a>",
"    ]. The following examples illustrate the range of experience:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a series of 114 consecutive patients with recurrent malignant gliomas treated with SRS, the median progression-free survival for patients with grade 3 and grade 4 tumors was 8.6 and 4.6 months, respectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/30/36328/abstract/22\">",
"       22",
"      </a>",
"      ]. With the exception of five patients treated by linear accelerator, all SRS treatments were delivered by gamma knife. Median marginal dose prescribed was 16 Gy with a range of 12 to 50 Gy. Radiation-induced necrosis was observed in 24 percent of cases.",
"     </li>",
"     <li>",
"      Results with SRT are illustrated by an observational series that included 101 patients with malignant gliomas, in which the median survival was 12 months for patients with grade III tumors and eight months for those with grade IV lesions [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/30/36328/abstract/23\">",
"       23",
"      </a>",
"      ]. The one-year survival rates were 65 and 23 percent for patients with grade III and IV lesions, respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    SRT has been combined with concurrent chemotherapy, although it is not clear whether this improves outcomes. This was illustrated by a series of 88 patients with recurrent GBM who received four weekly SRT treatments in conjunction with concurrent weekly",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36328/abstract/14\">",
"     14",
"    </a>",
"    ]. The one- and two-year survival rates were 17 and 3 percent for the entire group, although patients with a pretreatment tumor volume &le;30 cm3 had a 40 percent one-year survival rate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36328/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Brachytherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Interstitial brachytherapy has been used in patients with recurrent malignant gliomas, with several observational studies suggesting a survival benefit [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36328/abstract/13,26-28\">",
"     13,26-28",
"    </a>",
"    ]. In the largest series, the median survival in 66 patients with recurrent GBM was 49 weeks from the date of implantation and 52 weeks in the 67 patients with anaplastic astrocytomas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36328/abstract/26\">",
"     26",
"    </a>",
"    ]. The three-year survival rates in patients with GBMs and anaplastic astrocytomas were 15 and 24 percent, respectively.",
"   </p>",
"   <p>",
"    Brachytherapy is associated with a high incidence of radiation necrosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36328/abstract/26,29\">",
"     26,29",
"    </a>",
"    ]. Although 92 percent of patients in the above series had no acute toxicity, 40 percent required later reoperation for radiation necrosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36328/abstract/26\">",
"     26",
"    </a>",
"    ]. Some series suggest a lower rate of brachytherapy-related radiation necrosis in patients who undergo preimplantation surgical debulking [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36328/abstract/28,30\">",
"     28,30",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/22/37226?source=see_link&amp;anchor=H16#H16\">",
"     \"Complications of cranial irradiation\", section on 'Radiation necrosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An alternate form of brachytherapy uses an inflatable balloon catheter containing a liquid I-125 radioisotope (GliaSite) inserted at the time of surgical resection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36328/abstract/31-33\">",
"     31-33",
"    </a>",
"    ]. This approach allows delivery of a quantifiable dose of radiation to the tissue at highest risk for tumor recurrence. No randomized clinical trials have been reported comparing this form of brachytherapy to other approaches.",
"   </p>",
"   <p>",
"    Although these data suggest a long-term survival benefit with interstitial brachytherapy for patients with local recurrence, the role of interstitial brachytherapy is diminishing as experience with SRS and SRT evolves. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Stereotactic radiosurgery and stereotactic radiotherapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     SYSTEMIC THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;In initial clinical trials,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/47/11000?source=see_link\">",
"     temozolomide",
"    </a>",
"    was demonstrated to increase survival as second-line therapy. However, temozolomide is now generally used as a component of the initial treatment regimen. For patients with an adequate performance status (",
"    <a class=\"graphic graphic_table graphicRef58785 \" href=\"mobipreview.htm?2/11/2236\">",
"     table 1",
"    </a>",
"    ), participation in a research clinical study is the preferred approach whenever possible. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/13/19674?source=see_link\">",
"     \"Experimental treatment approaches for malignant gliomas\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For patients who have been treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/47/11000?source=see_link\">",
"     temozolomide",
"    </a>",
"    and are not candidates for a clinical study,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    , either alone or in combination with a cytotoxic chemotherapy agent, appears to be an active agent. Nitrosourea-based chemotherapy and dose-intense temozolomide may also be options in some patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Bevacizumab",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vascular endothelial growth factor (VEGF) plays a critical role in the development of the abnormal vasculature observed in malignant gliomas and other tumors. Antiangiogenic strategies targeting this pathway include the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    , a monoclonal antibody that binds circulating VEGF and prevents its interaction with VEGF receptors on the cell surface, as well as small molecules that inhibit the VEGF receptor tyrosine kinase. These agents may act by normalizing the tumor vasculature, which may in turn improve delivery of concurrently administered chemotherapeutic drugs and enhance the sensitivity of the tumor to cytotoxic therapies by improving oxygen delivery. Other possible mechanisms of action include inhibition of essential tumor blood supply or disruption of the perivascular-tumor stem cell niche. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/13/19674?source=see_link&amp;anchor=H5#H5\">",
"     \"Experimental treatment approaches for malignant gliomas\", section on 'Vascular endothelial growth factor pathway'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H530204213\">",
"    <span class=\"h3\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     Bevacizumab",
"    </a>",
"    demonstrated significant clinical activity in phase II studies using bevacizumab as a single agent or in combination with chemotherapy agents such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    for patients with grade 3 and grade 4 malignant gliomas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36328/abstract/34-36\">",
"     34-36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The most extensive experience with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    comes from a noncomparative phase II trial, in which 167 patients with recurrent GBMs were randomly assigned to bevacizumab (10",
"    <span class=\"nowrap\">",
"     mg/kg),",
"    </span>",
"    either as a single agent or at the same dose in conjunction with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    (125",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    for those not taking enzyme-inducing antiepileptic agents and 340",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    for those taking these agents) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36328/abstract/35\">",
"     35",
"    </a>",
"    ]. Treatment cycles were repeated every two weeks. All patients had received prior chemotherapy with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/47/11000?source=see_link\">",
"     temozolomide",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    The objective response rates with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    alone or in combination with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    were 28 and 38 percent, respectively, and the six-month progression-free survival rates and overall survival were 43 and 50 percent, and 9.2 and 8.7 months, respectively. Treatment with bevacizumab or bevacizumab plus irinotecan was generally well tolerated, and toxicity was limited to that expected with these agents. Steroid dosages were stable or reduced in almost all patients. An update of the results was presented at the 2010 American Society of Clinical Oncology (ASCO) meeting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36328/abstract/36\">",
"     36",
"    </a>",
"    ]. Overall safety and efficacy were similar to that previously presented; the 12 and 24-month survival rates were 38 and 16 to 17 percent on both treatment arms, which appear to be better than historical control series.",
"   </p>",
"   <p>",
"    One postulated mechanism for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    involves the increased delivery of cytotoxic chemotherapy to the tumor. However, continued treatment with bevacizumab and the addition of a chemotherapy agent or the substitution of a second cytotoxic agent, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    instead of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    , does not appear to have much activity in patients with progressive disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36328/abstract/34,37\">",
"     34,37",
"    </a>",
"    ]. However, this strategy has not been systematically evaluated.",
"   </p>",
"   <p>",
"    Although studies are limited, tumor progression while on",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    is associated with a poor prognosis and reduced likelihood of response to other agents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36328/abstract/34,38-41\">",
"     34,38-41",
"    </a>",
"    ]. There are no controlled trials in this setting. In patients who progress while receiving bevacizumab plus chemotherapy, continuation of bevacizumab and a change of chemotherapy agent to a drug with a different mechanism of action may be useful. In patients who progress on bevacizumab monotherapy, some experts recommend continuation of bevacizumab and addition of a cytotoxic agent.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     Bevacizumab",
"    </a>",
"    alone or in combination with chemotherapy has not been demonstrated to prolong overall survival. Pivotal studies to determine the impact of this agent on overall survival are ongoing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H530204220\">",
"    <span class=\"h3\">",
"     Side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     Bevacizumab",
"    </a>",
"    is associated with a wide spectrum of toxicities, including cardiovascular effects such as hypertension, thromboembolism, and left ventricular dysfunction, and non-cardiovascular effects, such as proteinuria, delayed wound healing, and bleeding. The full spectrum of toxicities associated with bevacizumab and their management are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/54/43882?source=see_link\">",
"     \"Toxicity of molecularly targeted antiangiogenic agents: Non-cardiovascular effects\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/43/36538?source=see_link\">",
"     \"Toxicity of molecularly targeted antiangiogenic agents: Cardiovascular effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     Bevacizumab",
"    </a>",
"    monotherapy is associated with an approximately 2 to 3 percent risk of intracranial hemorrhage (ICH) in patients with recurrent malignant glioma who are not receiving anticoagulation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36328/abstract/35,42,43\">",
"     35,42,43",
"    </a>",
"    ]. In patients receiving anticoagulants, the risk appears to be higher. This was illustrated by a retrospective review of 282 glioma patients treated with bevacizumab, of whom 64 received concurrent anticoagulation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36328/abstract/42\">",
"     42",
"    </a>",
"    ]. Both overall ICH rate (11 versus 3 percent) and serious ICH rate (3 versus 1 percent) were increased in patients who received anticoagulants compared with those who did not. Therefore, the decision regarding whether to treat patients with concurrent bevacizumab and anticoagulants must be based on a careful assessment of the risk to benefit ratio in individual patients. In many cases, however, the benefits of concurrent therapy are felt to justify the risks when progressive tumor and symptomatic venous thromboembolism warrant the use of both.",
"   </p>",
"   <p>",
"    Hypertension is a frequent side effect of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    . Guidelines for pretreatment assessment, monitoring, and management of elevated blood pressure in patients receiving bevacizumab are available (",
"    <a class=\"graphic graphic_table graphicRef73373 graphicRef63338 \" href=\"mobipreview.htm?37/10/38061\">",
"     table 2A-B",
"    </a>",
"    ). This subject is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/43/36538?source=see_link&amp;anchor=H21639449#H21639449\">",
"     \"Toxicity of molecularly targeted antiangiogenic agents: Cardiovascular effects\", section on 'Hypertension'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Nitrosoureas",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients who initially were treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/47/11000?source=see_link\">",
"     temozolomide",
"    </a>",
"    and are not candidates for a clinical study or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    , nitrosourea-based chemotherapy is a reasonable alternative. Nitrosoureas (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/39/33399?source=see_link\">",
"     carmustine",
"    </a>",
"    , fotemustine) either as single agents or in combination regimens such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/45/24279?source=see_link\">",
"     procarbazine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/27/37302?source=see_link\">",
"     lomustine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/29/1498?source=see_link\">",
"     vincristine",
"    </a>",
"    (PCV) (",
"    <a class=\"graphic graphic_table graphicRef57806 \" href=\"mobipreview.htm?2/45/2780\">",
"     table 3",
"    </a>",
"    ) have shown evidence of activity in phase II studies of previously treated patients and are reasonable options [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36328/abstract/44-46\">",
"     44-46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The most extensive data with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/27/37302?source=see_link\">",
"     lomustine",
"    </a>",
"    as second line therapy come from phase III trials of enzastaurin and cediranib, in which lomustine served as the control arm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36328/abstract/47,48\">",
"     47,48",
"    </a>",
"    ]. As an example, in the phase III trial evaluating enzastaurin in patients with recurrent GBM, median progression-free survival and overall survival durations with lomustine were 1.6 and 7.1 months, respectively. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/13/19674?source=see_link&amp;anchor=H3#H3\">",
"     \"Experimental treatment approaches for malignant gliomas\", section on 'Cytotoxic chemotherapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H608546354\">",
"    <span class=\"h2\">",
"     Dose-intense temozolomide",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dose-intense chemotherapy with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/47/11000?source=see_link\">",
"     temozolomide",
"    </a>",
"    using a variety of dosing schedules has been studied in several phase II studies of patients with recurrent malignant glioma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36328/abstract/39,49-54\">",
"     39,49-54",
"    </a>",
"    ]. In the largest study (RESCUE), continuous daily temozolomide (50",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day",
"    </span>",
"    for up to one year) was evaluated in 120 patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36328/abstract/49\">",
"     49",
"    </a>",
"    ]. For patients with GBM, the six month progression-free survival ranged from 15 to 29 percent, depending upon whether progression occurred during or after the original adjuvant temozolomide treatment. Patients who were rechallenged after completing an adjuvant regimen were the most likely to respond. For patients with an anaplastic glioma, the six month progression-free survival was 36 percent with dose-intense temozolomide.",
"   </p>",
"   <p>",
"    As with other agents, the use of dose-intense",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/47/11000?source=see_link\">",
"     temozolomide",
"    </a>",
"    in patients who have progressed on",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    -containing regimens is associated with a poor response rate and overall survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36328/abstract/39,55,56\">",
"     39,55,56",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     ASSESSMENT OF RESPONSE AND PROGRESSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patient management decisions require an assessment of both response to treatment as well as subsequent evidence of progressive disease. Traditionally, this approach has used the Macdonald criteria which rely upon measurement of areas of contrast enhancement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36328/abstract/57\">",
"     57",
"    </a>",
"    ]. New criteria have been proposed by the Response Assessment in Neuro-Oncology (RANO) working group to address problems in assessing patients with pseudoprogression or in assessing progressive disease in patients with nonenhancing lesions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36328/abstract/58\">",
"     58",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/45/4821?source=see_link\">",
"     \"Assessment of disease status and surveillance after treatment in patients with brain tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?7/52/8004?source=see_link\">",
"       \"Patient information: High-grade glioma in adults (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The malignant gliomas are rapidly progressive tumors that are best managed with a combined modality approach, incorporating maximal surgical resection, adjuvant postoperative radiation therapy (RT), and adjuvant chemotherapy.(See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/3/25657?source=see_link\">",
"     \"Clinical presentation and diagnosis of brain tumors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/38/4712?source=see_link\">",
"     \"Adjuvant radiation therapy for malignant gliomas\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/25/42391?source=see_link\">",
"     \"Adjuvant chemotherapy for malignant gliomas\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Despite the use of a combined modality approach, most patients eventually relapse. The management of patients with recurrent or progressive malignant glioma is difficult, and active reintervention has not been proven to prolong survival. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Benefit of active treatment'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An accurate diagnosis of recurrent or progressive disease is essential. The initial treatment may induce imaging changes that are difficult to distinguish from progressive disease. Continued treatment with adjuvant",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/47/11000?source=see_link\">",
"       temozolomide",
"      </a>",
"      is warranted until there is evidence that such imaging changes actually represent disease progression. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Early progression versus pseudoprogression'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Surgery may be useful in carefully selected patients to distinguish between tumor recurrence and treatment-induced necrosis, to debulk tumor, or to provide symptom palliation. Focal RT may also be useful if recurrent disease is present. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Surgery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with recurrent disease, we suggest systemic therapy with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"       bevacizumab",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). In phase II studies, bevacizumab has reduced requirements for steroid therapy and has been associated with imaging evidence of tumor response. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Bevacizumab'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Nitrosoureas and dose intense",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/47/11000?source=see_link\">",
"       temozolomide",
"      </a>",
"      are options for patients who are not candidates for therapy with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"       bevacizumab",
"      </a>",
"      or who have progressed on bevacizumab. Patients should be enrolled in a clinical study whenever possible. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Nitrosoureas'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?19/13/19674?source=see_link\">",
"       \"Experimental treatment approaches for malignant gliomas\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36328/abstract/1\">",
"      de Wit MC, de Bruin HG, Eijkenboom W, et al. Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression. Neurology 2004; 63:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36328/abstract/2\">",
"      Taal W, Brandsma D, de Bruin HG, et al. Incidence of early pseudo-progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide. Cancer 2008; 113:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36328/abstract/3\">",
"      Chamberlain MC, Glantz MJ, Chalmers L, et al. Early necrosis following concurrent Temodar and radiotherapy in patients with glioblastoma. J Neurooncol 2007; 82:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36328/abstract/4\">",
"      Brandes AA, Franceschi E, Tosoni A, et al. MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol 2008; 26:2192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36328/abstract/5\">",
"      Brandsma D, Stalpers L, Taal W, et al. Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. Lancet Oncol 2008; 9:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36328/abstract/6\">",
"      Hau P, Baumgart U, Pfeifer K, et al. Salvage therapy in patients with glioblastoma: is there any benefit? Cancer 2003; 98:2678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36328/abstract/7\">",
"      Ammirati M, Galicich JH, Arbit E, Liao Y. Reoperation in the treatment of recurrent intracranial malignant gliomas. Neurosurgery 1987; 21:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36328/abstract/8\">",
"      Harsh GR 4th, Levin VA, Gutin PH, et al. Reoperation for recurrent glioblastoma and anaplastic astrocytoma. Neurosurgery 1987; 21:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36328/abstract/9\">",
"      Barker FG 2nd, Chang SM, Gutin PH, et al. Survival and functional status after resection of recurrent glioblastoma multiforme. Neurosurgery 1998; 42:709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36328/abstract/10\">",
"      Kappelle AC, Postma TJ, Taphoorn MJ, et al. PCV chemotherapy for recurrent glioblastoma multiforme. Neurology 2001; 56:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36328/abstract/11\">",
"      Keles GE, Lamborn KR, Chang SM, et al. Volume of residual disease as a predictor of outcome in adult patients with recurrent supratentorial glioblastomas multiforme who are undergoing chemotherapy. J Neurosurg 2004; 100:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36328/abstract/12\">",
"      Rostomily RC, Spence AM, Duong D, et al. Multimodality management of recurrent adult malignant gliomas: results of a phase II multiagent chemotherapy study and analysis of cytoreductive surgery. Neurosurgery 1994; 35:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36328/abstract/13\">",
"      Gutin PH, Phillips TL, Wara WM, et al. Brachytherapy of recurrent malignant brain tumors with removable high-activity iodine-125 sources. J Neurosurg 1984; 60:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36328/abstract/14\">",
"      Lederman G, Wronski M, Arbit E, et al. Treatment of recurrent glioblastoma multiforme using fractionated stereotactic radiosurgery and concurrent paclitaxel. Am J Clin Oncol 2000; 23:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36328/abstract/15\">",
"      Dirks P, Bernstein M, Muller PJ, Tucker WS. The value of reoperation for recurrent glioblastoma. Can J Surg 1993; 36:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36328/abstract/16\">",
"      Landy HJ, Feun L, Schwade JG, et al. Retreatment of intracranial gliomas. South Med J 1994; 87:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36328/abstract/17\">",
"      Young B, Oldfield EH, Markesbery WR, et al. Reoperation for glioblastoma. J Neurosurg 1981; 55:917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36328/abstract/18\">",
"      Bloch O, Han SJ, Cha S, et al. Impact of extent of resection for recurrent glioblastoma on overall survival: clinical article. J Neurosurg 2012; 117:1032.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36328/abstract/19\">",
"      Brem H, Piantadosi S, Burger PC, et al. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group. Lancet 1995; 345:1008.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36328/abstract/20\">",
"      Valtonen S, Timonen U, Toivanen P, et al. Interstitial chemotherapy with carmustine-loaded polymers for high-grade gliomas: a randomized double-blind study. Neurosurgery 1997; 41:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36328/abstract/21\">",
"      Nieder C, Astner ST, Mehta MP, et al. Improvement, clinical course, and quality of life after palliative radiotherapy for recurrent glioblastoma. Am J Clin Oncol 2008; 31:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36328/abstract/22\">",
"      Kong DS, Lee JI, Park K, et al. Efficacy of stereotactic radiosurgery as a salvage treatment for recurrent malignant gliomas. Cancer 2008; 112:2046.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36328/abstract/23\">",
"      Combs SE, Thilmann C, Edler L, et al. Efficacy of fractionated stereotactic reirradiation in recurrent gliomas: long-term results in 172 patients treated in a single institution. J Clin Oncol 2005; 23:8863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36328/abstract/24\">",
"      Tsao MN, Mehta MP, Whelan TJ, et al. The American Society for Therapeutic Radiology and Oncology (ASTRO) evidence-based review of the role of radiosurgery for malignant glioma. Int J Radiat Oncol Biol Phys 2005; 63:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36328/abstract/25\">",
"      Fogh SE, Andrews DW, Glass J, et al. Hypofractionated stereotactic radiation therapy: an effective therapy for recurrent high-grade gliomas. J Clin Oncol 2010; 28:3048.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36328/abstract/26\">",
"      Scharfen CO, Sneed PK, Wara WM, et al. High activity iodine-125 interstitial implant for gliomas. Int J Radiat Oncol Biol Phys 1992; 24:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36328/abstract/27\">",
"      Simon JM, Cornu P, Boisserie G, et al. Brachytherapy of glioblastoma recurring in previously irradiated territory: predictive value of tumor volume. Int J Radiat Oncol Biol Phys 2002; 53:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36328/abstract/28\">",
"      Larson DA, Suplica JM, Chang SM, et al. Permanent iodine 125 brachytherapy in patients with progressive or recurrent glioblastoma multiforme. Neuro Oncol 2004; 6:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36328/abstract/29\">",
"      Chamberlain MC, Barba D, Kormanik P, et al. Concurrent cisplatin therapy and iodine 125 brachytherapy for recurrent malignant brain tumors. Arch Neurol 1995; 52:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36328/abstract/30\">",
"      Patel S, Breneman JC, Warnick RE, et al. Permanent iodine-125 interstitial implants for the treatment of recurrent glioblastoma multiforme. Neurosurgery 2000; 46:1123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36328/abstract/31\">",
"      Chan TA, Weingart JD, Parisi M, et al. Treatment of recurrent glioblastoma multiforme with GliaSite brachytherapy. Int J Radiat Oncol Biol Phys 2005; 62:1133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36328/abstract/32\">",
"      Tatter SB, Shaw EG, Rosenblum ML, et al. An inflatable balloon catheter and liquid 125I radiation source (GliaSite Radiation Therapy System) for treatment of recurrent malignant glioma: multicenter safety and feasibility trial. J Neurosurg 2003; 99:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36328/abstract/33\">",
"      Welsh J, Sanan A, Gabayan AJ, et al. GliaSite brachytherapy boost as part of initial treatment of glioblastoma multiforme: a retrospective multi-institutional pilot study. Int J Radiat Oncol Biol Phys 2007; 68:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36328/abstract/34\">",
"      Kreisl TN, Kim L, Moore K, et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 2009; 27:740.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36328/abstract/35\">",
"      Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 2009; 27:4733.",
"     </a>",
"    </li>",
"    <li>",
"     Cloughesy T, Vredenburgh JJ, Day B, et al. Updated safety and survival of patients with relapsed glioblastoma treated with bevacizumab in the BRAIN study (abstract #2008). J Clin Oncol 2010; 28:181s.",
"    </li>",
"    <li>",
"     Quant E, Norden AD, Drappatz J, et al. Role of a second chemotherapy in recurrent malignant glioma patients who progress on a bevacizumab-containing regimen (abstract). J Clin Oncol 2008; 26:91s.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36328/abstract/38\">",
"      Zuniga RM, Torcuator R, Jain R, et al. Rebound tumour progression after the cessation of bevacizumab therapy in patients with recurrent high-grade glioma. J Neurooncol 2010; 99:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36328/abstract/39\">",
"      Omuro A, Chan TA, Abrey LE, et al. Phase II trial of continuous low-dose temozolomide for patients with recurrent malignant glioma. Neuro Oncol 2013; 15:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36328/abstract/40\">",
"      Reardon DA, Desjardins A, Peters K, et al. Phase II study of metronomic chemotherapy with bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy. J Neurooncol 2011; 103:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36328/abstract/41\">",
"      Reardon DA, Desjardins A, Peters KB, et al. Phase 2 study of carboplatin, irinotecan, and bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy. Cancer 2011; 117:5351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36328/abstract/42\">",
"      Norden AD, Bartolomeo J, Tanaka S, et al. Safety of concurrent bevacizumab therapy and anticoagulation in glioma patients. J Neurooncol 2012; 106:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36328/abstract/43\">",
"      Fraum TJ, Kreisl TN, Sul J, et al. Ischemic stroke and intracranial hemorrhage in glioma patients on antiangiogenic therapy. J Neurooncol 2011; 105:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36328/abstract/44\">",
"      Brandes AA, Tosoni A, Amist&agrave; P, et al. How effective is BCNU in recurrent glioblastoma in the modern era? A phase II trial. Neurology 2004; 63:1281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36328/abstract/45\">",
"      Schmidt F, Fischer J, Herrlinger U, et al. PCV chemotherapy for recurrent glioblastoma. Neurology 2006; 66:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36328/abstract/46\">",
"      Fabrini MG, Silvano G, Lolli I, et al. A multi-institutional phase II study on second-line Fotemustine chemotherapy in recurrent glioblastoma. J Neurooncol 2009; 92:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36328/abstract/47\">",
"      Wick W, Puduvalli VK, Chamberlain MC, et al. Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma. J Clin Oncol 2010; 28:1168.",
"     </a>",
"    </li>",
"    <li>",
"     Batchelor T, Mulholland JP, Neyns B, et al. A phase III randomized study comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, with lomustine alone in recurrent glioblastoma patients (abstract# LBA7). Ann Oncol 2010; 21:viii4.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36328/abstract/49\">",
"      Perry JR, B&eacute;langer K, Mason WP, et al. Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study. J Clin Oncol 2010; 28:2051.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36328/abstract/50\">",
"      Khan RB, Raizer JJ, Malkin MG, et al. A phase II study of extended low-dose temozolomide in recurrent malignant gliomas. Neuro Oncol 2002; 4:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36328/abstract/51\">",
"      Brandes AA, Tosoni A, Cavallo G, et al. Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO). Br J Cancer 2006; 95:1155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36328/abstract/52\">",
"      Wick A, Felsberg J, Steinbach JP, et al. Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma. J Clin Oncol 2007; 25:3357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36328/abstract/53\">",
"      Abacioglu U, Caglar HB, Yumuk PF, et al. Efficacy of protracted dose-dense temozolomide in patients with recurrent high-grade glioma. J Neurooncol 2011; 103:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36328/abstract/54\">",
"      Kong DS, Lee JI, Kim JH, et al. Phase II trial of low-dose continuous (metronomic) treatment of temozolomide for recurrent glioblastoma. Neuro Oncol 2010; 12:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36328/abstract/55\">",
"      Desjardins A, Reardon DA, Coan A, et al. Bevacizumab and daily temozolomide for recurrent glioblastoma. Cancer 2012; 118:1302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36328/abstract/56\">",
"      Verhoeff JJ, Lavini C, van Linde ME, et al. Bevacizumab and dose-intense temozolomide in recurrent high-grade glioma. Ann Oncol 2010; 21:1723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36328/abstract/57\">",
"      Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 1990; 8:1277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36328/abstract/58\">",
"      Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 2010; 28:1963.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5205 Version 15.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-201.77.166.39-AB2AAAC1E4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_30_36328=[""].join("\n");
var outline_f35_30_36328=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EARLY PROGRESSION VERSUS PSEUDOPROGRESSION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      BENEFIT OF ACTIVE TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      SURGERY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Reoperation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Carmustine wafers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      RADIATION THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Involved field RT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Stereotactic radiosurgery and stereotactic radiotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Brachytherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      SYSTEMIC THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Bevacizumab",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H530204213\">",
"      - Efficacy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H530204220\">",
"      - Side effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Nitrosoureas",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H608546354\">",
"      Dose-intense temozolomide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      ASSESSMENT OF RESPONSE AND PROGRESSION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/5205\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/5205|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?2/11/2236\" title=\"table 1\">",
"      Karnofsky performance status scale",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?22/7/22652\" title=\"table 2A\">",
"      HTN with VEGF inhib",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?32/36/33356\" title=\"table 2B\">",
"      Risk factors BP VSP rx",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?2/45/2780\" title=\"table 3\">",
"      Chemo regimens brain tumors",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/25/42391?source=related_link\">",
"      Adjuvant chemotherapy for malignant gliomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/38/4712?source=related_link\">",
"      Adjuvant radiation therapy for malignant gliomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/45/4821?source=related_link\">",
"      Assessment of disease status and surveillance after treatment in patients with brain tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/17/36117?source=related_link\">",
"      Classification of gliomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/60/35784?source=related_link\">",
"      Clinical manifestations and initial surgical approach to patients with malignant gliomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/3/25657?source=related_link\">",
"      Clinical presentation and diagnosis of brain tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/22/37226?source=related_link\">",
"      Complications of cranial irradiation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/13/19674?source=related_link\">",
"      Experimental treatment approaches for malignant gliomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?7/52/8004?source=related_link\">",
"      Patient information: High-grade glioma in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/43/36538?source=related_link\">",
"      Toxicity of molecularly targeted antiangiogenic agents: Cardiovascular effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/54/43882?source=related_link\">",
"      Toxicity of molecularly targeted antiangiogenic agents: Non-cardiovascular effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/24/11655?source=related_link\">",
"      Treatment of oligodendroglial tumors",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_30_36329="Management of type 2 diabetes mellitus in children and adolescents";
var content_f35_30_36329=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Management of type 2 diabetes mellitus in children and adolescents",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/30/36329/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/30/36329/contributors\">",
"     Lori Laffel, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/30/36329/contributors\">",
"     Britta Svoren, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/30/36329/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/30/36329/contributors\">",
"     Joseph I Wolfsdorf, MB, BCh",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/30/36329/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/30/36329/contributors\">",
"     Alison G Hoppin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?35/30/36329/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 6, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are few studies on the management of children and adolescents with type 2 diabetes. In addition, data on the long-term outcome of childhood onset type 2 diabetes are only now becoming available from limited populations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36329/abstract/1-3\">",
"     1-3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Data from adults show that type 2 diabetes and its comorbidities are risk factors for adult vascular disease. As a result, it is presumed that identifying and treating children and adolescents with type 2 diabetes will improve long-term outcome. The largest clinical trial, Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY), suggests that medical treatment is not effective for a large percentage of adolescent patients with type 2 diabetes, as discussed below. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Therapeutic choices'",
"    </a>",
"    below.) In addition, data are emerging to help predict which young patients with type 2 diabetes will be successful in maintaining glycemic control.",
"   </p>",
"   <p>",
"    The management of type 2 diabetes mellitus in children and adolescents is presented here. The epidemiology, presentation, diagnosis, comorbidities, and complications of pediatric type 2 diabetes are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/25/4506?source=see_link\">",
"     \"Epidemiology, presentation, and diagnosis of type 2 diabetes mellitus in children and adolescents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/28/34249?source=see_link\">",
"     \"Comorbidities and complications of type 2 diabetes mellitus in children and adolescents\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GOALS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goals of managing a child or adolescent with type 2 diabetes include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      To achieve and maintain near-normal glycemic control (see",
"      <a class=\"local\" href=\"#H3\">",
"       'Glycemic control'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      To improve insulin sensitivity and secretion, which results in improved glycemic control",
"     </li>",
"     <li>",
"      To identify and treat, if necessary, comorbidities, such as hypertension, dyslipidemia, and nonalcoholic fatty liver disease (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/28/34249?source=see_link\">",
"       \"Comorbidities and complications of type 2 diabetes mellitus in children and adolescents\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      To prevent the vascular complications of type 2 diabetes (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/28/34249?source=see_link&amp;anchor=H11#H11\">",
"       \"Comorbidities and complications of type 2 diabetes mellitus in children and adolescents\", section on 'Vascular complications'",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Glycemic control",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most widely used clinical test to evaluate long-term glycemic control is blood glycated hemoglobin (also called A1C, hemoglobin A1C, glycohemoglobin, or glycosylated hemoglobin). In addition, plasma glucose can be monitored by the patient and family. &nbsp;Fasting, pre-meal, and inter-prandial plasma glucose concentrations provide direct feedback on daily glycemic control that can guide ongoing care. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/45/11993?source=see_link\">",
"     \"Estimation of blood glucose control in diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Both in children and adults, the goal of management is to maintain near-normal glycemic control, which has been shown to decrease the risk of long-term vascular complications in adults with type 2 diabetes and in children and adults with type 1 diabetes. In adults, a major randomized trial (United Kingdom Prospective Diabetes Study) demonstrated that strict glycemic control (A1C &le;7 percent) reduced the risk of microvascular complications. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/25/7578?source=see_link\">",
"     \"Glycemic control and vascular complications in type 2 diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/29/40410?source=see_link\">",
"     \"Complications and screening in children and adolescents with type 1 diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Similar data are lacking in children and adolescents with type 2 diabetes. However, based upon the evidence in adults and in children and adolescents with type 1 diabetes, we recommend strict glycemic control for children and adolescents with type 2 diabetes, defined as an A1C &lt;7 percent and a fasting plasma glucose (FPG) of &lt;130",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (7.2",
"    <span class=\"nowrap\">",
"     mmol/L).",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment for type 2 diabetes is divided into nonpharmacologic, pharmacologic, and surgical therapies (",
"    <a class=\"graphic graphic_algorithm graphicRef68128 \" href=\"mobipreview.htm?1/30/1504\">",
"     algorithm 1",
"    </a>",
"    ). All youth with type 2 diabetes and their families require standard diabetes education [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36329/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Nonpharmacologic therapy &ndash; Weight reduction and increased physical activity are important components in the treatment of type 2 diabetes. These lifestyle modifications improve glycemic control by increasing insulin sensitivity and insulin secretion. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Nonpharmacologic therapy'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Pharmacologic therapy &ndash; Several classes of medications are used to manage type 2 diabetes. They have different modes of action including replacing deficient insulin, increasing endogenous insulin secretion, decreasing hepatic glucose production, reducing insulin resistance, and decreasing the rate of intestinal carbohydrate absorption. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Pharmacologic therapy'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Surgical therapy &ndash; Individuals with severe obesity and type 2 diabetes benefit from the weight reduction and increased insulin sensitivity that follows weight loss surgery. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Surgical therapy'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Instruction and care by a multidisciplinary team (including an endocrinologist, nurse educator, dietitian, exercise physiologist, and a mental health professional) provide the ideal setting for the patient and family to acquire the knowledge and skills needed for successful care. Family involvement is essential to initiate and support the lifestyle changes required in the management of a pediatric patient with type 2 diabetes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36329/abstract/5,6\">",
"     5,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Initial therapeutic decisions (eg, nonpharmacologic therapy alone, or both nonpharmacologic and pharmacologic therapy) are based upon the severity of symptoms at presentation. Ongoing therapeutic choices are dependent upon the response to initial therapy. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Therapeutic choices'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     DEFINITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Type 2 diabetes is closely linked to excess weight. Several classifications, based upon body mass index (BMI), are used to define overweight and obesity (",
"    <a class=\"graphic graphic_table graphicRef78725 \" href=\"mobipreview.htm?23/40/24203\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef60784 graphicRef68478 \" href=\"mobipreview.htm?10/0/10247\">",
"     figure 1A-B",
"    </a>",
"    ). BMI provides a guideline for weight in relation to height, and is equal to the body weight in kilograms, divided by the height in meters squared (",
"    <a class=\"graphic graphic_table graphicRef71431 \" href=\"mobipreview.htm?0/28/459\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/5/32858?source=see_link&amp;anchor=H2#H2\">",
"     \"Definition; epidemiology; and etiology of obesity in children and adolescents\", section on 'Definitions'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In this review, the following definitions are used:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Overweight &ndash; BMI &ge;85th and &lt;95th percentile",
"     </li>",
"     <li>",
"      Obesity &ndash; BMI &ge;95th percentile",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     NONPHARMACOLOGIC THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Weight reduction resulting from decreased caloric intake and increased energy expenditure improves glycemic control. These lifestyle modifications are crucial components for the successful management of childhood type 2 diabetes, and should be initiated in all patients with this disorder (",
"    <a class=\"graphic graphic_algorithm graphicRef68128 \" href=\"mobipreview.htm?1/30/1504\">",
"     algorithm 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36329/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Nutrition therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Individualized nutrition therapy can be effective in improving glycemic control. Nutritional goals include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Maintain near-normal glycemic control by balancing food intake with physical activity and pharmacologic therapy as needed. This may include providing small meals to avoid wide glycemic excursions.",
"     </li>",
"     <li>",
"      Provide a diet that reduces caloric intake and avoids sugar-containing soft drinks, but includes the nutritional requirements for normal health and growth.",
"     </li>",
"     <li>",
"      Provide a diet that is culturally appropriate and sensitive to family resources. The diet should not be limited to the child but should include other family members, because an inclusive family approach is most effective in the treatment of overweight children [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/30/36329/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It is desirable for the patient and family to consult with a registered dietitian with experience in pediatric nutrition and diabetes. The dietitian can provide instruction on how to adjust dietary habits and behaviors to ensure adequate nutrition while reducing caloric intake. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Dietary prescription'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Weight goals",
"    </span>",
"    &nbsp;&mdash;&nbsp;Excessive weight increases peripheral resistance to insulin-mediated glucose uptake and decreases relative insulin secretion. In adults with type 2 diabetes, weight reduction reduces insulin resistance and increases insulin secretion. Although the extent of weight loss needed to decrease insulin resistance, or to ameliorate hyperglycemia in children with type 2 diabetes is not clear, insulin sensitivity improves in overweight children with a decrease in BMI &ge;0.5",
"    <span class=\"nowrap\">",
"     kg/m2",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36329/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/35/43577?source=see_link&amp;anchor=H6#H6\">",
"     \"Initial management of blood glucose in type 2 diabetes mellitus\", section on 'Diet'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The efficacy of a protein-sparing low caloric diet was demonstrated in a study of 20 adolescent patients with type 2 diabetes (mean age 14.5 years) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36329/abstract/10\">",
"     10",
"    </a>",
"    ]. After a mean duration of 60 days of dieting, BMI was reduced from 43.5 to 39.3",
"    <span class=\"nowrap\">",
"     kg/m2,",
"    </span>",
"    pharmacologic agents (pre-study, 11 patients received insulin therapy, and 6 received",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?12/59/13238?source=see_link\">",
"     metformin",
"    </a>",
"    ) were discontinued in all but one patient, and A1C levels decreased from 8.8 &plusmn; 0.6 to 7.4 &plusmn; 0.6 percent.",
"   </p>",
"   <p>",
"    In children, the decision on whether to recommend weight reduction versus weight maintenance depends on the age of the patient (ie, the potential for linear growth), the degree of obesity, and the presence of secondary comorbidities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36329/abstract/11\">",
"     11",
"    </a>",
"    ]. In patients who are growing still growing, weight maintenance will lead to a reduction in BMI. However, for most children with type 2 diabetes, weight reduction rather than weight maintenance is indicated.",
"   </p>",
"   <p>",
"    Initially, the patient and family should be encouraged to demonstrate the ability to maintain the child's weight. After successful weight maintenance, further dietary intervention, if indicated, can focus on gradual weight loss to reach a BMI &lt;85th percentile. The weight loss goal of 0.5 to 1.0 kg per week in adults is unrealistic in children and places undue pressure on the patient and family. A weight loss rate of 0.5 kg per month is a more realistic goal for children with normal linear growth potential. Adolescents who have completed puberty should have the same weight loss goals as adults.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Nutritional requirements",
"    </span>",
"    &nbsp;&mdash;&nbsp;The nutritional requirements of children with diabetes are the same as those of healthy children and adolescents.",
"   </p>",
"   <p>",
"    The Institute of Medicine's Food and Nutrition Board recommends the following goals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36329/abstract/12\">",
"     12",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Carbohydrate provides 45 to 65 percent of the total calories",
"     </li>",
"     <li>",
"      Protein provides 15 percent of the total calories",
"     </li>",
"     <li>",
"      Fat provides 30 percent of the total calories",
"     </li>",
"     <li>",
"      Less than 10 percent of energy should come from saturated fat",
"     </li>",
"     <li>",
"      Dietary cholesterol should be reduced to less than 300 mg per day",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although fiber goals are not higher in children with diabetes, fiber intake may reduce postprandial glycemic excursions and help with satiety, leading to decreased caloric intake [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36329/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Dietary prescription",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although dietary prescriptions for patients with diabetes have traditionally used meal planning (ie, patient receives recommendations for the number of servings to consume from the different food groups), they are not always easy to follow on a long-term basis. In addition, meal planning can place too much focus on the child, while detracting from the importance of family changes in eating.",
"   </p>",
"   <p>",
"    The focus on dietary treatment, especially for type 2 diabetes, has moved toward gradual change of family and individual dietary habits to better achieve long-term goals. The dietary prescription begins by determining the patient's and family's dietary preferences, patterns of physical activity, time and financial constraints, cultural background, and educational level. Once sufficient data are obtained, advice on moving the patient toward a more healthful diet can be given.",
"   </p>",
"   <p>",
"    The more marked the changes are from what the patient likes to eat, the less likely the patient is to adhere to the dietary prescription. Thus, dietary goals should include input from the child and family, and be measurable and achievable. Examples include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Decrease portion sizes.",
"     </li>",
"     <li>",
"      Substitute a fruit or vegetable for a carbohydrate-rich food.",
"     </li>",
"     <li>",
"      Decrease or discontinue high-caloric beverages (eg, soft drinks, juices) and replace them with water or calorie-free beverages.",
"     </li>",
"     <li>",
"      Reduce the frequency of eating out. In particular, children who consume fast food are more likely to have a higher caloric intake, leading to excess weight gain. Nutrition therapy should include guidance on the frequency and selection of food consumed away from home. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?41/61/42967?source=see_link\">",
"       \"Fast food for children and adolescents\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Because treatment often focuses on changing behaviors, frequent visits to the dietitian",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    practitioner may be needed for ongoing assessment and support. A suggested timeline of every four weeks, or more frequently if indicated, allows the family to implement changes and maintain motivation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Physical activity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Increased physical activity, independent of its effect on body weight, improves insulin sensitivity. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/50/20265?source=see_link\">",
"     \"Effects of exercise in diabetes mellitus in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Recommendations for increasing physical activity should be titrated and advanced slowly based upon the age, physical ability of the child or adolescent, and the degree of excess weight. Weight-bearing activities, for example, can place undue stress on bones and knees in overweight and obese children and may need to be delayed until the patient has lost some weight. An initial strategy for increasing activity is to decrease the amount of time devoted to sedentary activities, such as watching television or playing non-active video and computer games [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36329/abstract/11,14\">",
"     11,14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following is a guide to suggested physical activities based upon the weight status of the child [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36329/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Children who are overweight (BMI &ge;85th and &lt;95th percentile ) should engage in weight-bearing activities, such as walking, exercise machines, field sports, jump rope, dancing, and running games (eg, tag).",
"     </li>",
"     <li>",
"      Children who are obese (BMI &ge;95th percentile) should engage primarily in non-weight-bearing activities, such as swimming, cycling, strength training, and short walks. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?13/61/14298?source=see_link&amp;anchor=H3#H3\">",
"       \"Overview of physical activity and strength training in children and adolescents\", section on 'Physical activity'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Children who are &ge;97th percentile for BMI should only engage in non-weight-bearing activities until their BMI approaches the 95th percentile. They may require weekly supervision by a trained exercise professional.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     PHARMACOLOGIC THERAPY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although weight reduction and increased physical activity can improve glycemic control as the sole intervention, these nonpharmacologic modalities may not be able to successfully meet the targeted glycemic control goal (",
"    <a class=\"graphic graphic_algorithm graphicRef68128 \" href=\"mobipreview.htm?1/30/1504\">",
"     algorithm 1",
"    </a>",
"    ). In addition, adherence to lifestyle modifications can be difficult to attain and maintain.",
"   </p>",
"   <p>",
"    Pharmacologic therapy is initiated in two settings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In asymptomatic patients who fail to achieve glycemic control three months after the initiation of lifestyle modifications.",
"     </li>",
"     <li>",
"      In patients who are symptomatic at presentation (eg, polyuria and polydipsia), including those with ketosis. In these patients, it is important to distinguish type 2 from type 1 diabetes based upon clinical features, presentation, and laboratory studies [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/30/36329/abstract/16\">",
"       16",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Therapeutic choices'",
"      </a>",
"      below and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?4/25/4506?source=see_link\">",
"       \"Epidemiology, presentation, and diagnosis of type 2 diabetes mellitus in children and adolescents\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Medications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several different pharmacologic classes of medications are used in the treatment of type 2 diabetes.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Exogenous insulin (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/24/30089?source=see_link\">",
"       \"Insulin therapy in type 2 diabetes mellitus\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Biguanides (eg,",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?12/59/13238?source=see_link\">",
"       metformin",
"      </a>",
"      ) increase insulin responsiveness by improving insulin sensitivity and decreasing hepatic glucose production (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/26/38312?source=see_link\">",
"       \"Metformin in the treatment of diabetes mellitus\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Thiazolidinediones, such as",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?13/35/13879?source=see_link\">",
"       rosiglitazone",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/28/43463?source=see_link\">",
"       pioglitazone",
"      </a>",
"      , also increase insulin responsiveness and may also improve insulin secretion by preserving pancreatic beta cell function (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?20/50/21290?source=see_link\">",
"       \"Thiazolidinediones in the treatment of diabetes mellitus\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Sulfonylureas or meglitinides, both of which increase insulin secretion (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/46/35559?source=see_link\">",
"       \"Sulfonylureas and meglitinides in the treatment of diabetes mellitus\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Alpha-glucosidase inhibitors (eg,",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?24/46/25316?source=see_link\">",
"       acarbose",
"      </a>",
"      ) that delay the absorption of carbohydrates or lipase inhibitors that reduce the absorption of fat (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?3/0/3078?source=see_link\">",
"       \"Alpha-glucosidase inhibitors and lipase inhibitors for treatment of diabetes mellitus\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      DPP-IV inhibitors (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/31/5622?source=see_link\">",
"       sitagliptin",
"      </a>",
"      ) that increase insulin production and decrease the liver's production of glucose (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/25/38298?source=see_link&amp;anchor=H13#H13\">",
"       \"Glucagon-like peptide-1-based therapies for the treatment of type 2 diabetes mellitus\", section on 'DPP-4 inhibitors'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Incretin mimetics (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/2/14375?source=see_link\">",
"       exenatide",
"      </a>",
"      ) that act to increase glucose-dependent insulin secretion from beta cells and help to ensure an appropriate insulin response following ingestion of a meal (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/25/38298?source=see_link&amp;anchor=H13#H13\">",
"       \"Glucagon-like peptide-1-based therapies for the treatment of type 2 diabetes mellitus\", section on 'DPP-4 inhibitors'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Amylin analogs (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?13/22/13669?source=see_link\">",
"       pramlintide",
"      </a>",
"      acetate) that are used to slow gastric emptying and suppress glucagon secretion, which leads to suppression of endogenous glucose output from the liver (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?15/23/15734?source=see_link\">",
"       \"Amylin analogs for the treatment of diabetes mellitus\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Insulin and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?12/59/13238?source=see_link\">",
"     metformin",
"    </a>",
"    are the only agents approved by the Food and Drug Administration (FDA) for the treatment of type 2 diabetes in children. However, other agents have also been used, including sulfonylureas and meglitinides. The use of thiazolidinediones in pediatric patients was studied in the TODAY study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36329/abstract/2\">",
"     2",
"    </a>",
"    ]. However, these agents are not approved by the United States Food and Drug Administration (FDA) for use in pediatric patients with type 2 diabetes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Insulin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who present with ketosis or with severe hyperglycemia (plasma glucose &ge;200",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (11.1",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    A1C &gt;8.5 percent) should be treated with exogenous insulin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36329/abstract/17\">",
"     17",
"    </a>",
"    ]. Because patients with type 2 diabetes are insulin resistant, the insulin dose required to restore glycemic control may be as high as 2",
"    <span class=\"nowrap\">",
"     U/kg",
"    </span>",
"    per day. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/28/7626?source=see_link\">",
"     \"Treatment and complications of diabetic ketoacidosis in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Insulin therapy should continue until ketosis resolves and plasma glucose has returned to a normal or near normal concentration. At this point, it is important to be able to differentiate patients with type 2 diabetes from those with type 1 diabetes because of different management decisions. Distinguishing between the two causes of diabetes is based upon clinical presentation, history, and laboratory studies. As an example, if evidence of islet cell autoimmunity is absent and the fasting C-peptide level is &gt;0.6",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    (indicating substantial insulin production), then the diabetes is likely to be type 2. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/32/41480?source=see_link&amp;anchor=H3#H3\">",
"     \"Clinical features and diagnosis of diabetic ketoacidosis in children\", section on 'Epidemiology'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/25/4506?source=see_link\">",
"     \"Epidemiology, presentation, and diagnosis of type 2 diabetes mellitus in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients with type 2 diabetes who are euglycemic (or near euglycemic), the patient can be weaned from insulin and switched to",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?12/59/13238?source=see_link\">",
"     metformin",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    In some patients,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?12/59/13238?source=see_link\">",
"     metformin",
"    </a>",
"    and lifestyle modifications fail to maintain adequate glycemic control. These patients require additional therapy. Options include insulin therapy or an additional oral agent, such as sulfonylureas. In our practice, we use long-acting insulin analogs such as",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?16/50/17190?source=see_link\">",
"     insulin glargine",
"    </a>",
"    or detemir in this situation. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Ongoing care'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Metformin",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?12/59/13238?source=see_link\">",
"     Metformin",
"    </a>",
"    is the only biguanide available in the United States. It decreases hepatic glucose production and increases insulin-mediated glucose uptake in peripheral tissues.",
"   </p>",
"   <p>",
"    Studies in adults have shown that, in addition to improving glycemic control,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?12/59/13238?source=see_link\">",
"     metformin",
"    </a>",
"    has the benefit of producing modest weight loss or, at least, weight stabilization; this is in contrast to the weight gain often associated with insulin or sulfonylurea therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/26/38312?source=see_link\">",
"     \"Metformin in the treatment of diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In children with type 2 diabetes,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?12/59/13238?source=see_link\">",
"     metformin",
"    </a>",
"    is safe and effective, as shown in a randomized trial of 82 adolescents (10 to 16 years of age) with type 2 diabetes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36329/abstract/18\">",
"     18",
"    </a>",
"    ]. Patients treated with metformin compared to those who received placebo had significantly greater reductions in A1C, from a baseline value of 8.3 and 9 to 7.5 and 8.6 percent, respectively, and fasting plasma glucose (mean adjusted change from baseline of -43 versus +21",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (-2.4 versus +1.2",
"    <span class=\"nowrap\">",
"     mmol/L)).",
"    </span>",
"   </p>",
"   <p>",
"    No serious adverse event was seen with the administration of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?12/59/13238?source=see_link\">",
"     metformin",
"    </a>",
"    . Side effects in the patients who received metformin included abdominal pain (25 percent), nausea and vomiting (17 percent), diarrhea, and headaches, and are similar to those reported in adult trials. In adults, these side effects can be minimized by administering metformin with food,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    by lowering the dose and increasing it slowly as needed. Long-acting formulations of metformin may be associated with less GI upset and once daily dosing may improve adherence.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?12/59/13238?source=see_link\">",
"     Metformin",
"    </a>",
"    is used in children and adolescents with type 2 diabetes in the following settings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients who fail to attain glycemic control three months after the initiation of lifestyle modifications (weight reduction and increased physical activity).",
"     </li>",
"     <li>",
"      Patients who present with mild symptoms and mild to moderate hyperglycemia.",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?12/59/13238?source=see_link\">",
"       Metformin",
"      </a>",
"      is administered concurrently with lifestyle modifications.",
"     </li>",
"     <li>",
"      After plasma glucose approaches normal or near-normal concentration in patients who present with severe hyperglycemia",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      ketosis and were initially treated with insulin.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    We recommend that baseline liver enzymes (aminotransferases) be measured in all patients prior to initiation of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?12/59/13238?source=see_link\">",
"     metformin",
"    </a>",
"    therapy. If the levels are greater than 2.5 times the upper limit of normal, we do not recommend starting metformin. In this situation, insulin therapy should be continued or initiated, and liver enzyme levels should be measured after a period of three to six months.",
"   </p>",
"   <p>",
"    In pediatric patients,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?12/59/13238?source=see_link\">",
"     metformin",
"    </a>",
"    is started as an oral dose of 500 mg, administered once a day. The dose can be gradually increased by 500 mg increments, initially as 500 mg twice a day, to a maximum daily dose of 2000 mg given as 1000 mg twice a day.",
"   </p>",
"   <p>",
"    Patients taking",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?12/59/13238?source=see_link\">",
"     metformin",
"    </a>",
"    are advised to take a daily multivitamin, because the absorption of vitamin B12",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?21/31/22005?source=see_link\">",
"     folic acid",
"    </a>",
"    can be compromised. Metformin is contraindicated in patients with impaired renal function, cirrhosis, hepatitis, alcoholism, or cardiopulmonary insufficiency because it can cause lactic acidosis in these settings. Patients receiving metformin who are planning to undergo elective surgery should be advised to stop the metformin 24 hours prior to the surgery and to resume the metformin 48 hours after the procedure, provided there are no complications. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/26/38312?source=see_link&amp;anchor=H7#H7\">",
"     \"Metformin in the treatment of diabetes mellitus\", section on 'Lactic acidosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Type 2 diabetes mellitus and polycystic ovarian syndrome frequently co-occur. With",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?12/59/13238?source=see_link\">",
"     metformin",
"    </a>",
"    therapy, females who previously had irregular menses and anovulatory cycles may regain normal menstrual cycles, thereby increasing their risk of unplanned pregnancy. Therefore, all females treated with metformin should be counseled regarding the need for birth control.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Insulin secretagogues",
"    </span>",
"    &nbsp;&mdash;&nbsp;Insulin secretagogues (eg, sulfonylureas or meglitinides) increase insulin secretion. In adults, these agents have been shown to improve glycemic control, but sulfonylureas also increase body weight.",
"   </p>",
"   <p>",
"    The efficacy of the sulfonylurea",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/39/8823?source=see_link\">",
"     glimepiride",
"    </a>",
"    in pediatric patients was evaluated in a 26-week multinational clinical trial in 285 youth, ages 8 to 17 years old with type 2 diabetes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36329/abstract/19\">",
"     19",
"    </a>",
"    ]. Criteria for entry into the study were hemoglobin A1C &gt;7.1 percent, no evidence of pancreatic autoimmunity, and C-peptide positive. The subjects were randomized to receive glimepiride (1 to 8 mg daily) or",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?12/59/13238?source=see_link\">",
"     metformin",
"    </a>",
"    (500 to 1000 mg twice daily). There was an equivalent and significant reduction in A1c from baseline in both groups (-0.54 percent in glimepiride group, p = 0.001; -.071 percent in the metformin group, p = 0.0002). Similar proportions of patients in both groups achieved A1c levels &lt;7 percent after six months (42 percent and 48 percent, respectively). There was a significant difference in the mean change in BMI between groups (0.26",
"    <span class=\"nowrap\">",
"     kg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    for glimepiride, versus -0.33",
"    <span class=\"nowrap\">",
"     kg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    for metformin, p = 0.003). Rates of hypoglycemia and safety concerns were similar between groups.",
"   </p>",
"   <p>",
"    There are currently pediatric trials underway involving DPP-IV inhibitors and incretin mimetics. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Medications'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     THERAPEUTIC CHOICES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21976949\">",
"    <span class=\"h2\">",
"     TODAY study",
"    </span>",
"    &nbsp;&mdash;&nbsp;The best information about medical treatment of type 2 diabetes in adolescents comes from a large randomized trial (Treatment Options for Type 2 Diabetes in Adolescents and Youth study, TODAY) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36329/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. The TODAY study evaluated medical treatment options in 699 youth (ages 10 to 17 years) with type 2 diabetes of &lt;2 years duration, and a BMI &ge;85",
"    <sup>",
"     th",
"    </sup>",
"    percentile. All had no evidence of pancreatic autoimmunity and all were C-peptide positive. After a run-in period of two to six months, in which all study subjects received",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?12/59/13238?source=see_link\">",
"     metformin",
"    </a>",
"    alone and standard diabetes education that included attention to healthful eating and exercise and achieved an A1C of &lt;8 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36329/abstract/22\">",
"     22",
"    </a>",
"    ], subjects were randomly assigned to one of three treatments: metformin alone, metformin plus the insulin sensitizer",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?13/35/13879?source=see_link\">",
"     rosiglitazone",
"    </a>",
"    , or metformin plus an intensive lifestyle intervention. Metformin was titrated to 1000 mg twice daily and rosiglitazone to 4 mg twice daily. The intensive lifestyle intervention was focused on weight loss through family-focused efforts at healthy eating and exercise behaviors, delivered during face-to-face counseling sessions for the first two years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36329/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11242215\">",
"    <span class=\"h3\">",
"     Treatment failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary outcome of the TODAY study was treatment failure, which was defined as A1C &ge;8 percent for at least six months or sustained metabolic decompensation requiring insulin, and was the primary study outcome. During the TODAY study treatment period (mean 3.8 duration years, with a range from 2 to 6.5 years), the following glycemic control outcomes were seen in each treatment group [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36329/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?12/59/13238?source=see_link\">",
"       Metformin",
"      </a>",
"      alone &ndash; 51.7 percent treatment failure",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?12/59/13238?source=see_link\">",
"       Metformin",
"      </a>",
"      plus",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?13/35/13879?source=see_link\">",
"       rosiglitazone",
"      </a>",
"      &ndash; 38.6 percent treatment failure",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?12/59/13238?source=see_link\">",
"       Metformin",
"      </a>",
"      with intensive lifestyle intervention &ndash; 46.6 percent treatment failure &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Overall, 45.6 percent of study participants reached the primary outcome of loss of glycemic control, with a median time to failure of 11.5 months.",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?12/59/13238?source=see_link\">",
"     Metformin",
"    </a>",
"    plus",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?13/35/13879?source=see_link\">",
"     rosiglitazone",
"    </a>",
"    was superior to metformin alone (p = 0.006); metformin plus lifestyle intervention was intermediate but not significantly different from metformin alone or metformin plus rosiglitazone. The rates of treatment failure were higher than in comparable studies in adults; this was not thought to be due to nonadherence to the study drugs.",
"   </p>",
"   <p>",
"    The",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?12/59/13238?source=see_link\">",
"     metformin",
"    </a>",
"    plus",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?13/35/13879?source=see_link\">",
"     rosiglitazone",
"    </a>",
"    group experienced 25 percent less glycemic failure compared with metformin alone. However, we do not recommend use of rosiglitazone or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/28/43463?source=see_link\">",
"     pioglitazone",
"    </a>",
"    in youth with type 2 diabetes, because of the restrictions on the use of thiazolidinediones recommended by the US Food and Drug administration (FDA), due to cardiovascular concerns with rosiglitazone, bladder cancer concerns with pioglitazone, and bone concerns with both. Thus, the TODAY study results support the need for early combination therapy in some youth with type 2 diabetes. The choice of the second agent, whether it is insulin or another oral or injectable glucose lowering agent, requires additional study.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11242222\">",
"    <span class=\"h3\">",
"     Weight gain",
"    </span>",
"    &nbsp;&mdash;&nbsp;The TODAY study also examined the effects of each treatment on weight status, measured after six months of treatment because this was the predicted maximum weight loss. The weight loss target was a decrease of 7 percentage points in percent overweight. After six months, the following weight loss outcomes were seen in each treatment group [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36329/abstract/2\">",
"     2",
"    </a>",
"    ]: &nbsp;",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?12/59/13238?source=see_link\">",
"       Metformin",
"      </a>",
"      alone &ndash; 24.3 percent reached weight loss target",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?12/59/13238?source=see_link\">",
"       Metformin",
"      </a>",
"      plus",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?13/35/13879?source=see_link\">",
"       rosiglitazone",
"      </a>",
"      &ndash; 16.7 percent reached weight loss target",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?12/59/13238?source=see_link\">",
"       Metformin",
"      </a>",
"      with intensive lifestyle intervention &ndash; 31.2 percent reached weight loss target &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The percent of participants reaching the weight loss target at six months was significantly higher in the",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?12/59/13238?source=see_link\">",
"     metformin",
"    </a>",
"    plus lifestyle intervention group than in the metformin plus",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?13/35/13879?source=see_link\">",
"     rosiglitazone",
"    </a>",
"    group (p &lt;0.001), but not significantly different from metformin alone. BMI remained significantly different across treatment groups for up to 60 months, with the metformin plus rosiglitazone group demonstrating the greatest increase, the metformin plus lifestyle intervention group the smallest increase, and the metformin only group falling intermediate between the two.",
"   </p>",
"   <p>",
"    About 20 percent of subjects encountered serious adverse events (SAE) during the study, most of which were hospitalizations. The majority (87 percent) of SAEs were not considered related to study treatment. Severe hypoglycemia occurred in one patient in the",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?12/59/13238?source=see_link\">",
"     metformin",
"    </a>",
"    alone group, one patient in the",
"    <span class=\"nowrap\">",
"     metformin/",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?13/35/13879?source=see_link\">",
"      rosiglitazone",
"     </a>",
"    </span>",
"    group, and in two patients in the",
"    <span class=\"nowrap\">",
"     metformin/lifestyle",
"    </span>",
"    intervention group. There was one case of transient lactic acidosis in the metformin-alone group, associated with an asthma exacerbation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Initial treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the results of the TODAY trial suggest limited efficacy with any approach, about 50 percent of patients will have a sustained response to",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?12/59/13238?source=see_link\">",
"     metformin",
"    </a>",
"    . We base our initial management upon the severity of disease at presentation as follows: &nbsp;",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Asymptomatic patients are initially treated with only nonpharmacologic therapy (lifestyle intervention targeting weight loss and physical activity). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Nonpharmacologic therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Symptomatic patients (polydipsia and polyuria) with mild to moderate hyperglycemia without ketosis are treated with",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?12/59/13238?source=see_link\">",
"       metformin",
"      </a>",
"      and nonpharmacologic therapy. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Metformin'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with severe hyperglycemia, defined as a fasting plasma glucose &ge;200",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (11.1",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      A1C &ge;8.5 percent",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      ketosis, are initially treated with insulin and nonpharmacologic therapy. Once plasma glucose levels reach near normal concentrations,",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?12/59/13238?source=see_link\">",
"       metformin",
"      </a>",
"      is added, and an attempt is made to gradually wean the patient off of insulin. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Insulin'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H16\">",
"       'Metformin'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?7/28/7626?source=see_link\">",
"       \"Treatment and complications of diabetic ketoacidosis in children\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      For patients initially treated with insulin, it is important to differentiate patients with type 2 diabetes from those with type 1 diabetes before discontinuing insulin therapy. Distinguishing between the two causes of diabetes is based upon clinical presentation, history, and laboratory studies. Absence of autoantibodies directed against pancreatic beta-cell antigens (eg, islet-cell antibodies [ICA] or glutamic acid decarboxylase [GAD]), and presence of residual C-peptide are suggestive of type 2 diabetes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/30/36329/abstract/16\">",
"       16",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/59/40889?source=see_link&amp;anchor=H16#H16\">",
"       \"Epidemiology, presentation, and diagnosis of type 1 diabetes mellitus in children and adolescents\", section on 'Type 1 versus type 2 diabetes'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Ongoing care",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ongoing therapeutic choices are dependent upon the response of patients to initial therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Failure of nonpharmacologic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?12/59/13238?source=see_link\">",
"     Metformin",
"    </a>",
"    should be administered to children who were initially treated with only nonpharmacologic therapy and fail to meet glycemic targets. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Metformin'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11242319\">",
"    <span class=\"h3\">",
"     Failure of metformin",
"    </span>",
"    &nbsp;&mdash;&nbsp;In children initially treated with both nonpharmacologic therapy and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?12/59/13238?source=see_link\">",
"     metformin",
"    </a>",
"    who fail to achieve glycemic targets, a long-acting insulin analogue can be used to provide basal insulin coverage. For such patients, we administer",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?16/50/17190?source=see_link\">",
"     insulin glargine",
"    </a>",
"    or detemir at bedtime with a starting dose of 0.2",
"    <span class=\"nowrap\">",
"     units/kg",
"    </span>",
"    per day. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/24/30089?source=see_link\">",
"     \"Insulin therapy in type 2 diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H15\">",
"     'Insulin'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    We choose a long-acting insulin analog to minimize the risk of nocturnal hypoglycemia compared to intermediate-acting insulin (eg, NPH). There are no data comparing basal insulin with bedtime NPH in the pediatric population.",
"   </p>",
"   <p>",
"    Although others have suggested that sulfonylureas can be considered as an alternative to insulin therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36329/abstract/24\">",
"     24",
"    </a>",
"    ], sulfonylureas are not currently FDA approved for use in pediatric patients (see",
"    <a class=\"local\" href=\"#H17\">",
"     'Insulin secretagogues'",
"    </a>",
"    above). Similarly, thiazolidinediones such as",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?13/35/13879?source=see_link\">",
"     rosiglitazone",
"    </a>",
"    are not approved or generally used in pediatric patients, due to concerns about safety and weight gain (see",
"    <a class=\"local\" href=\"#H14\">",
"     'Medications'",
"    </a>",
"    above). &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     SURGICAL THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Severely obese adults with type 2 diabetes benefit from the weight reduction and increased insulin sensitivity that follows weight loss surgery (gastric bypass or adjustable banding). Seventy to 85 percent of adults with type 2 diabetes experience remission after gastric bypass [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36329/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. Moreover, the frequency of remission seems to be inversely related to age at time of surgery, duration of diabetes, and severity of disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36329/abstract/27-29\">",
"     27-29",
"    </a>",
"    ]. These observations suggest that earlier rather than delayed surgical intervention may be beneficial. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/31/33274?source=see_link&amp;anchor=H11#H11\">",
"     \"Surgical management of severe obesity\", section on 'Treatment for type 2 diabetes'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/19/28986?source=see_link&amp;anchor=H1665282#H1665282\">",
"     \"Management of persistent hyperglycemia in type 2 diabetes mellitus\", section on 'Surgical treatment of obesity'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Weight loss surgery is occasionally employed to treat severe obesity in adolescents, and outcomes from programs with the most experience generally show good efficacy and safety. Type 2 diabetes usually remits after surgery. For example, in a report of 11 adolescents with severe obesity (BMI 50 &plusmn; 5.9",
"    <span class=\"nowrap\">",
"     kg/m2)",
"    </span>",
"    and type 2 diabetes, the diabetes resolved after weight loss surgery in 91 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36329/abstract/28\">",
"     28",
"    </a>",
"    ]. In a comparison group of adolescents with type 2 diabetes mellitus who were followed during one year of medical treatment, there was no change in body weight, diabetes mellitus, or diabetic medication use. Another report compared gastric banding with weight loss by lifestyle change in 60 obese adults with type 2 diabetes for less than two years; both groups also received conventional diabetes therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36329/abstract/26\">",
"     26",
"    </a>",
"    ]. After two years of follow-up, 73 percent of the surgical group achieved remission of diabetes, compared with 13 percent of the group treated with lifestyle approaches to weight loss. Weight loss was significantly greater in the surgical group compared with the group treated with lifestyle intervention (p &lt;0.001). The remission of type 2 diabetes was related to weight loss and baseline A1c levels (p &lt;0.001).",
"   </p>",
"   <p>",
"    The experience with weight loss surgery in adolescents is limited but growing. Selection criteria for this age group are based on an evolving understanding of the special risks and benefits of surgery for this age group, as discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/47/16122?source=see_link\">",
"     \"Surgical management of severe obesity in adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The management goals of pediatric type 2 diabetes mellitus include maintenance of near-normal glycemic control, and treatment of identified comorbidities (hypertension, dyslipidemia, and nonalcoholic fatty liver diseases), with the expectation that these will reduce the risk of long-term vascular sequelae. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Goals'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/28/34249?source=see_link\">",
"       \"Comorbidities and complications of type 2 diabetes mellitus in children and adolescents\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We recommend strict glycemic control for children and adolescents with type 2 diabetes (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Our goal for strict glycemic control is maintenance of hemoglobin A1C below 7 percent and fasting plasma glucose (FPG) below 130",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (7.2",
"      <span class=\"nowrap\">",
"       mmol/L).",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Glycemic control'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment of type 2 diabetes is divided into nonpharmacologic, pharmacologic, and surgical therapy. Care by a multidisciplinary team provides the most ideal setting for the patient and family to acquire the knowledge and skills needed for successful management. Family involvement is essential to initiate and support the lifestyle changes required in the management of a pediatric patient with type 2 diabetes (",
"      <a class=\"graphic graphic_algorithm graphicRef68128 \" href=\"mobipreview.htm?1/30/1504\">",
"       algorithm 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Approach'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Nonpharmacologic therapy focuses on the reduction of excess weight by decreasing caloric intake while increasing physical activity and decreasing sedentary behaviors (ie, screen time). Because weight reduction improves glycemic control, we recommend that nonpharmacologic therapy be initiated in pediatric patients with type 2 disease (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Nonpharmacologic therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In children, the choice of weight management includes either weight reduction or weight maintenance and is dependent on the age of the patient (potential for linear growth), the degree of excessive weight, and the presence of comorbidities. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Weight goals'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Nutritional goals focus on changing the dietary habits of the patient and family. It is desirable for the family to consult with a registered dietitian who can provide instruction on how to adjust dietary behaviors to reduce caloric intake and assist the family, using approaches that are sensitive to the family&rsquo;s culture. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Dietary prescription'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Decreased sedentary behavior (eg, television, computer, video games) and increased physical activity improve insulin secretion. Activities should be titrated to the degree of excessive weight to avoid undue stress on the lower extremities. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Physical activity'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In our practice, we initiate pharmacologic therapy in symptomatic patients at presentation and in patients initially treated with nonpharmacologic therapy who fail to achieve strict glycemic control. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Pharmacologic therapy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H18\">",
"       'Therapeutic choices'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A large clinical trial showed that among adolescents with type 2 diabetes who initially respond to",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?12/59/13238?source=see_link\">",
"       metformin",
"      </a>",
"      , nearly half failed to maintain glycemic control after a median time of &lt;1 year. The failure rate for metformin plus lifestyle intervention was not significantly different from that for metformin alone. Adolescents receiving an intensive lifestyle intervention in addition to metformin had modest improvements in weight loss as compared to those treated with metformin alone. Combined treatment with metformin and the insulin sensitizer",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?13/35/13879?source=see_link\">",
"       rosiglitazone",
"      </a>",
"      to metformin reduced treatment failure by 25 percent compared with metformin alone, but also caused weight gain.",
"      <br/>",
"      <br/>",
"      Thus, almost 50 percent of subjects will respond to metformin. The addition of a second pharmacologic agent early in the course of type 2 diabetes in youth requires additional study before it can be recommended. (See",
"      <a class=\"local\" href=\"#H21976949\">",
"       'TODAY study'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Our approach at initial presentation, which is based upon the results of the above study and on clinical experience, is as follows:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Patients with severe hyperglycemia",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      ketosis are treated with insulin and nonpharmacologic therapy. Once plasma glucose approaches near-normal concentrations,",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?12/59/13238?source=see_link\">",
"       metformin",
"      </a>",
"      is added, and an attempt is made to gradually wean the patient off of insulin. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Insulin'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Symptomatic patients with mild hyperglycemia without ketosis are treated with",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?12/59/13238?source=see_link\">",
"       metformin",
"      </a>",
"      and nonpharmacologic therapy. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Metformin'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Asymptomatic patients are treated only with nonpharmacologic therapy. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Nonpharmacologic therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Our approach to ongoing care is as follows:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?12/59/13238?source=see_link\">",
"       Metformin",
"      </a>",
"      is administered to children who were initially treated with only nonpharmacologic therapy and fail to achieve strict glycemic control. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Metformin'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In children initially treated with both nonpharmacologic therapy and",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?12/59/13238?source=see_link\">",
"       metformin",
"      </a>",
"      , and who fail to meet glycemic targets, we use basal insulin analogs (glargine or detemir) as the next therapeutic agent. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Insulin'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Surgical weight loss may be considered for carefully selected severely obese adolescents with type 2 diabetes, particularly if the diabetes is not adequately controlled with pharmacologic intervention. Selection criteria for this age group are based on an evolving understanding of the special risks and benefits of surgery in this age group and careful assessment and management by a multidisciplinary team. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Surgical therapy'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?15/47/16122?source=see_link\">",
"       \"Surgical management of severe obesity in adolescents\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36329/abstract/1\">",
"      Pinhas-Hamiel O, Zeitler P. Acute and chronic complications of type 2 diabetes mellitus in children and adolescents. Lancet 2007; 369:1823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36329/abstract/2\">",
"      TODAY Study Group, Zeitler P, Hirst K, et al. A clinical trial to maintain glycemic control in youth with type 2 diabetes. N Engl J Med 2012; 366:2247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36329/abstract/3\">",
"      Dart AB, Sellers EA, Martens PJ, et al. High burden of kidney disease in youth-onset type 2 diabetes. Diabetes Care 2012; 35:1265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36329/abstract/4\">",
"      Grey M, Schreiner B, Pyle L. Development of a diabetes education program for youth with type 2 diabetes. Diabetes Educ 2009; 35:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36329/abstract/5\">",
"      Anderson BJ. Diabetes self-care: lessons from research on the family and broader contexts. Curr Diab Rep 2003; 3:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36329/abstract/6\">",
"      Anderson BJ, Cullen K, McKay S. Quality of life, family behavior, and health outcomes in children with type 2 diabetes. Pediatr Ann 2005; 34:722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36329/abstract/7\">",
"      American Diabetes Association Task Force for Writing Nutrition Principles and Recommendations for the Management of Diabetes and Related Complications. American Diabetes Association position statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes and related complications. J Am Diet Assoc 2002; 102:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36329/abstract/8\">",
"      Wrotniak BH, Epstein LH, Paluch RA, Roemmich JN. The relationship between parent and child self-reported adherence and weight loss. Obes Res 2005; 13:1089.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36329/abstract/9\">",
"      Reinehr T, Kiess W, Kapellen T, Andler W. Insulin sensitivity among obese children and adolescents, according to degree of weight loss. Pediatrics 2004; 114:1569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36329/abstract/10\">",
"      Willi SM, Martin K, Datko FM, Brant BP. Treatment of type 2 diabetes in childhood using a very-low-calorie diet. Diabetes Care 2004; 27:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36329/abstract/11\">",
"      Barlow SE, Dietz WH. Obesity evaluation and treatment: Expert Committee recommendations. The Maternal and Child Health Bureau, Health Resources and Services Administration and the Department of Health and Human Services. Pediatrics 1998; 102:E29.",
"     </a>",
"    </li>",
"    <li>",
"     Food and Nutrition Board Institute of Medicine of the National Academies of Science. Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids. 2002.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36329/abstract/13\">",
"      Ludwig DS, Pereira MA, Kroenke CH, et al. Dietary fiber, weight gain, and cardiovascular disease risk factors in young adults. JAMA 1999; 282:1539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36329/abstract/14\">",
"      Epstein LH, Roemmich JN, Paluch RA, Raynor HA. Influence of changes in sedentary behavior on energy and macronutrient intake in youth. Am J Clin Nutr 2005; 81:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36329/abstract/15\">",
"      Sothern MS. Exercise as a modality in the treatment of childhood obesity. Pediatr Clin North Am 2001; 48:995.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36329/abstract/16\">",
"      Dabelea D, Pihoker C, Talton JW, et al. Etiological approach to characterization of diabetes type: the SEARCH for Diabetes in Youth Study. Diabetes Care 2011; 34:1628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36329/abstract/17\">",
"      Gungor N, Hannon T, Libman I, et al. Type 2 diabetes mellitus in youth: the complete picture to date. Pediatr Clin North Am 2005; 52:1579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36329/abstract/18\">",
"      Jones KL, Arslanian S, Peterokova VA, et al. Effect of metformin in pediatric patients with type 2 diabetes: a randomized controlled trial. Diabetes Care 2002; 25:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36329/abstract/19\">",
"      Gottschalk M, Danne T, Vlajnic A, Cara JF. Glimepiride versus metformin as monotherapy in pediatric patients with type 2 diabetes: a randomized, single-blind comparative study. Diabetes Care 2007; 30:790.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36329/abstract/20\">",
"      TODAY Study Group, Zeitler P, Epstein L, et al. Treatment options for type 2 diabetes in adolescents and youth: a study of the comparative efficacy of metformin alone or in combination with rosiglitazone or lifestyle intervention in adolescents with type 2 diabetes. Pediatr Diabetes 2007; 8:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36329/abstract/21\">",
"      Copeland KC, Zeitler P, Geffner M, et al. Characteristics of adolescents and youth with recent-onset type 2 diabetes: the TODAY cohort at baseline. J Clin Endocrinol Metab 2011; 96:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36329/abstract/22\">",
"      Laffel L, Chang N, Grey M, et al. Metformin monotherapy in youth with recent onset type 2 diabetes: experience from the prerandomization run-in phase of the TODAY study. Pediatr Diabetes 2012; 13:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36329/abstract/23\">",
"      TODAY Study Group. Design of a family-based lifestyle intervention for youth with type 2 diabetes: the TODAY study. Int J Obes (Lond) 2010; 34:217.",
"     </a>",
"    </li>",
"    <li>",
"     Plotnick L. Diabetes Mellitus. In: Principles and Practice of Pediatric Endocrinology, Kappy SM, Allen DB, Geffner ME (Eds), Charles C. Thomas, Springfield 2005. p.635.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36329/abstract/25\">",
"      Schauer PR, Burguera B, Ikramuddin S, et al. Effect of laparoscopic Roux-en Y gastric bypass on type 2 diabetes mellitus. Ann Surg 2003; 238:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36329/abstract/26\">",
"      Dixon JB, O'Brien PE, Playfair J, et al. Adjustable gastric banding and conventional therapy for type 2 diabetes: a randomized controlled trial. JAMA 2008; 299:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36329/abstract/27\">",
"      Pories WJ, MacDonald KG Jr, Morgan EJ, et al. Surgical treatment of obesity and its effect on diabetes: 10-y follow-up. Am J Clin Nutr 1992; 55:582S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36329/abstract/28\">",
"      Inge TH, Miyano G, Bean J, et al. Reversal of type 2 diabetes mellitus and improvements in cardiovascular risk factors after surgical weight loss in adolescents. Pediatrics 2009; 123:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36329/abstract/29\">",
"      Dixon JB, Dixon AF, O'Brien PE. Improvements in insulin sensitivity and beta-cell function (HOMA) with weight loss in the severely obese. Homeostatic model assessment. Diabet Med 2003; 20:127.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5821 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.72.76.133-15E18CE5C3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_30_36329=[""].join("\n");
var outline_f35_30_36329=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GOALS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Glycemic control",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Approach",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      NONPHARMACOLOGIC THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Nutrition therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Weight goals",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Nutritional requirements",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Dietary prescription",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Physical activity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      PHARMACOLOGIC THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Indications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Medications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Insulin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Metformin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Insulin secretagogues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      THERAPEUTIC CHOICES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21976949\">",
"      TODAY study",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11242215\">",
"      - Treatment failure",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11242222\">",
"      - Weight gain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Initial treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Ongoing care",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Failure of nonpharmacologic therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11242319\">",
"      - Failure of metformin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      SURGICAL THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/5821\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5821|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?1/30/1504\" title=\"algorithm 1\">",
"      Rx type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5821|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?37/23/38257\" title=\"figure 1A\">",
"      CDC BMI for age boys 2 to 20 years",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?40/2/40993\" title=\"figure 1B\">",
"      CDC BMI for age girls 2 to 20 years",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5821|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/40/24203\" title=\"table 1\">",
"      Weight categories",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?0/28/459\" title=\"table 2\">",
"      Calculation of BMI",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/0/3078?source=related_link\">",
"      Alpha-glucosidase inhibitors and lipase inhibitors for treatment of diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/23/15734?source=related_link\">",
"      Amylin analogs for the treatment of diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/32/41480?source=related_link\">",
"      Clinical features and diagnosis of diabetic ketoacidosis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/28/34249?source=related_link\">",
"      Comorbidities and complications of type 2 diabetes mellitus in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/29/40410?source=related_link\">",
"      Complications and screening in children and adolescents with type 1 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/5/32858?source=related_link\">",
"      Definition; epidemiology; and etiology of obesity in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/50/20265?source=related_link\">",
"      Effects of exercise in diabetes mellitus in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/59/40889?source=related_link\">",
"      Epidemiology, presentation, and diagnosis of type 1 diabetes mellitus in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/25/4506?source=related_link\">",
"      Epidemiology, presentation, and diagnosis of type 2 diabetes mellitus in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/45/11993?source=related_link\">",
"      Estimation of blood glucose control in diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/61/42967?source=related_link\">",
"      Fast food for children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/25/38298?source=related_link\">",
"      Glucagon-like peptide-1-based therapies for the treatment of type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/25/7578?source=related_link\">",
"      Glycemic control and vascular complications in type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/35/43577?source=related_link\">",
"      Initial management of blood glucose in type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/24/30089?source=related_link\">",
"      Insulin therapy in type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/19/28986?source=related_link\">",
"      Management of persistent hyperglycemia in type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/26/38312?source=related_link\">",
"      Metformin in the treatment of diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/61/14298?source=related_link\">",
"      Overview of physical activity and strength training in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/46/35559?source=related_link\">",
"      Sulfonylureas and meglitinides in the treatment of diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/31/33274?source=related_link\">",
"      Surgical management of severe obesity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/47/16122?source=related_link\">",
"      Surgical management of severe obesity in adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/50/21290?source=related_link\">",
"      Thiazolidinediones in the treatment of diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/28/7626?source=related_link\">",
"      Treatment and complications of diabetic ketoacidosis in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_30_36330="Fish oil and marine omega-3 fatty acids";
var content_f35_30_36330=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"7\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Fish oil and marine omega-3 fatty acids",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/30/36330/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/30/36330/contributors\">",
"     Dariush Mozaffarian, MD, DrPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/30/36330/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/30/36330/contributors\">",
"     Robert H Fletcher, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/30/36330/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/30/36330/contributors\">",
"     David M Rind, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?35/30/36330/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 4, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ecologic studies found low rates of coronary heart disease (CHD) death among Greenland Eskimos consuming large amounts of seafood [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36330/abstract/1\">",
"     1",
"    </a>",
"    ]. Subsequent animal studies, observational studies, and clinical trials have examined the health effects of seafood consumption and identified the long-chain n-3 polyunsaturated fatty acids (n-3 PUFA) in fish oil, eicosapentaenoic acid (EPA, 20:5n-3), and docosahexaenoic acid (DHA, 22:6n-3) as the likely active constituents (",
"    <a class=\"graphic graphic_figure graphicRef58051 \" href=\"mobipreview.htm?36/55/37750\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36330/abstract/2-22\">",
"     2-22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    DHA also appears to be essential for early brain development during gestation and infancy. Maternal ingestion of fish during pregnancy and lactation are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/44/28362?source=see_link&amp;anchor=H22#H22\">",
"     \"Nutrition in pregnancy\", section on 'Fish'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/53/43864?source=see_link&amp;anchor=H24#H24\">",
"     \"Maternal nutrition during lactation\", section on 'Fish intake'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Fish oil consumption may also affect other clinical outcomes. These are discussed separately:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cognitive decline and dementia. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/25/41369?source=see_link&amp;anchor=H7#H7\">",
"       \"Prevention of dementia\", section on 'Low cholesterol and low fat diets'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/4/33865?source=see_link&amp;anchor=H1135167#H1135167\">",
"       \"Treatment of dementia\", section on 'Omega-3 fatty acids'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Depression and other neuropsychiatric disorders. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/52/30538?source=see_link&amp;anchor=H28#H28\">",
"       \"Psychopharmacological treatment for adolescent depression\", section on 'Omega-3 fatty acids'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Asthma and other inflammatory disorders. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/36/33354?source=see_link&amp;anchor=H29#H29\">",
"       \"Alternative and experimental agents for the treatment of asthma\", section on 'Dietary alterations'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PHARMACOKINETICS AND METABOLISM",
"    </span>",
"    &nbsp;&mdash;&nbsp;EPA and DHA are absorbed from the gastrointestinal tract and, as with other dietary fatty acids, are transported to the liver largely as triglycerides in chylomicron particles. From the liver, EPA and DHA are released into the circulation as triglycerides in lipoprotein particles (such as LDL-cholesterol [LDL-C] and HDL-cholesterol [HDL-C]) and as plasma phospholipids. Smaller amounts circulate as free fatty acids, largely bound to albumin.",
"   </p>",
"   <p>",
"    EPA and DHA are incorporated into cell membrane phospholipids throughout the body, particularly in the heart and brain, and stored in adipose tissue as triglycerides. Consumption of fish oil increases the concentration of EPA and DHA in plasma lipids and membrane phospholipids within days, with maximal incorporation at about two weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36330/abstract/23\">",
"     23",
"    </a>",
"    ]. Increases are dose-dependent but nonlinear, with a larger increase at lower doses and then smaller increments with increasing doses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36330/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Following cessation of consumption, washout occurs within one to three days in plasma lipid fractions, but takes much longer (one to two months) for cell membranes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36330/abstract/23\">",
"     23",
"    </a>",
"    ]. Relatively minor pharmacokinetic differences are seen between different oral formulations of fish oil (eg, triglycerides versus ethyl esters) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36330/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Compared with EPA and DHA, other n-3 PUFA such as docosapentaenoic acid (DPA, 22:5n-3) are present in much smaller amounts in fish oil, but may be biologically active and have important metabolites following consumption [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36330/abstract/25\">",
"     25",
"    </a>",
"    ]. EPA can also be metabolized to prostaglandin E3, an eicosanoid that mediates inflammation and thrombosis. Very little EPA (&lt;5 percent) is converted to DHA, although this conversion occurs to a greater extent in women, particularly during pregnancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36330/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For most health effects, the relative biologic importance of EPA versus DHA versus their associated metabolites is not well-established, except for early brain development for which DHA appears to be more important [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36330/abstract/27-30\">",
"     27-30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EFFECTS ON CARDIOVASCULAR RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fish oil influences several cardiovascular risk factors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36330/abstract/19,20,31-40\">",
"     19,20,31-40",
"    </a>",
"    ]. Generally speaking, the physiologic effects of fish oil occur within weeks of habitual consumption and may result from altered cell membrane fluidity and receptor responses following incorporation of n-3 PUFA into cell membranes and direct binding of n-3 PUFA to cytosolic receptors that regulate gene transcription [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36330/abstract/41-43\">",
"     41-43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These physiologic effects appear to have varying dose-responses and time-responses of effect (",
"    <a class=\"graphic graphic_figure graphicRef78417 \" href=\"mobipreview.htm?4/34/4640\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36330/abstract/22\">",
"     22",
"    </a>",
"    ]. At typical dietary intakes, antiarrhythmic effects predominate, and such effects may reduce the risk of sudden cardiac death and CHD death within weeks. At higher doses, maximum antiarrhythmic effects have been achieved, but other physiologic effects may begin to modestly impact other clinical outcomes, although some of these physiologic effects (such as triglyceride-lowering) may require months to years of consumption before lower risk of clinical outcomes is seen.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Blood lipids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fish oil consumption lowers serum triglyceride concentrations by 25 to 30 percent, an effect within the range of efficacy of other triglyceride-lowering drugs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36330/abstract/44-46\">",
"     44-46",
"    </a>",
"    ]. The potential cellular mechanisms for this effect have been previously reviewed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36330/abstract/47\">",
"     47",
"    </a>",
"    ]. The dose-response appears to be fairly linear [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36330/abstract/46\">",
"     46",
"    </a>",
"    ]: little triglyceride-lowering is seen with dietary doses or low-dose (&lt;1",
"    <span class=\"nowrap\">",
"     g/day)",
"    </span>",
"    supplementation, whereas higher doses (3 to 4",
"    <span class=\"nowrap\">",
"     g/day)",
"    </span>",
"    appreciably lower triglyceride levels (",
"    <a class=\"graphic graphic_figure graphicRef78417 \" href=\"mobipreview.htm?4/34/4640\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    However, the fish oil doses required to lower triglycerides are several-fold higher than the doses that may reduce coronary mortality (see below). Additionally, the clinical benefits of lowering elevated plasma triglyceride levels, by any pharmacologic means, have not yet been convincingly demonstrated. Thus, triglyceride-lowering per se is unlikely to account for benefits of low-dose fish oil (&lt;2",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    or less) for reducing CHD death, but such effects may contribute over time to modest risk reductions in other clinical outcomes (eg, nonfatal MI). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/47/35578?source=see_link&amp;anchor=H18#H18\">",
"     \"Approach to the patient with hypertriglyceridemia\", section on 'Pharmacologic therapy (including fish oil)'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Fish oil supplementation also modestly raises HDL-C concentrations (+3 percent) and, particularly in patients with hypertriglyceridemia, raises LDL-C concentrations (+5 percent) and lowers the proportion of small dense LDL-C particles [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36330/abstract/48-50\">",
"     48-50",
"    </a>",
"    ]. This increase in LDL particle size may in part account for the higher LDL-C concentrations; that is, LDL-C concentration may slightly increase but without appreciable change in the number of circulating LDL particles. Given the frequently coexisting relationship of high triglycerides, low HDL-C, and small dense LDL particles in many individuals, the effects of fish oil to lower triglycerides, raise HDL-C, and decrease the proportions of small dense LDL particles appear concordant. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/51/28474?source=see_link&amp;anchor=H2#H2\">",
"     \"Lipid lowering with diet or dietary supplements\", section on 'Fish oil and omega-3 fatty acids'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Blood pressure and systemic vascular resistance",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a meta-analysis of 36 randomized trials, fish oil supplementation (median dose 3.7 g",
"    <span class=\"nowrap\">",
"     /day,",
"    </span>",
"    median duration 8 weeks) among adults older than age 45 lowered systolic blood pressure (BP) by 3.5 mmHg and diastolic BP by 2.4 mmHg [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36330/abstract/35\">",
"     35",
"    </a>",
"    ]. In younger healthy adults (younger than age 45), the BP-lowering effects were less pronounced [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36330/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    At the fish oil doses used in these trials (one trial 0.2 g",
"    <span class=\"nowrap\">",
"     /day,",
"    </span>",
"    others ranging from 1.0 to 15.0 g",
"    <span class=\"nowrap\">",
"     /day),",
"    </span>",
"    the BP-lowering did not appear to be dose-dependent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36330/abstract/35\">",
"     35",
"    </a>",
"    ]. However, observational analyses suggest that, at lower dietary doses, the dose-response may be more linear [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36330/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Animal studies and observational studies in humans indicate that the BP-lowering effect of fish oil results from a reduction in systemic vascular resistance (ie, lower arteriolar resistance), with unchanged cardiac output [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36330/abstract/37,51\">",
"     37,51",
"    </a>",
"    ]. In vitro studies demonstrate that n-3 PUFA induce nitric oxide production, modulate endothelial activation, and modify the location and function of cell membrane caveolae proteins including eNOS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36330/abstract/52-55\">",
"     52-55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In short-term trials in humans, fish oil consumption increases biomarkers of nitric oxide production, mitigates peripheral vasoconstrictive responses to norepinephrine and angiotensin II, improves arterial wall compliance, and enhances vasodilatory responses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36330/abstract/33,34,56-58\">",
"     33,34,56-58",
"    </a>",
"    ]. These effects, separately or in sum, could account for lowering of systemic vascular resistance.",
"   </p>",
"   <p>",
"    In summary, the evidence indicates that fish oil consumption lowers systolic BP by approximately 3 to 5 mmHg and diastolic BP by approximately 2 to 3 mmHg, due to reductions in systemic vascular resistance, with a dose-response that appears more linear at lower (dietary) doses, and plateaus at higher (supplement) doses (",
"    <a class=\"graphic graphic_figure graphicRef78417 \" href=\"mobipreview.htm?4/34/4640\">",
"     figure 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/43/42679?source=see_link&amp;anchor=H11#H11\">",
"     \"Diet in the treatment and prevention of hypertension\", section on 'Fish oil'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Heart rate",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a meta-analysis of 30 randomized trials, fish oil supplementation (median dose 3.5 g",
"    <span class=\"nowrap\">",
"     /day,",
"    </span>",
"    median duration 8 weeks) reduced resting heart rate (HR) by 1.6 bpm (95% CI 0.6-2.5) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36330/abstract/36\">",
"     36",
"    </a>",
"    ]. The effect appeared to vary with duration of consumption: in trials of &lt;12 weeks duration, HR was reduced by 0.7 bpm, which was not statistically significant, while in trials of &ge;12 weeks duration, HR was reduced by 2.5 bpm.",
"   </p>",
"   <p>",
"    Similar to BP-lowering effects, the HR-lowering did not appear to be dose-dependent at the fish oil doses used in these trials (range 1 to 15 g",
"    <span class=\"nowrap\">",
"     /day)",
"    </span>",
"    but did appear to be dose-dependent at lower (dietary) doses with a threshold effect at approximately 300 mg",
"    <span class=\"nowrap\">",
"     /day",
"    </span>",
"    EPA+DHA (",
"    <a class=\"graphic graphic_figure graphicRef78417 \" href=\"mobipreview.htm?4/34/4640\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36330/abstract/36,37,59\">",
"     36,37,59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Resting HR is determined by intrinsic sinus node function, vagal and sympathetic activity, and systolic and diastolic cardiac function. Experimental studies in isolated rat myocytes, exercising dogs, and nonhuman primates confirm that fish oil lowers resting HR and suggest that this could result from direct cardiac electrophysiologic effects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36330/abstract/19,20,60\">",
"     19,20,60",
"    </a>",
"    ]. As an example, membrane n-3 PUFA may alter myocardial ion channel function to modulate sinus node automaticity or responsiveness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36330/abstract/19,20\">",
"     19,20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Fish oil may also lower HR by more indirect effects, such as by improving left ventricular diastolic filling (see below) or augmenting vagal tone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36330/abstract/61\">",
"     61",
"    </a>",
"    ]. Given the relationship of higher resting HR with risk of CHD death and sudden cardiac death [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36330/abstract/62-68\">",
"     62-68",
"    </a>",
"    ], the HR-lowering effect of fish oil may account in part for its potential clinical benefits.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Heart rate variability",
"    </span>",
"    &nbsp;&mdash;&nbsp;Heart rate variability (HRV) is influenced by underlying resting HR, autonomic function, circadian rhythms, and underlying cardiac health. Experimental trials evaluating fish oil and HRV have been inconsistent possibly due to small numbers, variable doses of fish oil used, relatively short durations of intake (weeks to months), or limited periods of HRV assessment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36330/abstract/61,69-77\">",
"     61,69-77",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, a study of patients undergoing coronary angiography found that tissue EPA and DHA levels were correlated with HRV [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36330/abstract/78\">",
"     78",
"    </a>",
"    ], and a population-based study found that increased dietary consumption of EPA and DHA was associated with favorable effects on HRV even after adjusting for resting HR [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36330/abstract/79\">",
"     79",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Cardiac relaxation, filling, and efficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Left ventricular diastolic filling consists of two phases: an early phase of active (energy-dependent) relaxation, and a second phase of more passive (compliance-dependent) filling (with a final brief phase due to atrial contraction). Abnormalities of early relaxation are among the earliest signs of ischemic heart disease, while abnormal passive filling (reduced compliance) often results from long-standing hypertensive heart disease or ischemic heart disease.",
"   </p>",
"   <p>",
"    In nonhuman primates, 24 months of fish oil consumption improved left ventricular diastolic filling, increasing both end-diastolic volume and stroke volume, and improved myocardial efficiency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36330/abstract/32,80\">",
"     32,80",
"    </a>",
"    ]. Consistent with this, seven weeks of fish oil (4 g",
"    <span class=\"nowrap\">",
"     /day)",
"    </span>",
"    improved the early phase of diastolic filling in a small experimental trial in healthy adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36330/abstract/81\">",
"     81",
"    </a>",
"    ]. This relatively acute improvement suggests a functional or metabolic, rather than structural, effect on energy-dependent filling.",
"   </p>",
"   <p>",
"    Fish oil may also improve the second (compliance-dependent) phase of diastolic filling by augmenting or preventing decline in ventricular compliance. In hypertensive rats, fish oil supplementation reduced left ventricular hypertrophy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36330/abstract/82\">",
"     82",
"    </a>",
"    ]. In a cohort study of older adults, habitual modest fish consumption was associated with a trend toward lower electrocardiographically-defined left ventricular mass, a measure of left ventricular size and hypertrophy, and with a higher",
"    <span class=\"nowrap\">",
"     E/A",
"    </span>",
"    ratio, a measure of more normal diastolic filling [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36330/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In healthy adults, fish oil does not appear to directly impact cardiac systolic function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36330/abstract/37,80,81\">",
"     37,80,81",
"    </a>",
"    ], except for higher-cardiac stroke volume as a result of slower resting heart rate (increasing filling time) and enhanced diastolic filling, [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36330/abstract/32,37\">",
"     32,37",
"    </a>",
"    ]. However, in patients with established heart failure, fish oil consumption improves left ventricular ejection fraction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36330/abstract/83,84\">",
"     83,84",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In both animal experiments and one randomized trial in humans, fish oil consumption improves myocardial efficiency, reducing myocardial oxygen demand without a decrement in performance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36330/abstract/85\">",
"     85",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Arrhythmic risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;In animal-experimental and in vitro studies, n-3 PUFA directly affect atrial and ventricular myocyte electrophysiology, mediated at least in part by effects on myocardial membrane ion channels and possibly cell-cell connexins [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36330/abstract/18-20,86-88\">",
"     18-20,86-88",
"    </a>",
"    ]. In isolated rat myocytes, particularly ischemic cells that are partially depolarized, both EPA and DHA reduce myocyte excitability and reduce cytosolic calcium fluctuations via inhibition of membrane Na+ and L-type Ca++ ion channels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36330/abstract/18-20\">",
"     18-20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, these experiments showed similar effects with n-6 PUFA, which in humans have neither comparable strength nor specificity for associations with CHD death or sudden cardiac death [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36330/abstract/16,89,90\">",
"     16,89,90",
"    </a>",
"    ]. Indeed, capsules containing n-6 PUFA have been used as controls in clinical trials of n-3 PUFA. This lack of specificity for n-3 PUFA makes it difficult to ascertain the relevance of these in vitro effects to observed clinical benefits of fish oil.",
"   </p>",
"   <p>",
"    Confirmation of a direct anti-arrhythmic effect of n-3 PUFA on hearts in humans is limited by the absence of any reliable and easily obtainable biomarker of such effects. Nevertheless, the strong relationships of n-3 PUFA consumption with risk of CHD death or sudden cardiac death (and possibly also atrial fibrillation) in both observational studies and clinical trials (reviewed below), together with documented effects of n-3 PUFA on heart rate (and likely also heart rate variability), indicate that fish oil has effects on cardiac electrophysiology that, either directly or indirectly, are likely to reduce the risk of arrhythmias.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Insulin sensitivity",
"    </span>",
"    &nbsp;&mdash;&nbsp;n-3 PUFA do not have major effects on biomarkers of glucose metabolism or insulin sensitivity. In a meta-analysis of 26 randomized trials, fish oil supplementation (2 to 22 g",
"    <span class=\"nowrap\">",
"     /day)",
"    </span>",
"    slightly raised fasting glucose levels among noninsulin-dependent diabetics and significantly lowered fasting glucose levels among insulin-dependent diabetics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36330/abstract/48\">",
"     48",
"    </a>",
"    ]. However, fish oil did not significantly affect hemoglobin A1c levels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36330/abstract/48\">",
"     48",
"    </a>",
"    ]. Two other meta-analyses in patients with noninsulin dependent diabetes found no overall effects of fish oil (0.9 to 18 g",
"    <span class=\"nowrap\">",
"     /day)",
"    </span>",
"    on fasting glucose or hemoglobin A1c levels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36330/abstract/91,92\">",
"     91,92",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a pooled analysis of three cohorts, estimated n-3 PUFA consumption from seafood was associated with modestly higher incidence of type 2 diabetes (comparing the top to the bottom quintile, 24 percent higher risk) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36330/abstract/93\">",
"     93",
"    </a>",
"    ]. In contrast, significant associations with diabetes have not been seen in other observational studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36330/abstract/94-96\">",
"     94-96",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In experimental studies, n-3 PUFA regulate hepatic genes such as PPAR-alpha and REBP-1 may modestly raise hepatic glucose production while also reducing hyperinsulinemia, but without causing peripheral insulin resistance or systemic metabolic dysfunction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36330/abstract/97,98\">",
"     97,98",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Given beneficial effects of fish oil on several markers of the metabolic syndrome, including lowering triglycerides, increasing HDL-C and LDL particle size, lowering BP, and lowering inflammation, it appears unlikely that small increases in fasting glucose levels would offset other metabolic and cardiovascular benefits. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Blood lipids'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H5\">",
"     'Blood pressure and systemic vascular resistance'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H12\">",
"     'Inflammation'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Coagulation and thrombosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;High doses of fish oil (3 to 15 g",
"    <span class=\"nowrap\">",
"     /day)",
"    </span>",
"    increase bleeding time, but this has not been associated with higher rates of clinical bleeding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36330/abstract/99\">",
"     99",
"    </a>",
"    ]. In a review of 9 randomized trials (n = 2,612), including people taking aspirin or warfarin, no consistent associations were seen between fish oil use or fish oil dose and bleeding risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36330/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    n-3 PUFA suppress platelet activating factor in experimental in vitro studies, but in human trials significant effects of fish oil consumption on platelet aggregation are not reliably seen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36330/abstract/46\">",
"     46",
"    </a>",
"    ]. Consistent changes in fibrinogen, factor VII, or factor VIII are also not identified in controlled trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36330/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thus, at least at doses up to 4 g",
"    <span class=\"nowrap\">",
"     /day",
"    </span>",
"    (and likely higher), clinically apparent effects of fish oil on bleeding risk are not evident. Effects on platelet function do not appear to be a major pathway for lower risk of cardiovascular outcomes, although subtle effects cannot be excluded as a possible contributing mechanism.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Inflammation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Potential anti-inflammatory effects of fish oil have received much attention in review articles and the lay press, given the role of EPA and DHA as precursors to specific eicosanoids and other inflammatory mediators. However, production and breakdown of these inflammatory metabolites is highly regulated, and thus it is unclear that changes in substrate due to consumption of EPA or DHA (from either diet or supplements) have major effects on these pathways in humans.",
"   </p>",
"   <p>",
"    Controlled trials have generally not detected significant effects of fish oil intake on C-reactive protein levels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36330/abstract/46,78\">",
"     46,78",
"    </a>",
"    ]. Conversely, fish oil supplementation does appear to inhibit production of cytokines, including interleukin-1beta and tumor necrosis factor-alpha [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36330/abstract/79\">",
"     79",
"    </a>",
"    ]. However, to achieve these effects, relative high doses (&gt;2 g",
"    <span class=\"nowrap\">",
"     /day)",
"    </span>",
"    of fish oil may be necessary, and it is not clear that lower doses produce substantial anti-inflammatory effects.",
"   </p>",
"   <p>",
"    Several, though not all, randomized trials in humans have demonstrated that fish oil consumption also lowers circulating markers of endothelial dysfunction, such as E-selectin, vascular cell adhesion molecule-1 (VCAM-1), and intercellular adhesion molecule-1 (ICAM-1) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36330/abstract/78,100\">",
"     78,100",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Experimental evidence suggests that other metabolites of EPA and DHA, including resolvins, protectins, and maresins, may play crucial roles in active resolution of inflammation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36330/abstract/101\">",
"     101",
"    </a>",
"    ]. In animal models, these metabolites protect a range of tissues from the adverse effects of acute inflammatory insults. The relevance of these pathways to clinically-observed benefits of fish or fish oil consumption in humans has not yet been studied.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     CARDIOVASCULAR OUTCOMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiovascular disease encompasses a diverse range of outcomes, including coronary heart disease (CHD), various ventricular and atrial cardiac arrhythmias, ischemic and hemorrhagic stroke, congestive heart failure, valvular heart diseases, and peripheral artery disease. CHD can be further subdivided into components, including chronic progression of stable atherosclerotic plaque (occurring over years, resulting in angina), plaque instability (occurring over weeks to months), acute plaque rupture (occurring over seconds, resulting in acute coronary syndrome), thrombosis and coagulation (occurring over minutes to hours), and secondary cardiac arrhythmia (occurring over seconds, resulting in sudden cardiac death or CHD death) (",
"    <a class=\"graphic graphic_figure graphicRef82187 \" href=\"mobipreview.htm?17/9/17566\">",
"     figure 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    While some risk factors for the different pathways leading to these conditions are shared (eg, high blood pressure is a risk factor for both chronic progression of atherosclerosis and acute plaque rupture), each of these pathways of risk also has distinct etiologic and physiologic determinants.",
"   </p>",
"   <p>",
"    Thus, just as fish oil has varying dose and time responses on pathways of cardiovascular risk, the effect of fish oil on clinical cardiovascular events also varies considerably depending on the specific endpoint and its pathophysiologic determinants [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36330/abstract/102\">",
"     102",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Atherosclerosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Observational studies and randomized trials have examined the long-term effects of fish oil on the development and progression of atherosclerosis.",
"   </p>",
"   <p>",
"    An observational study in 229 women found that after adjustment for other risk factors, during 3.2 years of follow-up, modest dietary consumption of n-3 PUFA was associated with less progression of coronary stenoses and fewer new lesions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36330/abstract/103\">",
"     103",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Results from randomized trials include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A small randomized trial (n = 59) did not detect significant effects of fish oil supplementation (6 g",
"      <span class=\"nowrap\">",
"       /day",
"      </span>",
"      for 2.3 years) on the progression of coronary atherosclerosis as measured by coronary angiography [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/30/36330/abstract/104\">",
"       104",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A randomized trial (n = 223) found modest but statistically significant effects of fish oil supplementation (1.65 g",
"      <span class=\"nowrap\">",
"       /day",
"      </span>",
"      for 2 years) on progression of coronary, but not carotid, atherosclerosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/30/36330/abstract/105,106\">",
"       105,106",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A third open-label randomized trial evaluated the effects of EPA (1.8 g",
"      <span class=\"nowrap\">",
"       /day",
"      </span>",
"      for 2.1 years) on progression of carotid atherosclerosis in 81 Japanese patients with type 2 diabetes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/30/36330/abstract/107\">",
"       107",
"      </a>",
"      ]. Individuals randomized to EPA had less progression of both mean and maximal intimal medial thickness.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although confirmation in additional studies is warranted, together these few studies suggest that fish oil consumption may modestly reduce chronic progression of atherosclerosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Coronary restenosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several clinical trials have evaluated the effect of fish oil supplementation on coronary artery restenosis following angioplasty, with mixed results [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36330/abstract/108\">",
"     108",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A meta-analysis of 12 randomized trials found a nonsignificant trend toward lower risk of restenosis with fish oil consumption (RR = 0.87, 95% CI = 0.73-1.05) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36330/abstract/108\">",
"     108",
"    </a>",
"    ]. However, there was significant heterogeneity among studies, and one of the largest negative trials (n = 447) was not included because it used a high (8 g",
"    <span class=\"nowrap\">",
"     /day)",
"    </span>",
"    dose of fish oil that was outside the inclusion criteria of the meta-analysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36330/abstract/109\">",
"     109",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thus, overall there is currently no convincing evidence that fish oil supplementation decreases the risk of coronary restenosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/25/29081?source=see_link&amp;anchor=H19#H19\">",
"     \"Possible role of long-term medical therapies to prevent restenosis following percutaneous coronary intervention\", section on 'Fish oil'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Acute coronary syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonfatal myocardial infarction (MI) and acute coronary syndrome (ACS) result from initial chronic progression of atherosclerosis, followed by development of plaque instability and acute plaque rupture, followed by acute thrombosis. Thus, benefits of n-3 PUFA on any or all of these processes could reduce risk of nonfatal",
"    <span class=\"nowrap\">",
"     MI/ACS.",
"    </span>",
"    A limited number of studies suggest that fish oil consumption may modestly reduce the chronic progression of stable arterial plaque [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36330/abstract/110\">",
"     110",
"    </a>",
"    ]; in contrast, appreciable effects on thrombosis are not seen until very high levels of supplementation (&gt;5-10 g",
"    <span class=\"nowrap\">",
"     /day)",
"    </span>",
"    are reached.",
"   </p>",
"   <p>",
"    Effects of fish oil consumption on plaque instability are not well-established. In one randomized trial among 188 patients undergoing carotid endarterectomy, n-3 PUFA supplementation (1.4 g",
"    <span class=\"nowrap\">",
"     /day",
"    </span>",
"    for median 42 days) resulted in fewer plaques with thin fibrous caps and signs of inflammation and more plaques with thick fibrous caps and no signs of inflammation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36330/abstract/111\">",
"     111",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The dose- and time-responses of effects of n-3 PUFA on risk factors for atherosclerosis progression and plaque rupture, such as triglyceride and blood pressure levels (",
"    <a class=\"graphic graphic_figure graphicRef78417 \" href=\"mobipreview.htm?4/34/4640\">",
"     figure 2",
"    </a>",
"    ), suggests that higher doses and prolonged durations of consumption may be necessary to lower risk of nonfatal",
"    <span class=\"nowrap\">",
"     MI/ACS",
"    </span>",
"    appreciably.",
"   </p>",
"   <p>",
"    Observational studies in Western populations consuming modest levels of n-3 PUFA (&lt;1 g",
"    <span class=\"nowrap\">",
"     /day)",
"    </span>",
"    have found equivocal benefits for nonfatal",
"    <span class=\"nowrap\">",
"     MI/ACS",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36330/abstract/3,8,9,12,14-16,110,112\">",
"     3,8,9,12,14-16,110,112",
"    </a>",
"    ]. In a prospective observational study among 41,578 Japanese men and women (in whom dietary intakes of n-3 PUFA are much higher than in Western populations), individuals in the highest quintile of dietary n-3 PUFA (median 2.1 g",
"    <span class=\"nowrap\">",
"     /day)",
"    </span>",
"    had a 67 percent lower incidence of nonfatal coronary events (95% CI = 37-83%) compared with those in the lowest quintile (median 0.3 g",
"    <span class=\"nowrap\">",
"     /day)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36330/abstract/113\">",
"     113",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some large RCTs of fish or fish oil have demonstrated significant reductions in acute coronary syndromes or other nonfatal CHD events [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36330/abstract/3,114-116\">",
"     3,114-116",
"    </a>",
"    ], while other large trials have not [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36330/abstract/117-121\">",
"     117-121",
"    </a>",
"    ]. Most of the positive trials demonstrated benefit with regard to CHD mortality only (see",
"    <a class=\"local\" href=\"#H17\">",
"     'CHD death and sudden cardiac death'",
"    </a>",
"    below). A 2012 meta-analysis of 13 randomized trials (N = 53,875) found a statistically-nonsignificant reduction in MI (relative risk 0.89, 95% CI 0.76-1.04) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36330/abstract/122\">",
"     122",
"    </a>",
"    ]. Thus, it is currently unclear that fish oil has any major effects on nonfatal cardiac events.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     CHD death and sudden cardiac death",
"    </span>",
"    &nbsp;&mdash;&nbsp;CHD death and sudden cardiac death are clinically defined events that physiologically overlap and often share the final common pathway of ventricular arrhythmia, often ischemia-induced ventricular fibrillation. Systematic reviews and meta-analyses have found significant reductions or strong trends toward reductions in total mortality, showing a decrease in CHD death while having little effect on other causes of mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36330/abstract/21,22,123-128\">",
"     21,22,123-128",
"    </a>",
"    ]. Representative studies include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A systematic review and meta-analysis pooled data from 19 large prospective cohort studies and randomized trials [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/30/36330/abstract/2-4,6-16,113,114,119,129-133\">",
"       2-4,6-16,113,114,119,129-133",
"      </a>",
"      ], including a total of 5319 cardiac deaths (CHD death or sudden death) in 356,028 participants consuming either fish or fish oil supplements, and found that consumption of marine n-3 PUFA significantly lowered the risk of CHD death and sudden cardiac death [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/30/36330/abstract/22\">",
"       22",
"      </a>",
"      ]. In contrast to the apparent graded dose-response for nonfatal CHD events, the dose-response for CHD death and sudden cardiac death appeared nonlinear: compared with little or no intake, modest consumption (approximately 250 to 500 mg",
"      <span class=\"nowrap\">",
"       /day",
"      </span>",
"      EPA+DHA) lowered relative risk by approximately 36 percent, and higher intakes did not substantially further lower CHD mortality. Effects appeared to be very similar comparing studies of generally healthy populations (ie, primary prevention; largely prospective cohort studies) versus studies of individuals with established heart disease (ie, secondary prevention; largely randomized trials).",
"     </li>",
"     <li>",
"      Several subsequent meta-analyses have included other prospective observational studies and large randomized trials evaluating the effects of fish or fish oil consumption on CHD outcomes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/30/36330/abstract/126-128\">",
"       126-128",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Subsequent meta-analyses have found smaller reductions in cardiovascular mortality than earlier analyses [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/30/36330/abstract/122,134\">",
"       122,134",
"      </a>",
"      ]. A 2012 meta-analysis of 13 randomized trials of fish oil supplementation (N = 56,407) found a reduction in cardiac mortality (relative risk [RR] 0.91, 95% CI 0.85-0.98) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/30/36330/abstract/122\">",
"       122",
"      </a>",
"      ]. The authors adjusted for multiple comparisons and concluded this RR reduction was not statistically significant; however, this adjustment may have been overly conservative. In this same meta-analysis (seven trials, N = 41,751), there was also a statistically-nonsignificant reduction in sudden death (RR 0.87, CI 0.75-1.01).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Overall, the findings from these studies suggest that consumption of fish or fish oil reduces CHD mortality, including risk of fatal MI and sudden cardiac death, in populations with and without established CHD.",
"   </p>",
"   <p>",
"    In patients at higher risk for ischemia-related cardiac arrhythmias, the time-course of any benefit may be relatively early. In the large GISSI-Prevenzione trial among patients with recent MI (n = 11,323), fish oil (1 g daily for one year) reduced mortality within 3 months, entirely due to fewer sudden cardiac deaths [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36330/abstract/116\">",
"     116",
"    </a>",
"    ]. Effects did not appear to vary whether or not patients were receiving antiplatelet medications, beta-blockers, ACE-inhibitors, or statins [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36330/abstract/135\">",
"     135",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast to these large trials showing benefits for cardiac death, more recent trials have not found significant effects on CHD mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36330/abstract/114,117-121\">",
"     114,117-121",
"    </a>",
"    ]. In recent secondary prevention trials, nearly all or the majority of participants received maximal medical therapy including",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    , angiotensin converting enzyme (ACE) inhibitors, beta-blockers, and cholesterol-lowering drugs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36330/abstract/118,120\">",
"     118,120",
"    </a>",
"    ]. It is possible that the beneficial effect of omega-3 fatty acids in reducing the risk of sudden cardiac death may be diminished in patients already receiving aggressive pharmacologic risk factor management for secondary prevention of CHD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36330/abstract/136\">",
"     136",
"    </a>",
"    ]. Larger trials are needed with long-term follow-up to clarify whether omega-3 fatty acids might improve cardiac mortality in patients receiving aggressive treatment for primary or secondary prevention of CHD.",
"   </p>",
"   <p>",
"    Overall, however, there is concordance of evidence from controlled trials of physiologic risk factors, prospective observational studies of clinical endpoints, and adequately powered randomized controlled trials of clinical endpoints that modest n-3 PUFA consumption, compared to little or none, reduces CHD mortality.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Total mortality",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a meta-analysis of randomized controlled trials, n-3 PUFA consumption appeared to reduce total mortality (RR 0.83, 95% CI 0.68-1.00) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36330/abstract/22\">",
"     22",
"    </a>",
"    ]. Subsequent meta-analyses of randomized trials similarly demonstrated significant reductions or strong trends toward reductions in total mortality with n-3 PUFA consumption [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36330/abstract/126,127\">",
"     126,127",
"    </a>",
"    ]. A 2012 meta-analysis of 17 randomized trials of fish oil supplementation (N = 63,279) found a statistically-nonsignificant trend toward a reduction in total mortality (RR 0.96, CI 0.91-1.02) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36330/abstract/122\">",
"     122",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The magnitudes of these effects on total mortality are consistent with modest expected benefits if n-3 PUFA consumption were to reduce CHD death without major effects on other causes of mortality. In other words, in given populations, the magnitude of reduction in total mortality appears to correspond to approximately one-third reduction in the proportion of all deaths due to",
"    <span class=\"nowrap\">",
"     CHD/sudden",
"    </span>",
"    cardiac death in that population. Most of the trials in the meta-analysis were performed in subjects with known CHD or at high risk for CHD, in whom approximately half of all deaths would be attributable to CHD or sudden cardiac death. Thus, a proportionally smaller effect of n-3 PUFA consumption on total mortality would be anticipated in populations having a lower proportion of total deaths attributable to CHD, eg, in the general population of middle-aged adults (in whom approximately one quarter of deaths would be due to CHD) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36330/abstract/137\">",
"     137",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Consistent with this, a cohort study involving 2692 older adults from four counties in the United States that had 16 years of follow-up found an association between total n-3 PUFA levels measured at baseline and total mortality (hazard ratio comparing the highest and lowest quintiles 0.73, 95% CI 0.61-0.86) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36330/abstract/138\">",
"     138",
"    </a>",
"    ]. This was primarily due to lower rates of cardiovascular mortality in those with higher levels of n-3 PUFA, with higher levels of DHA, in particular, associated with lower rates of arrhythmic death.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Recurrent ventricular tachyarrhythmias",
"    </span>",
"    &nbsp;&mdash;&nbsp;Three small randomized trials have examined whether fish oil supplementation affects recurrent ventricular tachyarrhythmias during one to two years follow-up in patients with preexisting ventricular tachyarrhythmias and implantable cardioverter-defibrillators (ICDs) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36330/abstract/139-141\">",
"     139-141",
"    </a>",
"    ]. One of these trials showed significant benefits, and two showed no significant effects.",
"   </p>",
"   <p>",
"    A meta-analysis of outcomes in these trials at one year follow-up found no overall effect of fish oil supplementation on recurrent tachyarrhythmia (RR 0.93, CI 0.70-1.24) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36330/abstract/142\">",
"     142",
"    </a>",
"    ]. There was, however, significant heterogeneity between trials. Additionally, the confidence interval around the relative risk is broad and includes both potential increases and decreases in recurrent tachyarrhythmia that might be clinically important if real, suggesting that further trials are needed. A second meta-analysis found similar results [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36330/abstract/143\">",
"     143",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The pathoetiology of recurrent (ectopic or reentrant) ventricular tachyarrhythmias in patients with ICDs, a small minority of patients, is likely to be different from the pathoetiology of first-onset (often ischemia-induced) ventricular fibrillation that causes CHD death and sudden cardiac death in the general population and in the great majority of patients with established CHD. Thus, it is uncertain whether the results of trials in patients with ICDs have direct relevance to the effects of n-3 PUFA on cardiac death in generally healthy individuals and those with established CHD (reviewed above).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Atrial fibrillation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although some observational studies have found positive results of n-3 PUFA intake in preventing atrial fibrillation (AF), randomized trials have not found convincing benefit.",
"   </p>",
"   <p>",
"    Some [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36330/abstract/144\">",
"     144",
"    </a>",
"    ], but not all [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36330/abstract/145-147\">",
"     145-147",
"    </a>",
"    ], observational studies have found an association between fish oil consumption and reduced risk of atrial fibrillation (AF). Experimental studies in vitro and in animal models suggest that fish oil may reduce myocardial vulnerability to atrial fibrillation, possibly by means of effects of n-3 PUFA on connexins [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36330/abstract/86,87,148-151\">",
"     86,87,148-151",
"    </a>",
"    ]. In one prospective cohort, serum levels of long chain n-3 PUFA, in particular DHA, were associated with lower incidence of AF: those in the highest quartile had 35 percent lower risk (RR 0.65, 95% CI 0.44-0.96) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36330/abstract/152\">",
"     152",
"    </a>",
"    ]. In another study among patients followed for one year post-myocardial infarction, n-3 PUFA intake was associated with an 81 percent reduction in incidence of AF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36330/abstract/153\">",
"     153",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although an open-label trial found a benefit for fish oil in prevention of postoperative AF in patients undergoing cardiac surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36330/abstract/154\">",
"     154",
"    </a>",
"    ], this was not confirmed in small, blinded randomized trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36330/abstract/155,156\">",
"     155,156",
"    </a>",
"    ]. A subsequent large randomized trial in patients scheduled to undergo cardiac surgery (N = 1516) found no difference in rates of postoperative AF with fish oil supplementation or placebo (30.7 versus 30.0 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36330/abstract/157\">",
"     157",
"    </a>",
"    ]. A 2013 meta-analysis of randomized trials that included this large trial also found no statistically-significant reduction in postoperative AF despite evidence of publication bias [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36330/abstract/158\">",
"     158",
"    </a>",
"    ]. A second 2013 meta-analysis also found evidence of publication bias and concluded that there was substantial heterogeneity across trials (I",
"    <sup>",
"     2",
"    </sup>",
"    = 52%) that could be explained by two small open-label trials that had found large beneficial effects; the pooled estimate from blinded trials did not show a statistically-significant reduction in postoperative AF with fish oil supplementation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36330/abstract/159\">",
"     159",
"    </a>",
"    ]. Other aspects of AF after cardiac surgery are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/59/28602?source=see_link\">",
"     \"Atrial fibrillation and flutter after cardiac surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients with documented AF, a meta-analysis of randomized trials found no difference in rates of recurrent AF between those receiving omega-3 fatty acids, compared to control; however, there was substantial heterogeneity across trials (I",
"    <sup>",
"     2",
"    </sup>",
"    = 72%) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36330/abstract/158\">",
"     158",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Overall, these studies provide high-quality evidence that short-term n-3 PUFA supplementation does not reduce post-operative AF. n-3 PUFA supplements also do not appear to reduce recurrent AF among patients with pre-existing AF, at least in the intermediate-term (six months to one year). Further investigation of potential effects of long-term dietary or supplemental intake on new-onset AF is still needed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Stroke",
"    </span>",
"    &nbsp;&mdash;&nbsp;Results of ecologic and retrospective case-control studies of dietary n-3 PUFA consumption and stroke risk have been conflicting; most did not separately evaluate ischemic versus hemorrhagic strokes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36330/abstract/160-165\">",
"     160-165",
"    </a>",
"    ]. Some early ecologic and experimental studies suggested that high intake of marine n-3 PUFA might increase the risk of hemorrhagic stroke, possibly due to inhibition of platelet function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36330/abstract/160,166,167\">",
"     160,166,167",
"    </a>",
"    ]. However, n-3 PUFA intake in these studies was markedly higher than in typical diets, and as reviewed above, fish oil appears to affect bleeding times only at high doses (3 to 15 g",
"    <span class=\"nowrap\">",
"     /day)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36330/abstract/99,168\">",
"     99,168",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Coagulation and thrombosis'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    More recent and larger prospective cohort studies, which generally better control for confounding and bias compared with ecologic or retrospective case-control studies, have generally observed inverse associations between modest dietary n-3 PUFA intake and incidence of stroke. In a meta-analysis of 9 prospective studies (including 3491 incident strokes among 200,575 individuals), modest fish consumption was associated with lower incidence of ischemic stroke; no significant associations were seen for hemorrhagic stroke [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36330/abstract/169\">",
"     169",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast to the prospective observational data, data from randomized trials have generally not shown important reductions in stroke [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36330/abstract/120,121,170\">",
"     120,121,170",
"    </a>",
"    ], and a 2012 meta-analysis of nine randomized trials (N = 52,589) found no effect of fish oil supplementation on stroke risk (relative risk 1.05, 95% CI 0.93-1.19).",
"   </p>",
"   <p>",
"    Overall, observational evidence suggest that fish consumption may reduce the risk of ischemic stroke, but there is no convincing evidence from randomized trials that fish consumption or fish oil supplementation either increases or decreases the risk of stroke.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Heart failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Limited data suggest that EPA and DHA consumption is associated with lower incidence of heart failure. Randomized trial data have found some benefit of fish oil supplementation in patients with existing heart failure.",
"   </p>",
"   <p>",
"    A prospective cohort of 2,735 adults without heart disease found that circulating n-3 fatty acids concentration, particularly of EPA, was associated with a lower incidence of heart failure in older adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36330/abstract/171\">",
"     171",
"    </a>",
"    ]. Another prospective cohort study found an independent association between consumption of baked or broiled fish and a lower risk of incident heart failure; consumption of fried fish was associated with an increased risk of heart failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36330/abstract/172\">",
"     172",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is minimal evidence from randomized trials regarding the effects of fish oil supplementation on risk of new-onset heart failure. One meta-analysis found that most of the reported events from clinical trials came from a single randomized trial where there are substantial concerns about the data [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36330/abstract/123\">",
"     123",
"    </a>",
"    ]. Potential effects of n-3 PUFA on preventing heart failure incidence require further study.",
"   </p>",
"   <p>",
"    Stronger evidence exists for potential effects of fish oil among patients with established heart failure. In one large trial, 7046 patients with chronic heart failure were randomly assigned to receive a daily 1 gram n-3 PUFA supplement or placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36330/abstract/115\">",
"     115",
"    </a>",
"    ]. After a median follow-up of 3.9 years, fewer patients treated with n-3 PUFA died (27 versus 29 percent, hazard ratio 0.91, 95% CI 0.83-1.00); significant improvements in left ventricular ejection fraction were also seen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36330/abstract/83\">",
"     83",
"    </a>",
"    ]. Approximately 30 percent of patients discontinued both n-3 PUFA and placebo. As in other studies, a large number of the prevented deaths appear to have been CHD deaths and sudden cardiac deaths. However, the time until benefit was longer in this trial than in trials where fish oil had been used after an acute coronary syndrome (see",
"    <a class=\"local\" href=\"#H17\">",
"     'CHD death and sudden cardiac death'",
"    </a>",
"    above). This may reflect the more steady risk of death in patients with stable heart failure, versus the high risk of arrhythmic deaths in the months soon after an acute coronary syndrome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     EARLY NEUROLOGIC DEVELOPMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;DHA is preferentially incorporated into the rapidly developing brain during the last trimester of pregnancy and the first two years of infancy, concentrating in brain gray-matter and retinal membranes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36330/abstract/27,30\">",
"     27,30",
"    </a>",
"    ]. Although infants can convert shorter-chain n-3 fatty acids to DHA to a greater extent than adults, it is not known whether such conversion is adequate for the developing brain in the absence of adequate maternal DHA intake [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36330/abstract/28,29,173\">",
"     28,29,173",
"    </a>",
"    ]. Maternal ingestion of fish during pregnancy and lactation are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/31/33273?source=see_link\">",
"     \"Risks and benefits of fish consumption and fish oil supplements during pregnancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/53/43864?source=see_link&amp;anchor=H24#H24\">",
"     \"Maternal nutrition during lactation\", section on 'Fish intake'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     SIDE EFFECTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a pooled analysis of randomized clinical trials, the most common side effects of fish oil consumption were gastrointestinal disturbances such as nausea, occurring in approximately 4 percent of individuals at doses below 3 g",
"    <span class=\"nowrap\">",
"     /day",
"    </span>",
"    and approximately 20 percent of individuals at doses of 4 g",
"    <span class=\"nowrap\">",
"     /day",
"    </span>",
"    or higher [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36330/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Perhaps the most common symptom causing discontinuation of fish oil supplements is \"fishy taste\" following eructation (burping). Freezing the fish oil, switching to a different formulation, consumption with meals, or intake at a different time of day may minimize this symptom in some people.",
"   </p>",
"   <p>",
"    The safety of fish oil supplements, including issues around bleeding, is discussed below. (See",
"    <a class=\"local\" href=\"#H28\">",
"     'Safety'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     ADMINISTRATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Preparations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many over-the-counter preparations and at least one prescription formulation of fish oil (Lovaza&reg; in the United States and Omacor&reg; elsewhere) are available. These are generally derived from small pelagic fish used for fish feed or from formulations produced by algae [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36330/abstract/174\">",
"     174",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Products commonly available at major drug or health food stores contain the labeled amount of EPA and DHA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36330/abstract/175\">",
"     175",
"    </a>",
"    ]. Different fish oil formulations contain variable amounts (between 20 and, with Lovaza&reg;, 85 percent) of EPA and DHA, with the remainder typically comprised of other n-3 PUFA, monounsaturated fats, saturated fats, and gelatin or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/32/14852?source=see_link\">",
"     glycerin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36330/abstract/174,176\">",
"     174,176",
"    </a>",
"    ]. Thus, a 1 g capsule may contain between 200 and 900 mg of EPA and DHA.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Dose and form",
"    </span>",
"    &nbsp;&mdash;&nbsp;Analysis of the dose-response suggests that modest consumption of fish oil (approximately 250 mg",
"    <span class=\"nowrap\">",
"     /day",
"    </span>",
"    EPA+DHA) from either dietary or supplement sources provides most of the risk reduction for CHD death. Given potential uncertainties inherent in such calculations and the absence of any significant adverse effects of fish oil at these or much higher doses, a reasonable target intake to prevent CHD death and sudden cardiac death would be 250 to 500 mg",
"    <span class=\"nowrap\">",
"     /day",
"    </span>",
"    of EPA+DHA. This could be approximated by a daily 1 g fish oil supplement (that would contain between 200 to 800 mg of EPA+DHA, depending on the formulation) or one to two servings per week of oily fish [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36330/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The dose-response is not well-established for other potential cardiovascular benefits of n-3 PUFA, such as possible effects on atherosclerosis progression, nonfatal MI and acute coronary syndromes, recurrent ventricular tachycardias in patients with ICDs, atrial fibrillation, or ischemic stroke.",
"   </p>",
"   <p>",
"    Based on effects of fish oil on cardiovascular risk factors, such as blood pressure, heart rate, and triglyceride levels (",
"    <a class=\"graphic graphic_figure graphicRef78417 \" href=\"mobipreview.htm?4/34/4640\">",
"     figure 2",
"    </a>",
"    ), the dose-responses for some of these clinical outcomes may be more graded, so that increasing doses may provide proportionally more benefit than lower doses. Consistent with this, findings from one randomized trial indicate that adding n-3 PUFA to even the very high background dietary fish consumption seen in Japan reduces nonfatal coronary events [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36330/abstract/114\">",
"     114",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because the current evidence is insufficient to conclude that consumption of either EPA or DHA alone is adequate to provide all cardiovascular benefits, consumption of both EPA and DHA is preferable (and no specific ratio or combination of EPA and DHA is supported by current evidence).",
"   </p>",
"   <p>",
"    Compared with supplements, consumption of fish and other seafood also provides potentially beneficial protein, vitamins, and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/37/13907?source=see_link\">",
"     selenium",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36330/abstract/25\">",
"     25",
"    </a>",
"    ]. Thus, regular dietary seafood consumption can be considered the optimal method to obtain n-3 PUFA, although attention should be given to the type of seafood species consumed to ensure that optimal quantities of n-3 PUFA are eaten (",
"    <a class=\"graphic graphic_table graphicRef79454 \" href=\"mobipreview.htm?40/29/41435\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    EPA+DHA-supplemented \"functional foods\" (eg, in dairy products, salad dressings, cereals) can also provide some n-3 PUFA to individuals not consuming seafood [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36330/abstract/177\">",
"     177",
"    </a>",
"    ]. However, many supplemented foods contain the plant-based n-3 PUFA (alpha-linoleic acid, ALA), rather than marine n-3 PUFA, that may also be beneficial for cardiovascular health but cannot yet be considered a replacement for EPA+DHA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36330/abstract/178\">",
"     178",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Safety",
"    </span>",
"    &nbsp;&mdash;&nbsp;In small trials, fish oil capsules up to 12 g",
"    <span class=\"nowrap\">",
"     /day",
"    </span>",
"    (containing 6 g",
"    <span class=\"nowrap\">",
"     /day",
"    </span>",
"    n-3 PUFA) have been administered for more than 2 years without serious adverse events [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36330/abstract/104\">",
"     104",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although even these very high doses of fish oil appear to be safe, the US FDA recommends for the general population that dietary supplements not recommend or suggest in their labeling, or under ordinary conditions of use, daily intakes of more than 2 g EPA and DHA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36330/abstract/179\">",
"     179",
"    </a>",
"    ] and that total intakes up to 3 g per day of EPA and DHA are Generally Recognized As Safe (GRAS) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36330/abstract/180\">",
"     180",
"    </a>",
"    ] to \"safeguard against the possible adverse effects of these fatty acids on increased bleeding time\" in the general population. Thus, higher dosing should generally be under the guidance of a clinician.",
"   </p>",
"   <p>",
"    The US Federal Drug Administration has approved fish oil supplements at a dose of 4 g",
"    <span class=\"nowrap\">",
"     /day",
"    </span>",
"    for prescription therapy of hypertriglyceridemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36330/abstract/174\">",
"     174",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Bleeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;Risk of bleeding was evaluated in nine trials including 2612 participants, including individuals taking",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    . No bleeding was seen in four trials, and in the other five trials no consistent associations were seen between fish oil dose and bleeding risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36330/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These randomized trials of fish oil supplementation (often 6",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    or more) have included patients at relatively high risk for bleeding, including patients undergoing percutaneous coronary intervention, carotid endarterectomy, and cardiac surgery. Thus, the evidence indicates that at doses at least as high as 4",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    (and likely higher) there is probably no clinically significant effect on bleeding risk.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h3\">",
"     Contaminants",
"    </span>",
"    &nbsp;&mdash;&nbsp;Only a few large predator fish species (eg, shark, swordfish, king mackerel, tilefish, albacore tuna) contain appreciable amounts of mercury. Given cost considerations, such species would be used only very rarely to produce unusual \"specialty\" supplements [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36330/abstract/22\">",
"     22",
"    </a>",
"    ]. Furthermore, mercury is tightly bound to fish proteins, rather than present in the lipid fraction. Similar to most fish species, commercially available fish oil capsules contain little to no mercury [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36330/abstract/22,181\">",
"     22,181",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Fish oil capsules contain small amounts of polychlorinated biphenyls (PCBs; 0 to 450",
"    <span class=\"nowrap\">",
"     ng/g)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36330/abstract/182,183\">",
"     182,183",
"    </a>",
"    ], and dioxins (0.2 to 11 TEQ",
"    <span class=\"nowrap\">",
"     pg/g)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36330/abstract/184,185\">",
"     184,185",
"    </a>",
"    ], with concentrations proportional to those in the fish species from which the fish oil is derived. Notably, given the small absolute quantities of fish oil that would be consumed (1 to 4 g",
"    <span class=\"nowrap\">",
"     /day),",
"    </span>",
"    the absolute amounts of PCBs or dioxins that can be consumed from fish oil supplementation is extremely low.",
"   </p>",
"   <p>",
"    Thus, similar to dietary consumption of the great majority of fish and seafood species, significant exposure to contaminants from fish oil is not a clinical concern [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36330/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2251422914\">",
"    <span class=\"h3\">",
"     Cancer risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;A posthoc subgroup analysis from a randomized trial in 2501 adults with known cardiovascular disease found an association between supplementation with 600 mg of EPA and DHA and a higher risk of cancer in women, but not in the group as a whole [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36330/abstract/186\">",
"     186",
"    </a>",
"    ]. These findings should be interpreted with caution, as, in addition to being a subgroup analysis, they were based on a total of only 29 cancer events. Additionally, other larger randomized trials of fish oil did not report finding increased cancer risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36330/abstract/9,114\">",
"     9,114",
"    </a>",
"    ], and a wide range of animal models demonstrate benefits of fish oil for incidence and severity of many cancers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36330/abstract/187-190\">",
"     187-190",
"    </a>",
"    ]. Systematic reviews and meta-analyses of numerous large prospective observational studies have found no significant effects of fish consumption on risk of any type of cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/30/36330/abstract/191,192\">",
"     191,192",
"    </a>",
"    ]. Overall, the current evidence does not support any major effects of fish or fish oil consumption on cancer risk.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Animal and human studies have identified the long-chain n-3 polyunsaturated fatty acids (n-3 PUFA), eicosapentaenoic acid (EPA, 20:5n-3), and docosahexaenoic acid (DHA, 22:6n-3) as the likely major active constituents in fish oil. In numerous randomized trials, fish oil supplementation improves several cardiovascular risk factors. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Effects on cardiovascular risk factors'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Observational studies in generally healthy adults and randomized trials in patients with established coronary heart disease (CHD) indicate that modest fish oil consumption (approximately 250",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    EPA+DHA) may reduce the risk of CHD death and sudden cardiac death, with little if any risk. This is of particular importance in patients with established CHD or at high risk for CHD. Several more recent randomized trials have failed to demonstrate significant effects, although a meta-analysis of placebo-controlled trials demonstrated modest reductions in CHD mortality. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'CHD death and sudden cardiac death'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    For preventing CHD death, the evidence suggests that some consumption (about 250",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    is better than none, but that higher consumption may not substantially further reduce risk. The dose-response for other potential cardiovascular benefits requires further study.",
"   </p>",
"   <p>",
"    There is limited evidence that long-term consumption of fish oil supplements may reduce the risk of atherosclerosis and cardiovascular events other than CHD death and sudden cardiac death. (See",
"    <a class=\"local\" href=\"#H1\">",
"     'Introduction'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H13\">",
"     'Cardiovascular outcomes'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Given the evidence for potentially-beneficial effects on CHD death and sudden cardiac death, and no evidence to suggest harm (see",
"      <a class=\"local\" href=\"#H17\">",
"       'CHD death and sudden cardiac death'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      We recommend that most adults without known CHD who are seeking information on a healthy diet be counseled to consume at least one to two servings per week of oily fish (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). We suggest that most adults who do not consume this much fish take a daily fish oil supplement (about 1",
"      <span class=\"nowrap\">",
"       g/day)",
"      </span>",
"      (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      We recommend that patients with known CHD or who are at high risk for CHD be counseled to consume at least one to two servings per week of oily fish (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). In such patients who are unable or unwilling to consume this much fish, we suggest prescribing a daily fish oil supplement (about 1",
"      <span class=\"nowrap\">",
"       g/day)",
"      </span>",
"      (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fish consumption in women who are pregnant, nursing, or who may become pregnant is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/44/28362?source=see_link&amp;anchor=H22#H22\">",
"       \"Nutrition in pregnancy\", section on 'Fish'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/53/43864?source=see_link&amp;anchor=H24#H24\">",
"       \"Maternal nutrition during lactation\", section on 'Fish intake'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Average fish consumption to achieve 250",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      of EPA+DHA is shown in a table (",
"      <a class=\"graphic graphic_table graphicRef79454 \" href=\"mobipreview.htm?40/29/41435\">",
"       table 1",
"      </a>",
"      ). When a fish oil supplement is used, it should contain both EPA and DHA; a 1 g daily supplement (containing 200 to 800 mg of EPA and DHA) is a reasonable option. (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Dose and form'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Fish oil supplements are generally derived from small pelagic fish used for fish feed or from formulations produced by algae. Similar to dietary consumption of the great majority of fish and seafood species, significant exposure to contaminants from fish oil is not a major concern. (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Preparations'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H30\">",
"       'Contaminants'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Bang HO, Dyerberg J. Lipid metabolism and ischemic heart disease in Greenland Eskimos. In: Advances in nutrition research, Draper H.  (Ed), Plenum Press, New York 1980. p.1&ndash;22.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36330/abstract/2\">",
"      Kromhout D, Bosschieter EB, de Lezenne Coulander C. The inverse relation between fish consumption and 20-year mortality from coronary heart disease. N Engl J Med 1985; 312:1205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36330/abstract/3\">",
"      Burr ML, Fehily AM, Gilbert JF, et al. Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: diet and reinfarction trial (DART). Lancet 1989; 2:757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36330/abstract/4\">",
"      Dolecek TA, Granditis G. Dietary polyunsaturated fatty acids and mortality in the Multiple Risk Factor Intervention Trial (MRFIT). World Rev Nutr Diet 1991; 66:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36330/abstract/5\">",
"      Siscovick DS, Raghunathan TE, King I, et al. Dietary intake and cell membrane levels of long-chain n-3 polyunsaturated fatty acids and the risk of primary cardiac arrest. JAMA 1995; 274:1363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36330/abstract/6\">",
"      Kromhout D, Feskens EJ, Bowles CH. The protective effect of a small amount of fish on coronary heart disease mortality in an elderly population. Int J Epidemiol 1995; 24:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36330/abstract/7\">",
"      Daviglus ML, Stamler J, Orencia AJ, et al. Fish consumption and the 30-year risk of fatal myocardial infarction. N Engl J Med 1997; 336:1046.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36330/abstract/8\">",
"      Albert CM, Hennekens CH, O'Donnell CJ, et al. Fish consumption and risk of sudden cardiac death. JAMA 1998; 279:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36330/abstract/9\">",
"      Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. Lancet 1999; 354:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36330/abstract/10\">",
"      Oomen CM, Feskens EJ, R&auml;s&auml;nen L, et al. Fish consumption and coronary heart disease mortality in Finland, Italy, and The Netherlands. Am J Epidemiol 2000; 151:999.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36330/abstract/11\">",
"      Yuan JM, Ross RK, Gao YT, Yu MC. Fish and shellfish consumption in relation to death from myocardial infarction among men in Shanghai, China. Am J Epidemiol 2001; 154:809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36330/abstract/12\">",
"      Hu FB, Bronner L, Willett WC, et al. Fish and omega-3 fatty acid intake and risk of coronary heart disease in women. JAMA 2002; 287:1815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36330/abstract/13\">",
"      Albert CM, Campos H, Stampfer MJ, et al. Blood levels of long-chain n-3 fatty acids and the risk of sudden death. N Engl J Med 2002; 346:1113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36330/abstract/14\">",
"      Lemaitre RN, King IB, Mozaffarian D, et al. n-3 Polyunsaturated fatty acids, fatal ischemic heart disease, and nonfatal myocardial infarction in older adults: the Cardiovascular Health Study. Am J Clin Nutr 2003; 77:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36330/abstract/15\">",
"      Mozaffarian D, Lemaitre RN, Kuller LH, et al. Cardiac benefits of fish consumption may depend on the type of fish meal consumed: the Cardiovascular Health Study. Circulation 2003; 107:1372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36330/abstract/16\">",
"      Mozaffarian D, Ascherio A, Hu FB, et al. Interplay between different polyunsaturated fatty acids and risk of coronary heart disease in men. Circulation 2005; 111:157.",
"     </a>",
"    </li>",
"    <li>",
"     Yokoyama, M, Origasu, H, Matsuzaki, M, et al. Effects of eicosapentaenoic acid (EPA) on major cardiovascular events in hypercholesterolemic patients: The Japan EPA Lipid Intervention Study (JELIS). Paper presented at American Heart Association Scientific Sessions, Dallas, TX, Nov 17, 2005 .",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36330/abstract/18\">",
"      Kang JX, Leaf A. Prevention of fatal cardiac arrhythmias by polyunsaturated fatty acids. Am J Clin Nutr 2000; 71:202S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36330/abstract/19\">",
"      McLennan PL. Myocardial membrane fatty acids and the antiarrhythmic actions of dietary fish oil in animal models. Lipids 2001; 36 Suppl:S111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36330/abstract/20\">",
"      Leaf A, Kang JX, Xiao YF, Billman GE. Clinical prevention of sudden cardiac death by n-3 polyunsaturated fatty acids and mechanism of prevention of arrhythmias by n-3 fish oils. Circulation 2003; 107:2646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36330/abstract/21\">",
"      Wang C, Harris WS, Chung M, et al. n-3 Fatty acids from fish or fish-oil supplements, but not alpha-linolenic acid, benefit cardiovascular disease outcomes in primary- and secondary-prevention studies: a systematic review. Am J Clin Nutr 2006; 84:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36330/abstract/22\">",
"      Mozaffarian D, Rimm EB. Fish intake, contaminants, and human health: evaluating the risks and the benefits. JAMA 2006; 296:1885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36330/abstract/23\">",
"      Masson S, Latini R, Tacconi M, Bernasconi R. Incorporation and washout of n-3 polyunsaturated fatty acids after diet supplementation in clinical studies. J Cardiovasc Med (Hagerstown) 2007; 8 Suppl 1:S4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36330/abstract/24\">",
"      Nord&oslash;y A, Barstad L, Connor WE, Hatcher L. Absorption of the n-3 eicosapentaenoic and docosahexaenoic acids as ethyl esters and triglycerides by humans. Am J Clin Nutr 1991; 53:1185.",
"     </a>",
"    </li>",
"    <li>",
"     US Department of Agriculture. USDA National Nutrient Database for Standard Reference: Release 18 (2005). US Department of Agriculture, Agricultural Research Service, 2006.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36330/abstract/26\">",
"      Burdge GC, Calder PC. Conversion of alpha-linolenic acid to longer-chain polyunsaturated fatty acids in human adults. Reprod Nutr Dev 2005; 45:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36330/abstract/27\">",
"      Martinez M. Tissue levels of polyunsaturated fatty acids during early human development. J Pediatr 1992; 120:S129.",
"     </a>",
"    </li>",
"    <li>",
"     Food and Nutrition Board, Institute of Medicine. Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids (Micronutrients). The National Academies Press; Washington, DC 2002/2005.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36330/abstract/29\">",
"      McCann JC, Ames BN. Is docosahexaenoic acid, an n-3 long-chain polyunsaturated fatty acid, required for development of normal brain function? An overview of evidence from cognitive and behavioral tests in humans and animals. Am J Clin Nutr 2005; 82:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36330/abstract/30\">",
"      Lewin GA, Schachter HM, Yuen D, et al. Effects of omega-3 fatty acids on child and maternal health. Evid Rep Technol Assess (Summ) 2005; :1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36330/abstract/31\">",
"      Mori TA, Beilin LJ. Omega-3 fatty acids and inflammation. Curr Atheroscler Rep 2004; 6:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36330/abstract/32\">",
"      Charnock JS, McLennan PL, Abeywardena MY. Dietary modulation of lipid metabolism and mechanical performance of the heart. Mol Cell Biochem 1992; 116:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36330/abstract/33\">",
"      Kenny D, Warltier DC, Pleuss JA, et al. Effect of omega-3 fatty acids on the vascular response to angiotensin in normotensive men. Am J Cardiol 1992; 70:1347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36330/abstract/34\">",
"      Chin JP, Gust AP, Nestel PJ, Dart AM. Marine oils dose-dependently inhibit vasoconstriction of forearm resistance vessels in humans. Hypertension 1993; 21:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36330/abstract/35\">",
"      Geleijnse JM, Giltay EJ, Grobbee DE, et al. Blood pressure response to fish oil supplementation: metaregression analysis of randomized trials. J Hypertens 2002; 20:1493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36330/abstract/36\">",
"      Mozaffarian D, Geelen A, Brouwer IA, et al. Effect of fish oil on heart rate in humans: a meta-analysis of randomized controlled trials. Circulation 2005; 112:1945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36330/abstract/37\">",
"      Mozaffarian D, Gottdiener JS, Siscovick DS. Intake of tuna or other broiled or baked fish versus fried fish and cardiac structure, function, and hemodynamics. Am J Cardiol 2006; 97:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36330/abstract/38\">",
"      Nestel PJ. Fish oil and cardiovascular disease: lipids and arterial function. Am J Clin Nutr 2000; 71:228S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36330/abstract/39\">",
"      Christensen JH. n-3 fatty acids and the risk of sudden cardiac death. Emphasis on heart rate variability. Dan Med Bull 2003; 50:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36330/abstract/40\">",
"      Kristensen SD, Iversen AM, Schmidt EB. n-3 polyunsaturated fatty acids and coronary thrombosis. Lipids 2001; 36 Suppl:S79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36330/abstract/41\">",
"      Clandinin MT, Cheema S, Field CJ, et al. Dietary fat: exogenous determination of membrane structure and cell function. FASEB J 1991; 5:2761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36330/abstract/42\">",
"      Feller SE, Gawrisch K. Properties of docosahexaenoic-acid-containing lipids and their influence on the function of rhodopsin. Curr Opin Struct Biol 2005; 15:416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36330/abstract/43\">",
"      Vanden Heuvel JP. Diet, fatty acids, and regulation of genes important for heart disease. Curr Atheroscler Rep 2004; 6:432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36330/abstract/44\">",
"      Harris WS. n-3 fatty acids and serum lipoproteins: human studies. Am J Clin Nutr 1997; 65:1645S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36330/abstract/45\">",
"      Balk EM, Lichtenstein AH, Chung M, et al. Effects of omega-3 fatty acids on serum markers of cardiovascular disease risk: a systematic review. Atherosclerosis 2006; 189:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36330/abstract/46\">",
"      Wang C, Chung M, Lichtenstein A, et al. Effects of omega-3 fatty acids on cardiovascular disease. Evid Rep Technol Assess (Summ) 2004; :1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36330/abstract/47\">",
"      Harris WS, Bulchandani D. Why do omega-3 fatty acids lower serum triglycerides? Curr Opin Lipidol 2006; 17:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36330/abstract/48\">",
"      Friedberg CE, Janssen MJ, Heine RJ, Grobbee DE. Fish oil and glycemic control in diabetes. A meta-analysis. Diabetes Care 1998; 21:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36330/abstract/49\">",
"      Minihane AM, Khan S, Leigh-Firbank EC, et al. ApoE polymorphism and fish oil supplementation in subjects with an atherogenic lipoprotein phenotype. Arterioscler Thromb Vasc Biol 2000; 20:1990.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36330/abstract/50\">",
"      Griffin MD, Sanders TA, Davies IG, et al. Effects of altering the ratio of dietary n-6 to n-3 fatty acids on insulin sensitivity, lipoprotein size, and postprandial lipemia in men and postmenopausal women aged 45-70 y: the OPTILIP Study. Am J Clin Nutr 2006; 84:1290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36330/abstract/51\">",
"      Demaison L, Blet J, Sergiel JP, et al. Effect of dietary polyunsaturated fatty acids on contractile function of hearts isolated from sedentary and trained rats. Reprod Nutr Dev 2000; 40:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36330/abstract/52\">",
"      Omura M, Kobayashi S, Mizukami Y, et al. Eicosapentaenoic acid (EPA) induces Ca(2+)-independent activation and translocation of endothelial nitric oxide synthase and endothelium-dependent vasorelaxation. FEBS Lett 2001; 487:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36330/abstract/53\">",
"      De Caterina R, Liao JK, Libby P. Fatty acid modulation of endothelial activation. Am J Clin Nutr 2000; 71:213S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36330/abstract/54\">",
"      Li Q, Zhang Q, Wang M, et al. Eicosapentaenoic acid modifies lipid composition in caveolae and induces translocation of endothelial nitric oxide synthase. Biochimie 2007; 89:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36330/abstract/55\">",
"      Li Q, Zhang Q, Wang M, et al. Docosahexaenoic acid affects endothelial nitric oxide synthase in caveolae. Arch Biochem Biophys 2007; 466:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36330/abstract/56\">",
"      Harris WS, Rambj&oslash;r GS, Windsor SL, Diederich D. n-3 fatty acids and urinary excretion of nitric oxide metabolites in humans. Am J Clin Nutr 1997; 65:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36330/abstract/57\">",
"      Mori TA, Watts GF, Burke V, et al. Differential effects of eicosapentaenoic acid and docosahexaenoic acid on vascular reactivity of the forearm microcirculation in hyperlipidemic, overweight men. Circulation 2000; 102:1264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36330/abstract/58\">",
"      McVeigh GE, Brennan GM, Cohn JN, et al. Fish oil improves arterial compliance in non-insulin-dependent diabetes mellitus. Arterioscler Thromb 1994; 14:1425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36330/abstract/59\">",
"      Mozaffarian D, Prineas RJ, Stein PK, Siscovick DS. Dietary fish and n-3 fatty acid intake and cardiac electrocardiographic parameters in humans. J Am Coll Cardiol 2006; 48:478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36330/abstract/60\">",
"      Billman GE, Kang JX, Leaf A. Prevention of ischemia-induced cardiac sudden death by n-3 polyunsaturated fatty acids in dogs. Lipids 1997; 32:1161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36330/abstract/61\">",
"      O'Keefe JH Jr, Abuissa H, Sastre A, et al. Effects of omega-3 fatty acids on resting heart rate, heart rate recovery after exercise, and heart rate variability in men with healed myocardial infarctions and depressed ejection fractions. Am J Cardiol 2006; 97:1127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36330/abstract/62\">",
"      Dyer AR, Persky V, Stamler J, et al. Heart rate as a prognostic factor for coronary heart disease and mortality: findings in three Chicago epidemiologic studies. Am J Epidemiol 1980; 112:736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36330/abstract/63\">",
"      Kannel WB, Kannel C, Paffenbarger RS Jr, Cupples LA. Heart rate and cardiovascular mortality: the Framingham Study. Am Heart J 1987; 113:1489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36330/abstract/64\">",
"      Shaper AG, Wannamethee G, Macfarlane PW, Walker M. Heart rate, ischaemic heart disease, and sudden cardiac death in middle-aged British men. Br Heart J 1993; 70:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36330/abstract/65\">",
"      Wannamethee G, Shaper AG, Macfarlane PW, Walker M. Risk factors for sudden cardiac death in middle-aged British men. Circulation 1995; 91:1749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36330/abstract/66\">",
"      Palatini P, Casiglia E, Julius S, Pessina AC. High heart rate: a risk factor for cardiovascular death in elderly men. Arch Intern Med 1999; 159:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36330/abstract/67\">",
"      Jouven X, Zureik M, Desnos M, et al. Resting heart rate as a predictive risk factor for sudden death in middle-aged men. Cardiovasc Res 2001; 50:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36330/abstract/68\">",
"      Palatini P, Thijs L, Staessen JA, et al. Predictive value of clinic and ambulatory heart rate for mortality in elderly subjects with systolic hypertension. Arch Intern Med 2002; 162:2313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36330/abstract/69\">",
"      Russo C, Olivieri O, Girelli D, et al. Omega-3 polyunsaturated fatty acid supplements and ambulatory blood pressure monitoring parameters in patients with mild essential hypertension. J Hypertens 1995; 13:1823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36330/abstract/70\">",
"      Christensen JH, Gustenhoff P, Korup E, et al. Effect of fish oil on heart rate variability in survivors of myocardial infarction: a double blind randomised controlled trial. BMJ 1996; 312:677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36330/abstract/71\">",
"      Christensen JH, Aar&oslash;e J, Knudsen N, et al. Heart rate variability and n-3 fatty acids in patients with chronic renal failure--a pilot study. Clin Nephrol 1998; 49:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36330/abstract/72\">",
"      Christensen JH, Christensen MS, Dyerberg J, Schmidt EB. Heart rate variability and fatty acid content of blood cell membranes: a dose-response study with n-3 fatty acids. Am J Clin Nutr 1999; 70:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36330/abstract/73\">",
"      Villa B, Calabresi L, Chiesa G, et al. Omega-3 fatty acid ethyl esters increase heart rate variability in patients with coronary disease. Pharmacol Res 2002; 45:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36330/abstract/74\">",
"      Geelen A, Zock PL, Swenne CA, et al. Effect of n-3 fatty acids on heart rate variability and baroreflex sensitivity in middle-aged subjects. Am Heart J 2003; 146:E4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36330/abstract/75\">",
"      Holguin F, T&eacute;llez-Rojo MM, Lazo M, et al. Cardiac autonomic changes associated with fish oil vs soy oil supplementation in the elderly. Chest 2005; 127:1102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36330/abstract/76\">",
"      Dyerberg J, Eskesen DC, Andersen PW, et al. Effects of trans- and n-3 unsaturated fatty acids on cardiovascular risk markers in healthy males. An 8 weeks dietary intervention study. Eur J Clin Nutr 2004; 58:1062.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36330/abstract/77\">",
"      Fiedler R, Mall M, Wand C, Osten B. Short-term administration of omega-3 fatty acids in hemodialysis patients with balanced lipid metabolism. J Ren Nutr 2005; 15:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36330/abstract/78\">",
"      Robinson JG, Stone NJ. Antiatherosclerotic and antithrombotic effects of omega-3 fatty acids. Am J Cardiol 2006; 98:39i.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36330/abstract/79\">",
"      James MJ, Gibson RA, Cleland LG. Dietary polyunsaturated fatty acids and inflammatory mediator production. Am J Clin Nutr 2000; 71:343S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36330/abstract/80\">",
"      McLennan PL, Barnden LR, Bridle TM, et al. Dietary fat modulation of left ventricular ejection fraction in the marmoset due to enhanced filling. Cardiovasc Res 1992; 26:871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36330/abstract/81\">",
"      Grimsgaard S, B&oslash;naa KH, Hansen JB, Myhre ES. Effects of highly purified eicosapentaenoic acid and docosahexaenoic acid on hemodynamics in humans. Am J Clin Nutr 1998; 68:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36330/abstract/82\">",
"      von Au D, Br&auml;ndle M, Rupp H, Jacob R. Influence of a diet rich in fish oil on blood pressure, body weight and cardiac hypertrophy in spontaneously hypertensive rats. Eur J Appl Physiol Occup Physiol 1988; 58:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36330/abstract/83\">",
"      Ghio S, Scelsi L, Latini R, et al. Effects of n-3 polyunsaturated fatty acids and of rosuvastatin on left ventricular function in chronic heart failure: a substudy of GISSI-HF trial. Eur J Heart Fail 2010; 12:1345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36330/abstract/84\">",
"      Nodari S, Triggiani M, Campia U, et al. Effects of n-3 polyunsaturated fatty acids on left ventricular function and functional capacity in patients with dilated cardiomyopathy. J Am Coll Cardiol 2011; 57:870.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36330/abstract/85\">",
"      Peoples GE, McLennan PL, Howe PR, Groeller H. Fish oil reduces heart rate and oxygen consumption during exercise. J Cardiovasc Pharmacol 2008; 52:540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36330/abstract/86\">",
"      Zhang YW, Morita I, Yao XS, Murota S. Pretreatment with eicosapentaenoic acid prevented hypoxia/reoxygenation-induced abnormality in endothelial gap junctional intercellular communication through inhibiting the tyrosine kinase activity. Prostaglandins Leukot Essent Fatty Acids 1999; 61:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36330/abstract/87\">",
"      Sarrazin JF, Comeau G, Daleau P, et al. Reduced incidence of vagally induced atrial fibrillation and expression levels of connexins by n-3 polyunsaturated fatty acids in dogs. J Am Coll Cardiol 2007; 50:1505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36330/abstract/88\">",
"      Mozaffarian D. Fish oil and prevention of atrial fibrillation. J Am Coll Cardiol 2007; 50:1513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36330/abstract/89\">",
"      Kang JX, Leaf A. Protective effects of free polyunsaturated fatty acids on arrhythmias induced by lysophosphatidylcholine or palmitoylcarnitine in neonatal rat cardiac myocytes. Eur J Pharmacol 1996; 297:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36330/abstract/90\">",
"      Kang JX, Leaf A. Evidence that free polyunsaturated fatty acids modify Na+ channels by directly binding to the channel proteins. Proc Natl Acad Sci U S A 1996; 93:3542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36330/abstract/91\">",
"      Hartweg J, Perera R, Montori V, et al. Omega-3 polyunsaturated fatty acids (PUFA) for type 2 diabetes mellitus. Cochrane Database Syst Rev 2008; :CD003205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36330/abstract/92\">",
"      Montori VM, Farmer A, Wollan PC, Dinneen SF. Fish oil supplementation in type 2 diabetes: a quantitative systematic review. Diabetes Care 2000; 23:1407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36330/abstract/93\">",
"      Kaushik M, Mozaffarian D, Spiegelman D, et al. Long-chain omega-3 fatty acids, fish intake, and the risk of type 2 diabetes mellitus. Am J Clin Nutr 2009; 90:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36330/abstract/94\">",
"      Wang L, Folsom AR, Zheng ZJ, et al. Plasma fatty acid composition and incidence of diabetes in middle-aged adults: the Atherosclerosis Risk in Communities (ARIC) Study. Am J Clin Nutr 2003; 78:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36330/abstract/95\">",
"      Laaksonen DE, Lakka TA, Lakka HM, et al. Serum fatty acid composition predicts development of impaired fasting glycaemia and diabetes in middle-aged men. Diabet Med 2002; 19:456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36330/abstract/96\">",
"      van Dam RM, Willett WC, Rimm EB, et al. Dietary fat and meat intake in relation to risk of type 2 diabetes in men. Diabetes Care 2002; 25:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36330/abstract/97\">",
"      Jump DB. N-3 polyunsaturated fatty acid regulation of hepatic gene transcription. Curr Opin Lipidol 2008; 19:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36330/abstract/98\">",
"      Giacco R, Cuomo V, Vessby B, et al. Fish oil, insulin sensitivity, insulin secretion and glucose tolerance in healthy people: is there any effect of fish oil supplementation in relation to the type of background diet and habitual dietary intake of n-6 and n-3 fatty acids? Nutr Metab Cardiovasc Dis 2007; 17:572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36330/abstract/99\">",
"      Knapp HR, Reilly IA, Alessandrini P, FitzGerald GA. In vivo indexes of platelet and vascular function during fish-oil administration in patients with atherosclerosis. N Engl J Med 1986; 314:937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36330/abstract/100\">",
"      Kris-Etherton PM, Harris WS, Appel LJ, American Heart Association. Nutrition Committee. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation 2002; 106:2747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36330/abstract/101\">",
"      Spite M, Serhan CN. Novel lipid mediators promote resolution of acute inflammation: impact of aspirin and statins. Circ Res 2010; 107:1170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36330/abstract/102\">",
"      De Caterina R. n-3 fatty acids in cardiovascular disease. N Engl J Med 2011; 364:2439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36330/abstract/103\">",
"      Erkkil&auml; AT, Lichtenstein AH, Mozaffarian D, Herrington DM. Fish intake is associated with a reduced progression of coronary artery atherosclerosis in postmenopausal women with coronary artery disease. Am J Clin Nutr 2004; 80:626.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36330/abstract/104\">",
"      Sacks FM, Stone PH, Gibson CM, et al. Controlled trial of fish oil for regression of human coronary atherosclerosis. HARP Research Group. J Am Coll Cardiol 1995; 25:1492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36330/abstract/105\">",
"      von Schacky C, Angerer P, Kothny W, et al. The effect of dietary omega-3 fatty acids on coronary atherosclerosis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1999; 130:554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36330/abstract/106\">",
"      Angerer P, Kothny W, St&ouml;rk S, von Schacky C. Effect of dietary supplementation with omega-3 fatty acids on progression of atherosclerosis in carotid arteries. Cardiovasc Res 2002; 54:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36330/abstract/107\">",
"      Mita T, Watada H, Ogihara T, et al. Eicosapentaenoic acid reduces the progression of carotid intima-media thickness in patients with type 2 diabetes. Atherosclerosis 2007; 191:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36330/abstract/108\">",
"      Balk EM, Lichtenstein AH, Chung M, et al. Effects of omega-3 fatty acids on coronary restenosis, intima-media thickness, and exercise tolerance: a systematic review. Atherosclerosis 2006; 184:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36330/abstract/109\">",
"      Leaf A, Jorgensen MB, Jacobs AK, et al. Do fish oils prevent restenosis after coronary angioplasty? Circulation 1994; 90:2248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36330/abstract/110\">",
"      Morris MC, Manson JE, Rosner B, et al. Fish consumption and cardiovascular disease in the physicians' health study: a prospective study. Am J Epidemiol 1995; 142:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36330/abstract/111\">",
"      Thies F, Garry JM, Yaqoob P, et al. Association of n-3 polyunsaturated fatty acids with stability of atherosclerotic plaques: a randomised controlled trial. Lancet 2003; 361:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36330/abstract/112\">",
"      Block RC, Harris WS, Reid KJ, et al. EPA and DHA in blood cell membranes from acute coronary syndrome patients and controls. Atherosclerosis 2008; 197:821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36330/abstract/113\">",
"      Iso H, Kobayashi M, Ishihara J, et al. Intake of fish and n3 fatty acids and risk of coronary heart disease among Japanese: the Japan Public Health Center-Based (JPHC) Study Cohort I. Circulation 2006; 113:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36330/abstract/114\">",
"      Yokoyama M, Origasa H, Matsuzaki M, et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet 2007; 369:1090.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36330/abstract/115\">",
"      Gissi-HF Investigators, Tavazzi L, Maggioni AP, et al. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 2008; 372:1223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36330/abstract/116\">",
"      Marchioli R, Barzi F, Bomba E, et al. Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI)-Prevenzione. Circulation 2002; 105:1897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36330/abstract/117\">",
"      Kromhout D, Giltay EJ, Geleijnse JM, Alpha Omega Trial Group. n-3 fatty acids and cardiovascular events after myocardial infarction. N Engl J Med 2010; 363:2015.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36330/abstract/118\">",
"      Rauch B, Schiele R, Schneider S, et al. OMEGA, a randomized, placebo-controlled trial to test the effect of highly purified omega-3 fatty acids on top of modern guideline-adjusted therapy after myocardial infarction. Circulation 2010; 122:2152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36330/abstract/119\">",
"      Burr ML, Ashfield-Watt PA, Dunstan FD, et al. Lack of benefit of dietary advice to men with angina: results of a controlled trial. Eur J Clin Nutr 2003; 57:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36330/abstract/120\">",
"      Galan P, Kesse-Guyot E, Czernichow S, et al. Effects of B vitamins and omega 3 fatty acids on cardiovascular diseases: a randomised placebo controlled trial. BMJ 2010; 341:c6273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36330/abstract/121\">",
"      ORIGIN Trial Investigators, Bosch J, Gerstein HC, et al. n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia. N Engl J Med 2012; 367:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36330/abstract/122\">",
"      Rizos EC, Ntzani EE, Bika E, et al. Association between omega-3 fatty acid supplementation and risk of major cardiovascular disease events: a systematic review and meta-analysis. JAMA 2012; 308:1024.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36330/abstract/123\">",
"      Hooper L, Thompson RL, Harrison RA, et al. Omega 3 fatty acids for prevention and treatment of cardiovascular disease. Cochrane Database Syst Rev 2004; :CD003177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36330/abstract/124\">",
"      He K, Song Y, Daviglus ML, et al. Accumulated evidence on fish consumption and coronary heart disease mortality: a meta-analysis of cohort studies. Circulation 2004; 109:2705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36330/abstract/125\">",
"      Saravanan P, Davidson NC, Schmidt EB, Calder PC. Cardiovascular effects of marine omega-3 fatty acids. Lancet 2010; 376:540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36330/abstract/126\">",
"      Le&oacute;n H, Shibata MC, Sivakumaran S, et al. Effect of fish oil on arrhythmias and mortality: systematic review. BMJ 2008; 337:a2931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36330/abstract/127\">",
"      Marik PE, Varon J. Omega-3 dietary supplements and the risk of cardiovascular events: a systematic review. Clin Cardiol 2009; 32:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36330/abstract/128\">",
"      Mente A, de Koning L, Shannon HS, Anand SS. A systematic review of the evidence supporting a causal link between dietary factors and coronary heart disease. Arch Intern Med 2009; 169:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36330/abstract/129\">",
"      Fraser GE, Sabat&eacute; J, Beeson WL, Strahan TM. A possible protective effect of nut consumption on risk of coronary heart disease. The Adventist Health Study. Arch Intern Med 1992; 152:1416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36330/abstract/130\">",
"      Mann JI, Appleby PN, Key TJ, Thorogood M. Dietary determinants of ischaemic heart disease in health conscious individuals. Heart 1997; 78:450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36330/abstract/131\">",
"      Osler M, Andreasen AH, Hoidrup S. No inverse association between fish consumption and risk of death from all-causes, and incidence of coronary heart disease in middle-aged, Danish adults. J Clin Epidemiol 2003; 56:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36330/abstract/132\">",
"      Folsom AR, Demissie Z. Fish intake, marine omega-3 fatty acids, and mortality in a cohort of postmenopausal women. Am J Epidemiol 2004; 160:1005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36330/abstract/133\">",
"      Nakamura Y, Ueshima H, Okamura T, et al. Association between fish consumption and all-cause and cause-specific mortality in Japan: NIPPON DATA80, 1980-99. Am J Med 2005; 118:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36330/abstract/134\">",
"      Kwak SM, Myung SK, Lee YJ, et al. Efficacy of omega-3 fatty acid supplements (eicosapentaenoic acid and docosahexaenoic acid) in the secondary prevention of cardiovascular disease: a meta-analysis of randomized, double-blind, placebo-controlled trials. Arch Intern Med 2012; 172:686.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36330/abstract/135\">",
"      Marchioli R, Marfisi RM, Borrelli G, et al. Efficacy of n-3 polyunsaturated fatty acids according to clinical characteristics of patients with recent myocardial infarction: insights from the GISSI-Prevenzione trial. J Cardiovasc Med (Hagerstown) 2007; 8 Suppl 1:S34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36330/abstract/136\">",
"      Eussen SR, Geleijnse JM, Giltay EJ, et al. Effects of n-3 fatty acids on major cardiovascular events in statin users and non-users with a history of myocardial infarction. Eur Heart J 2012; 33:1582.",
"     </a>",
"    </li>",
"    <li>",
"     Anderson, RN, Smith, LB. Deaths: Leading Causes for 2002. Centers for Disease Control and Prevention, National Vital Statistics System. www.cdc.gov/nchs/data/nvsr/nvsr53/nvsr53_17.pd (Accessed on September 20, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36330/abstract/138\">",
"      Mozaffarian D, Lemaitre RN, King IB, et al. Plasma Phospholipid Long-Chain &omega;-3 Fatty Acids and Total and Cause-Specific Mortality in Older Adults: A Cohort Study. Ann Intern Med 2013; 158:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36330/abstract/139\">",
"      Raitt MH, Connor WE, Morris C, et al. Fish oil supplementation and risk of ventricular tachycardia and ventricular fibrillation in patients with implantable defibrillators: a randomized controlled trial. JAMA 2005; 293:2884.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36330/abstract/140\">",
"      Leaf A, Albert CM, Josephson M, et al. Prevention of fatal arrhythmias in high-risk subjects by fish oil n-3 fatty acid intake. Circulation 2005; 112:2762.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36330/abstract/141\">",
"      Brouwer IA, Zock PL, Camm AJ, et al. Effect of fish oil on ventricular tachyarrhythmia and death in patients with implantable cardioverter defibrillators: the Study on Omega-3 Fatty Acids and Ventricular Arrhythmia (SOFA) randomized trial. JAMA 2006; 295:2613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36330/abstract/142\">",
"      Jenkins DJ, Josse AR, Beyene J, et al. Fish-oil supplementation in patients with implantable cardioverter defibrillators: a meta-analysis. CMAJ 2008; 178:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36330/abstract/143\">",
"      Brouwer IA, Raitt MH, Dullemeijer C, et al. Effect of fish oil on ventricular tachyarrhythmia in three studies in patients with implantable cardioverter defibrillators. Eur Heart J 2009; 30:820.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36330/abstract/144\">",
"      Mozaffarian D, Psaty BM, Rimm EB, et al. Fish intake and risk of incident atrial fibrillation. Circulation 2004; 110:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36330/abstract/145\">",
"      Frost L, Vestergaard P. n-3 Fatty acids consumed from fish and risk of atrial fibrillation or flutter: the Danish Diet, Cancer, and Health Study. Am J Clin Nutr 2005; 81:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36330/abstract/146\">",
"      Brouwer IA, Heeringa J, Geleijnse JM, et al. Intake of very long-chain n-3 fatty acids from fish and incidence of atrial fibrillation. The Rotterdam Study. Am Heart J 2006; 151:857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36330/abstract/147\">",
"      Berry JD, Prineas RJ, van Horn L, et al. Dietary fish intake and incident atrial fibrillation (from the Women's Health Initiative). Am J Cardiol 2010; 105:844.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36330/abstract/148\">",
"      Jahangiri A, Leifert WR, Patten GS, McMurchie EJ. Termination of asynchronous contractile activity in rat atrial myocytes by n-3 polyunsaturated fatty acids. Mol Cell Biochem 2000; 206:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36330/abstract/149\">",
"      Sakabe M, Shiroshita-Takeshita A, Maguy A, et al. Omega-3 polyunsaturated fatty acids prevent atrial fibrillation associated with heart failure but not atrial tachycardia remodeling. Circulation 2007; 116:2101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36330/abstract/150\">",
"      da Cunha DN, Hamlin RL, Billman GE, Carnes CA. n-3 (omega-3) polyunsaturated fatty acids prevent acute atrial electrophysiological remodeling. Br J Pharmacol 2007; 150:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36330/abstract/151\">",
"      Champeil-Potokar G, Chaumontet C, Guesnet P, et al. Docosahexaenoic acid (22:6n-3) enrichment of membrane phospholipids increases gap junction coupling capacity in cultured astrocytes. Eur J Neurosci 2006; 24:3084.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36330/abstract/152\">",
"      Virtanen JK, Mursu J, Voutilainen S, Tuomainen TP. Serum long-chain n-3 polyunsaturated fatty acids and risk of hospital diagnosis of atrial fibrillation in men. Circulation 2009; 120:2315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36330/abstract/153\">",
"      Macchia A, Monte S, Pellegrini F, et al. Omega-3 fatty acid supplementation reduces one-year risk of atrial fibrillation in patients hospitalized with myocardial infarction. Eur J Clin Pharmacol 2008; 64:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36330/abstract/154\">",
"      Cal&ograve; L, Bianconi L, Colivicchi F, et al. N-3 Fatty acids for the prevention of atrial fibrillation after coronary artery bypass surgery: a randomized, controlled trial. J Am Coll Cardiol 2005; 45:1723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36330/abstract/155\">",
"      Savelieva I, Kakouros N, Kourliouros A, Camm AJ. Upstream therapies for management of atrial fibrillation: review of clinical evidence and implications for European Society of Cardiology guidelines. Part I: primary prevention. Europace 2011; 13:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36330/abstract/156\">",
"      Armaganijan L, Lopes RD, Healey JS, et al. Do omega-3 fatty acids prevent atrial fibrillation after open heart surgery? A meta-analysis of randomized controlled trials. Clinics (Sao Paulo) 2011; 66:1923.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36330/abstract/157\">",
"      Mozaffarian D, Marchioli R, Macchia A, et al. Fish oil and postoperative atrial fibrillation: the Omega-3 Fatty Acids for Prevention of Post-operative Atrial Fibrillation (OPERA) randomized trial. JAMA 2012; 308:2001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36330/abstract/158\">",
"      Mariani J, Doval HC, Nul D, et al. N-3 polyunsaturated fatty acids to prevent atrial fibrillation: updated systematic review and meta-analysis of randomized controlled trials. J Am Heart Assoc 2013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36330/abstract/159\">",
"      Mozaffarian D, Wu JH, de Oliveira Otto MC, et al. Fish Oil and Post-Operative Atrial Fibrillation - A Meta-Analysis of Randomized Controlled Trials. J Am Coll Cardiol 2013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36330/abstract/160\">",
"      Kromann N, Green A. Epidemiological studies in the Upernavik district, Greenland. Incidence of some chronic diseases 1950-1974. Acta Med Scand 1980; 208:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36330/abstract/161\">",
"      Bjerregaard P, Dyerberg J. Mortality from ischaemic heart disease and cerebrovascular disease in Greenland. Int J Epidemiol 1988; 17:514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36330/abstract/162\">",
"      Caicoya M. Fish consumption and stroke: a community case-control study in Asturias, Spain. Neuroepidemiology 2002; 21:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36330/abstract/163\">",
"      Hunter DJ, Kazda I, Chockalingam A, Fodor JG. Fish consumption and cardiovascular mortality in Canada: an inter-regional comparison. Am J Prev Med 1988; 4:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36330/abstract/164\">",
"      Jamrozik K, Broadhurst RJ, Anderson CS, Stewart-Wynne EG. The role of lifestyle factors in the etiology of stroke. A population-based case-control study in Perth, Western Australia. Stroke 1994; 25:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36330/abstract/165\">",
"      Zhang J, Sasaki S, Amano K, Kesteloot H. Fish consumption and mortality from all causes, ischemic heart disease, and stroke: an ecological study. Prev Med 1999; 28:520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36330/abstract/166\">",
"      Agren JJ, H&auml;nninen O, H&auml;nninen A, Sepp&auml;nen K. Dose responses in platelet fatty acid composition, aggregation and prostanoid metabolism during moderate freshwater fish diet. Thromb Res 1990; 57:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36330/abstract/167\">",
"      Middaugh JP. Cardiovascular deaths among Alaskan Natives, 1980-86. Am J Public Health 1990; 80:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36330/abstract/168\">",
"      Parkinson AJ, Cruz AL, Heyward WL, et al. Elevated concentrations of plasma omega-3 polyunsaturated fatty acids among Alaskan Eskimos. Am J Clin Nutr 1994; 59:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36330/abstract/169\">",
"      He K, Song Y, Daviglus ML, et al. Fish consumption and incidence of stroke: a meta-analysis of cohort studies. Stroke 2004; 35:1538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36330/abstract/170\">",
"      Tanaka K, Ishikawa Y, Yokoyama M, et al. Reduction in the recurrence of stroke by eicosapentaenoic acid for hypercholesterolemic patients: subanalysis of the JELIS trial. Stroke 2008; 39:2052.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36330/abstract/171\">",
"      Mozaffarian D, Lemaitre RN, King IB, et al. Circulating long-chain &omega;-3 fatty acids and incidence of congestive heart failure in older adults: the cardiovascular health study: a cohort study. Ann Intern Med 2011; 155:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36330/abstract/172\">",
"      Mozaffarian D, Bryson CL, Lemaitre RN, et al. Fish intake and risk of incident heart failure. J Am Coll Cardiol 2005; 45:2015.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36330/abstract/173\">",
"      Uauy R, Mena P, Wegher B, et al. Long chain polyunsaturated fatty acid formation in neonates: effect of gestational age and intrauterine growth. Pediatr Res 2000; 47:127.",
"     </a>",
"    </li>",
"    <li>",
"     Omacor: Consumer Drug Information Sheet - Approval Label. US Food And Drug Administration, Center for Drug Evaluation and Research. Available at: www.fda.gov/cder/foi/label/2004/21654lbl.pdf (Accessed on December 21, 2007).",
"    </li>",
"    <li>",
"     Santerre, C. Personal communication, Nov 9, 2007.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36330/abstract/176\">",
"      Chee KM, Gong JX, Rees DM, et al. Fatty acid content of marine oil capsules. Lipids 1990; 25:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36330/abstract/177\">",
"      Patch CS, Tapsell LC, Mori TA, et al. The use of novel foods enriched with long-chain n-3 fatty acids to increase dietary intake: a comparison of methodologies assessing nutrient intake. J Am Diet Assoc 2005; 105:1918.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36330/abstract/178\">",
"      Mozaffarian D. Does alpha-linolenic acid intake reduce the risk of coronary heart disease? A review of the evidence. Altern Ther Health Med 2005; 11:24.",
"     </a>",
"    </li>",
"    <li>",
"     Letter responding to a request to reconsider the qualified claim for a dietary supplement health claim for omega-3 fatty acids and coronary heart disease. Office of Nutritional Products, Labeling, and Dietary Supplements, Center for Food Safety and Applied Nutrition, US Food and Drug Administration. February 2002. Available at: www.cfsan.fda.gov/~dms/ds-ltr28.html (Accessed on December 21, 2007).",
"    </li>",
"    <li>",
"     Substances affirmed as Generally Recognized As Safe: menhaden oil. Department of Health and Human Services, US Food and Drug Administration. Available at: www.fda.gov/OHRMS/DOCKETS/98fr/05-5641.htm (Accessed on June 30, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36330/abstract/181\">",
"      Foran SE, Flood JG, Lewandrowski KB. Measurement of mercury levels in concentrated over-the-counter fish oil preparations: is fish oil healthier than fish? Arch Pathol Lab Med 2003; 127:1603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36330/abstract/182\">",
"      Jacobs MN, Covaci A, Schepens P. Investigation of selected persistent organic pollutants in farmed Atlantic salmon (Salmo salar), salmon aquaculture feed, and fish oil components of the feed. Environ Sci Technol 2002; 36:2797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36330/abstract/183\">",
"      Storelli MM, Storelli A, Marcotrigiano GO. Polychlorinated biphenyls, hexachlorobenzene, hexachlorocyclohexane isomers, and pesticide organochlorine residues in cod-liver oil dietary supplements. J Food Prot 2004; 67:1787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36330/abstract/184\">",
"      Jimenez B, Wright C, Kelly M, Startin JR. Levels of PCDDs, PCDFs and non-ortho PCBs in dietary supplement fish oil obtained in Spain. Chemosphere 1996; 32:461.",
"     </a>",
"    </li>",
"    <li>",
"     Summary of investigation of dioxins, furans, and PCBs in farmed salmon, wild salmon, farmed trout and fish oil capsules. Food Safety Authority of Ireland., March 2002.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36330/abstract/186\">",
"      Andreeva VA, Touvier M, Kesse-Guyot E, et al. B vitamin and/or &omega;-3 fatty acid supplementation and cancer: ancillary findings from the supplementation with folate, vitamins B6 and B12, and/or omega-3 fatty acids (SU.FOL.OM3) randomized trial. Arch Intern Med 2012; 172:540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36330/abstract/187\">",
"      Wendel M, Heller AR. Anticancer actions of omega-3 fatty acids--current state and future perspectives. Anticancer Agents Med Chem 2009; 9:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36330/abstract/188\">",
"      Spencer L, Mann C, Metcalfe M, et al. The effect of omega-3 FAs on tumour angiogenesis and their therapeutic potential. Eur J Cancer 2009; 45:2077.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36330/abstract/189\">",
"      Keijer J, Bekkenkamp-Grovenstein M, Venema D, Dommels YE. Bioactive food components, cancer cell growth limitation and reversal of glycolytic metabolism. Biochim Biophys Acta 2011; 1807:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36330/abstract/190\">",
"      Cockbain AJ, Toogood GJ, Hull MA. Omega-3 polyunsaturated fatty acids for the treatment and prevention of colorectal cancer. Gut 2012; 61:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36330/abstract/191\">",
"      Wiseman M. The second World Cancer Research Fund/American Institute for Cancer Research expert report. Food, nutrition, physical activity, and the prevention of cancer: a global perspective. Proc Nutr Soc 2008; 67:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/30/36330/abstract/192\">",
"      Sala-Vila A, Calder PC. Update on the relationship of fish intake with prostate, breast, and colorectal cancers. Crit Rev Food Sci Nutr 2011; 51:855.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5365 Version 27.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-61.234.146.186-DCF38A056D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_30_36330=[""].join("\n");
var outline_f35_30_36330=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H31\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PHARMACOKINETICS AND METABOLISM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EFFECTS ON CARDIOVASCULAR RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Blood lipids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Blood pressure and systemic vascular resistance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Heart rate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Heart rate variability",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Cardiac relaxation, filling, and efficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Arrhythmic risk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Insulin sensitivity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Coagulation and thrombosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Inflammation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      CARDIOVASCULAR OUTCOMES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Atherosclerosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Coronary restenosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Acute coronary syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      CHD death and sudden cardiac death",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Total mortality",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Recurrent ventricular tachyarrhythmias",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Stroke",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      EARLY NEUROLOGIC DEVELOPMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      SIDE EFFECTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      ADMINISTRATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Preparations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Dose and form",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Safety",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Bleeding",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      - Contaminants",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2251422914\">",
"      - Cancer risk",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PC/5365\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/5365|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?36/55/37750\" title=\"figure 1\">",
"      EPA DPA DHA chemicals",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?4/34/4640\" title=\"figure 2\">",
"      Effects n3 PUFA consumption",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?17/9/17566\" title=\"figure 3\">",
"      Spectrum of CHD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/5365|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?40/29/41435\" title=\"table 1\">",
"      Ingested oz for EPA DHA",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/36/33354?source=related_link\">",
"      Alternative and experimental agents for the treatment of asthma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/47/35578?source=related_link\">",
"      Approach to the patient with hypertriglyceridemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/59/28602?source=related_link\">",
"      Atrial fibrillation and flutter after cardiac surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/43/42679?source=related_link\">",
"      Diet in the treatment and prevention of hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/51/28474?source=related_link\">",
"      Lipid lowering with diet or dietary supplements",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/53/43864?source=related_link\">",
"      Maternal nutrition during lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/44/28362?source=related_link\">",
"      Nutrition in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/25/29081?source=related_link\">",
"      Possible role of long-term medical therapies to prevent restenosis following percutaneous coronary intervention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/25/41369?source=related_link\">",
"      Prevention of dementia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/52/30538?source=related_link\">",
"      Psychopharmacological treatment for adolescent depression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/31/33273?source=related_link\">",
"      Risks and benefits of fish consumption and fish oil supplements during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/4/33865?source=related_link\">",
"      Treatment of dementia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_30_36331="Factors contributing to HF";
var content_f35_30_36331=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F73383&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F73383&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Factors potentially contributing to worsening heart failure",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Cardiovascular factors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Superimposed ischema or infarction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Uncontrolled hypertension",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Unrecognized primary valvular disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Worsening secondary mitral regurgitation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        New onset or uncontrolled atrial fibrillation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Excessive tachycardia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pulmonary embolism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Systemic factors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Inappropriate medications",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Superimposed infection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Anemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Uncontrolled diabetes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Thyroid dysfunction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Electrolyte disorders",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pregnancy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Patient-related factors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Medication noncompliance",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dietary indiscretion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Alcohol consumption",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Substance abuse",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_30_36331=[""].join("\n");
var outline_f35_30_36331=null;
var title_f35_30_36332="ACCESS criteria sarcoid B";
var content_f35_30_36332=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F72769&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F72769&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    ACCESS study criteria for organ involvement in patients with biopsy-confirmed sarcoidosis - II",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Organ",
"       </td>",
"       <td class=\"subtitle1\">",
"        Definite",
"       </td>",
"       <td class=\"subtitle1\">",
"        Probable",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Nonthoracic lymph node",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        &nbsp;",
"       </td>",
"       <td>",
"        1. New palpable node above waist",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2. Lymph node &gt;2 cm by computed tomographic (CT) scan",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Parotid/salivary glands",
"       </td>",
"       <td>",
"        1. Symmetrical parotitis with syndrome of mumps",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2. Positive gallium scan (\"Panda sign\")",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Renal",
"       </td>",
"       <td>",
"        1. Treatment responsive renal failure",
"       </td>",
"       <td>",
"        1. Steroid responsive renal failure in patient with diabetes and/or hypertension",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Liver",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        1. Liver function tests &gt; three times normal",
"       </td>",
"       <td>",
"        1. Compatible computed tomographic (CT) scan",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2. Elevated alkaline phosphatase",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"4\">",
"        Spleen",
"       </td>",
"       <td class=\"sublist1_start\" colspan=\"1\" rowspan=\"4\">",
"        &nbsp;",
"       </td>",
"       <td class=\"sublist1_start\">",
"        1. Enlargement by:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Exam",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\" colspan=\"1\">",
"        Computed tomographic (CT) scan",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Radioisotope scan",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"3\">",
"        Bone marrow",
"       </td>",
"       <td>",
"        1. Unexplained anemia",
"       </td>",
"       <td colspan=\"1\" rowspan=\"3\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2. Leukopenia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3. Thrombocytopenia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bone/joints",
"       </td>",
"       <td>",
"        1. Cystic changes on hand or feet phalanges",
"       </td>",
"       <td>",
"        1. Asymmetric painful clubbing",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ears/Nose/Throat",
"       </td>",
"       <td colspan=\"1\">",
"        1. Unexplained hoarseness with exam consistent with granulomatous involvement",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Muscles",
"       </td>",
"       <td>",
"        1. Increased creatine phosphokinase (CK) aldolase which decreases with treatment",
"       </td>",
"       <td>",
"        1. Increased creatine, phosphokinase (CK)/aldolase",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Judson, MA, RP Baughman, AS. Teirstein, ML Terrin, and H Yeager, Jr. 1999. Defining organ involvement in sarcoidosis: the ACCESS proposed instrument. ACCESS Research Group. A Case Control Etiologic Study of Sarcoidosis. Sarcoidosis, Vasculitis, and Diffuse Lung Diseases 16:75-86. Copyright &copy; 1999 Sarcoidosis, Vasculitis, and Diffuse Lung Diseases.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_30_36332=[""].join("\n");
var outline_f35_30_36332=null;
var title_f35_30_36333="Types of airway stents";
var content_f35_30_36333=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F58596%7EPULM%2F54642&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=8\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F58596%7EPULM%2F54642&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=8\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Advantages and disadvantages of different airway stents",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Advantages",
"       </td>",
"       <td class=\"subtitle1\">",
"        Disadvantages",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"1\">",
"        Silicone stents",
"       </td>",
"       <td colspan=\"1\" rowspan=\"1\">",
"        <p>",
"         Easily inserted",
"        </p>",
"        <p>",
"         Repositioning and removal are easily accomplished",
"        </p>",
"       </td>",
"       <td colspan=\"1\" rowspan=\"1\">",
"        <p>",
"         Rigid bronchoscopy and general anesthesia required",
"        </p>",
"        <p>",
"         Stent migration is common",
"        </p>",
"        <p>",
"         Granulation tissue may obstruct proximal or distal ends of stent",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"1\">",
"        Metal stents",
"       </td>",
"       <td colspan=\"1\" rowspan=\"1\">",
"        <p>",
"         May be introduced with fiberoptic scope without general anesthesia",
"        </p>",
"        <p>",
"         Self-expanding; resist extrinsic compression",
"        </p>",
"        <p>",
"         Minimal migration after placement",
"        </p>",
"       </td>",
"       <td colspan=\"1\" rowspan=\"1\">",
"        <p>",
"         Cannot be easily removed or repositioned",
"        </p>",
"        <p>",
"         Granulation tissue or tumor easily grows through spaces between metal struts",
"        </p>",
"        <p>",
"         Expansile force may rupture airways and vascular structures",
"        </p>",
"        <p>",
"         More expensive than silicone stents",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"1\">",
"        Hybrid stents",
"       </td>",
"       <td colspan=\"1\" rowspan=\"1\">",
"        <p>",
"         Resist extrinsic compression",
"        </p>",
"        <p>",
"         Silicone membrane resists ingrowth of tumor or granulation tissue",
"        </p>",
"       </td>",
"       <td colspan=\"1\" rowspan=\"1\">",
"        <p>",
"         Cannot be easily removed or repositioned",
"        </p>",
"        <p>",
"         Most expensive",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Commercially-available airway stents",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Brand",
"       </td>",
"       <td class=\"subtitle1\">",
"        Material",
"       </td>",
"       <td class=\"subtitle1\">",
"        Shapes",
"       </td>",
"       <td class=\"subtitle1\">",
"        Specific problems/complications",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dumon",
"       </td>",
"       <td>",
"        Silicone",
"       </td>",
"       <td>",
"        Straight, Y, J",
"       </td>",
"       <td>",
"        Migration in benign disease (straight)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Orlowski",
"       </td>",
"       <td>",
"        Silicone, armored with metal rings",
"       </td>",
"       <td>",
"        Straight",
"       </td>",
"       <td>",
"        Very stiff",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hood",
"       </td>",
"       <td>",
"        Silicone",
"       </td>",
"       <td>",
"        Straight, Y",
"       </td>",
"       <td>",
"        Difficult to insert (Y)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gianturco",
"       </td>",
"       <td>",
"        Stainless steel, self-expandable",
"       </td>",
"       <td>",
"        Straight",
"       </td>",
"       <td>",
"        Stent fracture, airway perforation, fatal hemoptysis,",
"occlusion by tissue growth",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Strecker",
"       </td>",
"       <td>",
"        Tantalum, balloon-expandable",
"       </td>",
"       <td>",
"        Straight",
"       </td>",
"       <td>",
"        Stent collapse, occlusion by tissue growth",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Palmaz",
"       </td>",
"       <td>",
"        Stainless steel, balloon-expandable",
"       </td>",
"       <td>",
"        Straight",
"       </td>",
"       <td>",
"        Stent collapse, occlusion by tissue growth",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Wallstent",
"       </td>",
"       <td>",
"        Cobalt-based alloy, uncovered, self-expandable",
"       </td>",
"       <td>",
"        Straight",
"       </td>",
"       <td>",
"        Granuloma, occlusion by tissue growth",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Wallstent (Covered)",
"       </td>",
"       <td>",
"        Cobalt-based alloy, polyurethane covering,",
"self-expandable",
"       </td>",
"       <td>",
"        Straight",
"       </td>",
"       <td>",
"        Granuloma at stent ends, airway perforation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ultraflex",
"       </td>",
"       <td>",
"        Nitinol, self-expandable covered and uncovered",
"       </td>",
"       <td>",
"        Straight",
"       </td>",
"       <td>",
"        Granuloma formation, stent fracture",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Polyflex",
"       </td>",
"       <td>",
"        Polyester wire, silicone covering, self-expandable",
"       </td>",
"       <td>",
"        Straight, Y, J",
"       </td>",
"       <td>",
"        Migration (straight), difficult to insert (Y)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Screw-thread",
"       </td>",
"       <td>",
"        Tygon",
"       </td>",
"       <td>",
"        Straight",
"       </td>",
"       <td>",
"        Only tracheal sizes, mucus retention",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dynamic",
"       </td>",
"       <td>",
"        Silicone, metal hoops",
"       </td>",
"       <td>",
"        Y",
"       </td>",
"       <td>",
"        Difficult to insert",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Montgomery",
"       </td>",
"       <td>",
"        Silicone",
"       </td>",
"       <td>",
"        T-tube",
"       </td>",
"       <td>",
"        Difficult to insert, tracheostomy necessary",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     Manufacturer's details for all brands are as follows: Dumon: Endoxane&reg;, Novatech SA, Grasse, France; Orlowski: R&uuml;sch AG, Kernen, Germany; Hood: Hood Laboratories, Pembroke, MA, USA; Gianturco: Cook, Bjaeverskov, Denmark; Strecker: Microvasive-Boston Scientific, Natick, MA, USA; Palmaz: Corning/Johnson and Johnson, Warren, NJ, USA; Wallstent and Covered Wallstent: Microvasive-Boston Scientific; Ultraflex: Microvasive-Boston Scientific; Polyflex: R&uuml;sch AG; Screw-thread: Reynders Medical Supply, Lennik, Belgium; Dynamic: R&uuml;sch AG; Montgomery: Boston Medical Products, Inc., Waltham, MA, USA.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Bolliger, CT, Mathur, PN, Beamis, JF, et al. Eur Respir J 2002; 19:365. Copyright &copy; 2002 European Respiratory Society Journals Ltd.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_30_36333=[""].join("\n");
var outline_f35_30_36333=null;
var title_f35_30_36334="Contents: Tuberculosis";
var content_f35_30_36334=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"mobipreview.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"mobipreview.htm?15/21/15710\">",
"       Infectious Diseases",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Tuberculosis",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"mobipreview.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Tuberculosis",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Diagnosis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?20/10/20648\">",
"           Diagnosis of latent tuberculosis infection in HIV-negative adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?8/56/9098\">",
"           Diagnosis of pulmonary tuberculosis in HIV-negative patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?31/52/32586\">",
"           Diagnosis, treatment, and prevention of drug-resistant tuberculosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?1/10/1194\">",
"           Epidemiology, clinical manifestations, and diagnosis of tuberculosis in HIV-infected patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?36/18/37160\">",
"           Interferon-gamma release assays for diagnosis of latent tuberculosis infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?12/35/12856\">",
"           Tuberculous pleural effusions in HIV-negative patients",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Drug resistant disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?5/53/5978\">",
"           Clinical manifestations, diagnosis, and treatment of extensively drug-resistant tuberculosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?31/52/32586\">",
"           Diagnosis, treatment, and prevention of drug-resistant tuberculosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?7/20/7497\">",
"           Epidemiology and molecular mechanisms of drug-resistant tuberculosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?33/59/34743\">",
"           Epidemiology of extensively drug-resistant tuberculosis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Extrapulmonary disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?28/2/28713\">",
"           Central nervous system tuberculosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?20/21/20826\">",
"           Clinical manifestations, diagnosis, and treatment of extrapulmonary and miliary tuberculosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?33/22/34150\">",
"           Epidemiology and pathology of extrapulmonary and miliary tuberculosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?36/49/37656\">",
"           Skeletal tuberculosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?5/40/5767\">",
"           Tuberculosis and the eye",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?27/7/27768\">",
"           Tuberculous lymphadenitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?2/36/2633\">",
"           Tuberculous pericarditis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?35/48/36614\">",
"           Tuberculous peritonitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?12/35/12856\">",
"           Tuberculous pleural effusions in HIV-negative patients",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         HIV infection",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?19/43/20154\">",
"           Approach to the HIV-infected patient with pulmonary symptoms",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?11/46/12009\">",
"           Diagnosis of latent tuberculosis infection in HIV-infected patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?1/10/1194\">",
"           Epidemiology, clinical manifestations, and diagnosis of tuberculosis in HIV-infected patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?16/55/17272\">",
"           Monitoring the HIV-infected patient on antituberculous medications",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?4/12/4298\">",
"           Treatment of latent tuberculosis infection in HIV-infected patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?18/35/19002\">",
"           Treatment of pulmonary tuberculosis in the HIV-infected patient",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?21/47/22261\">",
"           Tuberculous pleural effusions in HIV-infected patients",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Other",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?18/13/18649\">",
"           Epidemiology of tuberculosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?42/17/43289\">",
"           Immunology of tuberculosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?12/53/13143\">",
"           Latent tuberculosis infection in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?21/54/22378\">",
"           Microbiology and pathogenesis of tuberculosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?16/14/16614\">",
"           Mycobacterium bovis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?13/43/14005\">",
"           Renal disease in tuberculosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?23/4/23625\">",
"           Tuberculosis disease in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?28/26/29096\">",
"           Tuberculosis in pregnancy",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Prevention",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?39/12/40136\">",
"           BCG vaccination",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?11/46/12009\">",
"           Diagnosis of latent tuberculosis infection in HIV-infected patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?4/12/4298\">",
"           Treatment of latent tuberculosis infection in HIV-infected patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?9/13/9432\">",
"           Treatment of latent tuberculosis infection in HIV-negative adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?19/52/20294\">",
"           Tuberculosis transmission and control",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Pulmonary disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?38/47/39673\">",
"           Clinical manifestations and evaluation of pulmonary tuberculosis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Treatment",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?10/6/10341\">",
"           Adherence to tuberculosis treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?31/52/32586\">",
"           Diagnosis, treatment, and prevention of drug-resistant tuberculosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?30/2/30757\">",
"           Ethambutol: An overview",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?40/61/41943\">",
"           Isoniazid hepatotoxicity",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?18/44/19142\">",
"           Isoniazid: An overview",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?33/62/34788\">",
"           Pyrazinamide: An overview",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?24/26/24998\">",
"           Rifampin and other rifamycins",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?17/60/18375\">",
"           Second-line antituberculous therapy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?19/21/19802\">",
"           Treatment of pulmonary tuberculosis in HIV-negative patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?18/35/19002\">",
"           Treatment of pulmonary tuberculosis in the HIV-infected patient",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?28/26/29096\">",
"           Tuberculosis in pregnancy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?12/35/12856\">",
"           Tuberculous pleural effusions in HIV-negative patients",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-7DC04E1177-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f35_30_36334=[""].join("\n");
var outline_f35_30_36334=null;
var title_f35_30_36335="Birdshot choroidopathy";
var content_f35_30_36335=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F58904&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F58904&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Birdshot choroidopathy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 433px; height: 322px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple round chorioretinal lesions characteristic of a rare form of uveitis known as birdshot choroidopathy.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of James T Rosenbaum.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_30_36335=[""].join("\n");
var outline_f35_30_36335=null;
